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General introduction 
The statement that food may provide therapeutic benefits is clearly not new. The tenet, ‘Let 
food be thy medicine and medicine be thy food’ was embraced already about 2500 years 
ago by Hippocrates. Initially, scientific focus was given on the identification of essential 
elements (e.g. vitamins) and their role in the prevention and therapy of various dietary 
deficiency diseases. In recent years, the focus has shifted to explore the role of diet in 
diseases linked to excess food intake and ‘overnutrition’. Furthermore, food is now being 
examined intensively to identify physiologically active components that potentially have 
health promoting effects, particularly in chronic diseases or premalignant and malignant 
disorders or in mild disturbances of organ physiology. This food category is now recognized 
as ‘functional foods’. 
In this thesis, we aim to investigate the effects of several nutritional interventions on 
gastrointestinal and metabolic health. To study these effects we not only focused on healthy, 
lean subjects but also on obese individuals. 
Overweight, obesity and high-fat diet 
The prevalence of overweight, obesity and related diseases (e.g. cardiovascular diseases 
(CVD) and diabetes mellitus type 2 (DM2)) is increasing worldwide. Adults with a body mass 
index (BMI) of >25 kg/m2 are categorized as overweight, those with a BMI of >30 kg/m2 as 
obese.1 In the Netherlands in 2015, 50.3% of the adults aged 20 years and older were 
overweight and 13.7% were obese.2 Worldwide in 2014, approximately 39% of people 
aged 18 years and over were overweight and 13% obese.3 The increased prevalence of 
obesity and associated diseases is primarily due to an increase in caloric availability and fat 
consumption, and a reduction in physical activity in daily life.4 Growing evidence supports 
the idea that also the gut microbiome plays an important role in the development of fat 
mass and energy homeostasis.5 Common features associated with overweight and obesity 
are alterations in gut microbiota,6,7 impaired gut barrier function,8-10 (gastrointestinal) and 
systemic low-grade inflammation,11-14 endothelial dysfunction,15 hypertension,16 glucose 
homeostasis disorders4 and lipid homeostasis disorders.17 Obesity and the associated 
gastrointestinal and systemic metabolic abnormalities are well-recognized risk factors for 
the development of DM2 and CVD.18-20 
Obesity imposes a tremendous economic burden on society through increased total direct 
(treatment obesity-associated diseases) and indirect (productivity losses) medical costs. In 
Europe, it has been calculated that in general the direct health care costs of obesity 
account already for up to total 4% of national health expenditure. It is indicated that indirect 
health care costs could amount to twice the direct health care costs.21 Significant reduction 
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in these costs could be accomplished by prevention of overweight or by a delay in the 
onset of overweight, obesity and associated diseases. 
Gastrointestinal and systemic metabolic consequences 
Gut barrier 
Every day, our gastrointestinal tract is exposed to a multitude of different microorganisms 
and nutrient compounds for subsequent interaction. Balancing this interaction requires a 
complex control system that is able to prevent entry of antigens and microorganisms into the 
body, while it allows exchange of molecules between host and environment and absorption 
of nutrients from the diet.22,23 In a healthy organism, the gut barrier is able to fulfill all these 
needs simultaneously. The gut barrier is a functional unit, organized as a multi-layer system 
comprising the mucus, epithelial cells, the innate and adaptive immune cells forming the gut-
associated lymphoid tissue (GALT) and the gut microbiota.24 
Mucus protects the epithelium from potentially harmful microorganisms and antigens, but 
also functions as a lubricating agent for food particles. The mucus layer is dense and only 
allows low amounts of bacteria to get close to or penetrate the epithelium, which would 
potentially induce an increase in intestinal permeability with subsequent inflammatory 
reaction. Furthermore, it is the habitat of the gut microbiota. In addition, the mucus layer 
serves as food and a binding site for the bacteria, and is probably involved in the selection 
of specific microbial species, essential for the maintenance of intestinal integrity, homeostasis 
and function.24,25 
The gastrointestinal epithelium is a single cell layer which is comprised of different cell types, 
acting as a physical barrier by inhibiting the passage of luminal contents into the systemic 
circulation through the formation of complex protein-protein networks that mechanically 
connect adjacent cells and seal intercellular spaces.26 Tight junctions (TJ), adherent junctions 
(AJ) and desmosomes are the three main junctional complexes connecting adjacent 
epithelial cells. TJ consist of transmembrane proteins (occludins, claudins, junctional adhesion 
molecule-A) connected to the actin cytoskeleton via plaque proteins (ZO-1, ZO-2 and α-
catenin) and these proteins regulate paracellular permeability of the epithelium. AJ and 
desmosomes anchor epithelial cells to one another and confer mechanical strength to the 
epithelial barrier.27-29 
Obesity is associated with changes in gut microbiota, which in turn may affect the intestinal 
permeability via changes in the expression, localization and distribution of TJ proteins9,10,12,30 
and via the endocannabinoid system (eCB). This system consists of endogenous bioactive 
lipids that are able to alter the distribution of TJ proteins by activating cannabinoid 
receptors, expressed throughout the gastrointestinal tract.31 A ‘leak’ in the paracellular 
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absorption route enables antigens to pass from the intestinal milieu, challenging the immune 
system to produce an immune response resulting in inflammation and oxidative stress. Gut 
barrier dysfunction is regarded as an early event or trigger in the development of various 
intestinal diseases, and of metabolic endotoxemia present in obesity, DM2 and CVD.32,33 
GALT, gut-associated lymphoid tissue, is a complex network of immune cells representing a 
functional barrier that protects the ‘milieu interieur’ from external threats. GALT drives 
immunological responses to pathogenic microorganisms. Proper functioning of such networks 
is essential for the maintenance of gut homeostasis, preventing transport of luminal contents 
towards and into the systemic circulation thus preventing the activation of an immune 
response and the induction of an inflammatory state. This underlies the pathogenesis of 
many gastrointestinal diseases, such as inflammatory bowel diseases (IBD) and celiac 
disease.34 
Gut microbiota 
The human gut microbiome refers to the entire population of microorganisms colonizing the 
gut. It is a complex ecosystem that includes at least 1014 bacteria and also other microbes, 
such as yeasts and viruses.24 It is an organ by itself, which plays an important role within our 
body, being involved in many functional processes essential for our homeostasis, such as the 
metabolism of nutrients and drugs, the regulation of many metabolic pathways, the 
maintenance of epithelial integrity, the modulation of gastrointestinal motility, the stimulation 
and maturation of both systemic and mucosal immunity, and the production of vitamins and 
micronutrients.35,36 The majority of the gut bacteria is non-pathogenic and co-habit with the 
gut mucosa in a symbiotic relationship. Intestinal microbiota convert undigested food 
components into various metabolites, such as short-chain fatty acids (SCFA), which can be 
further processed by the host and appear to be important signalling molecules. Many of the 
beneficial physiologic properties of the microbiota can be attributed to the production of 
these SCFA, particularly acetate, propionate and butyrate.37-39 
In humans, the interaction between genetic and environmental factors (diet and physical 
activity) is considered as the main contributor for the development of obesity. Recently, gut 
microbiota have emerged as a potentially important factor influencing development of 
overweight. However, the exact mechanisms through which the gut microbiota contribute to 
obesity are still unclear. It has been suggested that the microbiome has the capacity to 
increase energy harvested from the diet, and that it is able to influence host energy balance 
and metabolism by modulating host signaling pathways.5,40-42 Furthermore, the gut 
microbiome might contribute to the development of low-grade inflammation by production 
of lipopolysaccharide (LPS), a powerful pro-inflammatory molecule from the cell wall of 
Gram-negative bacteria, which is continuously produced in the host gut with the death and 
lysis of Gram-negative bacteria.7,11 Today, many questions still remain to be answered: for 
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instance whether changes in gut microbiota composition and diversity are a cause or a 
consequence of the observed pathology. 
Low-grade inflammation 
Persistently high circulating levels of inflammatory cytokines (IFN-gamma and TNF-alpha) 
are often observed in obese humans, and may cause an impaired gut barrier function by 
affecting TJ proteins.43,44 An increased intestinal permeability may lead to translocation of 
bacterial endotoxins, such as LPS, into the systemic circulation where it is able to activate 
inflammatory pathways.45 Other processes contributing to these elevated LPS levels are an 
increase in chylomicron-driven LPS transport and a decrease in processes involved in 
intestinal LPS degradation (alkaline phosphatase activity).12,30,46 Additionally, the state of 
insulin resistance, often observed in obese individuals, promotes inflammation by impairing 
the anti-inflammatory effects of insulin.47,48 
Vascular function 
The vascular endothelium is a monolayer of cells between the lumen and the vascular 
smooth muscle cells. It plays a crucial role in the maintenance of vascular homeostasis by 
keeping a refined balance between vasodilation and vasoconstriction.49 Nitric oxide (NO), 
generated by endothelial nitric oxide synthase (eNOS), is of pivotal importance in regulating 
the arterial tone and thus in regulating endothelial function (EF).50 It is able to dilate all types 
of blood vessels, is considered to be a potent inhibitor of platelet aggregation and adhesion 
and can also inhibit leukocyte adhesion.51 Two important events in atherogenesis are the 
recruitment and differentiation of circulating monocytes to the endothelium, and the uptake 
of cholesterol and oxidized low-density lipoproteins (LDL) by tissue macrophages to form 
lipid-foam cells. Cellular adhesion molecules, such as vascular cell adhesion molecule-1 
(VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectins participate in 
leukocyte-endothelial interactions and are strongly expressed on macrophages within 
atherosclerotic plaques.52,53 Therefore, based on the combination of its effects, endothelial 
NO is considered an important anti-atherogenic defense mechanism in vasculature. 
Exposing endothelial cells to obesity and cardiovascular risk factors leads to oxidative stress. 
As a result, endothelial dysfunction (ED) can occur due to a decreased NO bioavailability 
by a reduction in eNOS expression or acceleration in NO degradation.15,51 Subsequently, it 
plays a key role in the development and progression of atherosclerosis. ED is often 
manifested by an impaired capacity of the vascular endothelium to dilate, which can be 
quantified by the degree of flow-mediated dilation (FMD), a non-invasive NO-dependent 
endothelial function assessment.54 
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Another aspect of vascular function that can be affected by obesity is blood pressure. Both 
animal and human studies have revealed a strong relationship between obesity and 
hypertension.55 Several mechanisms have been identified as potential causes of obesity-
induced hypertension. As mentioned above, in obesity-associated ED the vasodilating 
properties of the endothelium are impaired.56 Also, increase in both peripheral 
vasoconstriction and renal tubular sodium reabsorption,57 increase in sympathetic activity by 
obesity-related factors (leptin, hyperinsulinemia, circulating free fatty acids (FFA)),58-62 
overactivation of the renin-angiotensin system (RAS)63,64 and insulin resistance65,66 are 
proposed additional mechanisms mediating hypertension in obesity. A linear relationship 
exists between blood pressure (BP) and mortality from stroke and ischemic heart disease.67 
Hence, interventions aimed at preventing or improving obesity would greatly impact the 
management of ED, obesity-induced hypertension and related diseases. 
Glucose and insulin metabolism 
In healthy individuals, plasma glucose is tightly controlled by the balance between glucose 
absorption from the intestine, production by the liver and uptake and metabolism by 
peripheral tissues. Insulin serves as the primary regulator of plasma glucose, by increasing 
glucose uptake from muscle and fat, and by inhibiting hepatic glucose production. 
Furthermore, it stimulates glycogen synthesis.68 
Obese individuals are at risk for developing resistance to the cellular actions of insulin. This 
is characterized by an impaired ability of insulin to inhibit glucose output from the liver and 
to promote glucose uptake in fat and muscle.68,69 Proposed mechanisms, explaining the 
relationship between increased adipose mass and systemic insulin resistance, focus on 
dysregulation of interconnected endocrine (FFA, adipokines and cortisol), inflammatory, 
neural and cell-autonomous pathways.70 Insulin resistance is considered the key etiological 
factor in DM2.  
Lipid metabolism 
Numerous metabolic processes are involved in the uptake, transport and storage of lipids. In 
the intestinal lumen, triglycerides (TG) are lipolyzed into FFA and taken up by the 
enterocyte, where they are assembled in TG again. Cholesterol is in the enterocyte 
transformed into cholesterol-esters. TG, cholesterol-esters, phospholipids and apolipoprotein 
B together form chylomicrons, which enter the systemic circulation. After food-derived TG 
and FFA reach the liver, TG-rich lipoproteins called very low density lipoproteins (VLDL), are 
synthesized. Adequate lipolysis of chylomicrons and VLDL by lipoprotein lipase (LPL) delivers 
FFA to the heart, skeletal muscle and adipose tissue for energy expenditure and storage. 
The liberated FFA is then taken up by adipocytes and re-synthesized into TG. During the 
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process of lipolysis also chylomicron remnants and dense LDL are formed, these products 
are taken up by the liver. The intestine and liver also play an important role in the reverse 
cholesterol transport by the synthesis of high-density lipoproteins (HDL). HDL promotes the 
uptake of cholesterol from peripheral tissues and returns it to the liver.71 
Typical dyslipidemia in obesity consists of hypertriglyceridemia in combination with an 
increase in small dense LDL and a low HDL.17 In hypertriglyceridemia, increased FFA fluxes 
to the liver are a consequence of increased FFA release from adipose tissue and reduced 
FFA clearance from plasma. The increased FFA flux results in hepatic accumulation of TG 
followed by an increase in VLDL synthesis. Lipolysis of TG-rich lipoproteins is impaired in 
obesity, due to competition for lipolysis between VLDL and chylomicrons, reduced LPL 
expression in adipose tissue and reduced LPL activity. Also, HDL metabolism is affected by 
obesity. An increased number of TG-rich lipoproteins results in an increased exchange of 
cholesterolesters from HDL for TG from VLDL and LDL. In addition, TG-depleted small dense 
LDL is formed by removing TG and phospholipids from LDL.71-73 Furthermore, also insulin 
plays an important role in lipid metabolism as it stimulates LPL activity, facilitates FFA uptake, 
inhibits hydrolysis of intracellular lipids postprandially, and regulates FFA mobilization from 
adipose tissue during fasting states.68 Dyslipidemia in obesity is an established independent 
risk factor for the development of CVD.74 
Nutritional interventions in healthy, overweight and obese 
individuals 
Prevention or improvement of gastrointestinal and chronic metabolic diseases by a 
nutritional intervention appears to be a promising approach in health and obesity. At 
present, a number of dietary strategies are available. 
Prolyl endoproteases 
Gluten is a storage protein present in wheat, barley and rye and is exceptionally rich in 
proline. Proline-cleaving proteases are absent in the human gastrointestinal tract, ensuring 
long proline-rich gluten peptides to enter the small intestine upon ingestion, subsequently 
triggering an abnormal immune response in subjects suffering from wheat allergy or coeliac 
disease.75-77 Subjects with non-coeliac gluten sensitivity also experience distress after gluten 
intake, but no allergic or autoimmune mechanisms are involved in this condition.78-81 It has 
been proposed that in these subjects a gluten-induced activation of the innate immune 
system occurs.79 In general, treatment of these gluten-related disorders is based on 
excluding gluten-containing cereals from the diet, which is often difficult to comply with as 
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gluten-free products may not always be labeled as such or may not always be at hand 
during social events or travelling.82-84 
The Aspergillus Niger-derived prolyl endoprotease (AN-PEP) belongs to a family of 
enzymes having the ability of cleaving at internal proline residues within a peptide.85 The 
use of AN-PEP seems to be a promising approach to digest unintended dietary gluten as in 
vitro studies have shown that this enzyme is capable of degrading gluten under acidic 
stomach conditions and is safe for human use.86-89 However, in vivo data confirming these 
promising in vitro results regarding the gastric degradation of gluten are still lacking. 
Prebiotics 
Prebiotics are non-digestible compounds that selectively stimulate growth and/or activity of 
one or a limited number of microbial species in the gut with potential health benefits to the 
host.90 Prebiotic fermentation leads to beneficial host effects by the following major 
mechanisms: (1) by increasing the relative abundance of beneficial bacteria (i.e. 
bifidobacteria, lactobacilli), (2) by increasing SCFA production and reducing the production 
of putrefactive compounds, and (3) by impacting on the gut’s immune system.91,92 The most 
common prebiotics used in gut microbiota modulation are the inulins, fructooligosaccharides, 
various types of galactooligosaccharides and resistant starches. A limitation of these 
prebiotics is their rapid fermentation in the proximal colon.93,94 Dietary carbohydrate is the 
main fermentable substrate in the proximal colon and as it is degraded during bacterial 
fermentation, protein takes over as the dominant fermentable substrate towards the distal 
colon. However, bacterial protein metabolism produces toxic and potentially carcinogenic 
compounds, playing an important role in the development of distal intestinal chronic 
diseases.95 Thus, there is currently much interest in the development of prebiotics having the 
ability to persist towards the distal region of the colon. 
Arabinoxylans (AX), the most abundant non-digestible carbohydrates present in wheat, form 
an interesting novel class of potential prebiotics.96-98 Due to their structure, AX rely on a 
whole spectrum of (microbial) enzymes for degradation, resulting in a more distal 
fermentation and activity.97-99 Furthermore, AX exist in different forms, ranging from long-
chains to enzymatically modified short-chain fractions.100 Previous studies indicate that AX 
structure affects the fermentation pattern and immune modulation, with the highest activity 
observed for high-molecular weight AX.99,101,102 Prior in vitro and animal studies have shown 
promising effects of high-molecular weight AX on several aspects of the gut barrier,93,103-105 
immune system103 and metabolic markers.103 To date, no human studies have been published 
exploring the effect of such AX extract on these parameters. 
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Probiotics 
Another proposed nutritional intervention, able to change gut microbiota composition, is the 
use of probiotics. The internationally endorsed definition of probiotics is live microorganisms 
that, when administered in adequate amounts, confer a health benefit on the host.106 In 
order to establish an effect, probiotic bacteria will have to survive passage through the 
gastrointestinal tract. The effects can be classified in three modes of action; they are able to 
(1) inhibit the action of pathogenic bacteria, (2) stimulate and modulate host defenses and 
gut barrier, and (3) produce important metabolites for the host.107,108 Most probiotic 
products currently on the market contain lactic acid bacteria, such as lactobacilli and 
streptococci, or bifidobacteria.109 These bacteria are all normal constituents of the human 
gut microbiota. 
In this thesis we investigate the probiotic effects of a Bacillus indicus strain. Bacillus species 
as probiotics are attractive as they form heat-stable spores. These spores are capable of 
surviving the gastric barrier without loss of function, are stable to many food-processing 
steps and can be stored at room temperature.110,111 No previous human study investigating 
the effect of this specific strain on gut microbiota composition, activity and gut barrier is 
available, but animal and human studies exploring the effect of other bacillus strains have 
shown beneficial effects.112-117 
Phytonutrients 
Phytonutrients, also known as phytochemicals, are chemicals produced by plants. These 
phytochemicals are used to protect the plant from UV light, insects or pests and produces 
color and other organoleptic characteristics.118 Many of these phytochemicals have 
antioxidant properties and might have the potential to improve health. In this thesis we 
discuss two different phytonutrients, polyphenols and carotenoids. 
Polyphenols are a large group of bioactive plant compounds and are divided into different 
classes based upon their chemical structure. The gut microbiota plays a critical role in 
transforming dietary polyphenols into absorbable biologically active species.119 Recent 
animal and human studies have shown that dietary polyphenols are able to modulate the 
human gut microbiota.120,121 In addition, large epidemiological studies link increased 
consumption of polyphenol-rich foods with reductions in CVD morbidity and mortality.122-124 
Flavonoids are the largest class of polyphenols, present in many foods of plant origin.125 
Hesperidin, a flavonoid abundantly present in the peels of citrus fruits, to a large extent 
reaches the colon intact where it is subsequently deglycosylated by intestinal microbiota to 
produce the active aglycone hesperitin.126,127 Several human intervention studies have 
shown promising effects of hesperidin on different cardiovascular biomarkers, such as low-
grade inflammation, endothelial function, blood pressure, glucose / insulin metabolism and 
 General introduction 
19 
blood lipid profiles.128-132 However, in humans hesperidin is poorly soluble, resulting in a 
limited bioavailability and biological activity. While natural hesperidin products contain high 
concentrations of the most active form of hesperidin (hesperitin-7-O-rutinoside 2S), typical 
hesperidin extracts on the market mainly contain the less active 2R enantiomer. In this thesis, 
we study the bioavailability and biological activity of a hesperidin 2S extract with a specific 
enantiomer configuration similar to natural hesperidin. 
Carotenoids are organic pigments, synthesized mainly in plants but have also been isolated 
from yeasts, fungi, marine algae, micro-algae and some species of bacteria. Humans are not 
able to synthesize carotenoids themselves, and therefore must absorb them from their diet. 
The incidence of CVD is notably reduced in areas where a ‘Mediterranean diet’, containing 
large amounts of fruit and vegetables, and thus carotenoids, predominates.133,134 In part, the 
protective effects of carotenoids seem to be related to their potent antioxidant activity. A 
link between carotenoid intake and protection from LDL oxidation, atherosclerotic 
progression, hypertension, low-grade inflammation and endothelial dysfunction has been 
shown.135-137 The majority of commercially available carotenoids are derived from plant-
based materials. However, the quality and consistency of the end product varies 
tremendously according to the plant growth conditions.138,139 In addition, these carotenoids 
are often rapidly degraded in the human gastrointestinal tract by the action of gastric juice. 
As indicated before, carotenoids can also be synthesized by some species of bacteria. Of 
specific interest are carotenoids produced by a variety of spore-forming bacillus strains, as 
these strains are able to deliver gastric-stable carotenoids with equal or even higher 
bioavailability levels than well-established sources of dietary carotenoids in use today.140 In 
addition, in an in vitro model these bacterial carotenoids showed to have a 10-fold higher 
antioxidant activity compared to lycopene, one of the most potent antioxidants known (data 
not published yet). However, no human data regarding the bioavailability, antioxidant 
activity and systemic effects of these bacterial carotenoids are available up to now. 
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Aim and outline of the thesis 
In this thesis, we aimed to investigate the effects of nutritional interventions on 
gastrointestinal and metabolic health in healthy, overweight and obese individuals. The 
efficacy of AN-PEP in the gastric degradation of gluten was assessed in healthy (lean) 
individuals. We chose to study the effect of several other nutritional interventions in 
overweight and obese subjects. We consider overweight and obesity as “mild disease”, 
associated with a broad spectrum of well-recognized risk factors for the development of 
chronic metabolic diseases such as CVD and DM2. Figure 1.1 gives an overview of these 
risk factors, the (inter)relationship between obesity, high-fat diet and risk factors, and the 
chapters in which each risk factor is measured and discussed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 Schematic overview of (inter)relationship between obesity, high-fat diet and associated risk factors. 
The numbers below a risk factor demonstrate the chapters in which the respective risk factor is 
measured and discussed. 
 
 
The first part of this thesis (Chapters 2 & 3) focuses on investigating the efficacy of AN-PEP 
on gastric gluten degradation in healthy individuals. Furthermore, also the effect of meal 
caloric density and gastric emptying rate on the enzyme’s efficacy was assessed (Chapter 
2). In order to display a systemic (patho)biological effect, a compound has to be absorbed 
from the gastrointestinal tract. The onset of systemic effects depends on the rate of 
absorption and on gastric emptying rate. In Chapter 3 we critically evaluate the use of 
paracetamol as a non-invasive method for measuring gastric emptying rate. 
The second part of this thesis (Chapter 4-8) explores the impact of different nutritional 
compounds on parameters of gut and systemic metabolism in overweight and obese, yet 
healthy, individuals. In Chapter 4 we investigate the effects of 6 weeks daily 
supplementation of AX on the gut barrier. The study was specifically designed to integrate 
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both the analysis of TJ proteins structure and functioning of this barrier. The aspects of the 
gut barrier we studied include gene transcription and protein expression of TJ proteins in 
sigmoid colon mucosa, gastrointestinal permeability, microbial community composition and its 
metabolic activity. In addition, we also assessed whether AX are capable of modulating the 
immune response. Another nutritional compound we studied is hesperidin, a flavonoid found 
in citrus fruits. In humans, low solubility of hesperidin limits its bioavailability and biological 
activity. In Chapter 5 we studied the in vivo bioavailability of hesperidin. First, we compared 
the bioavailability of a single intake of standard hesperidin with a hesperidin 2S extract, 
which was specifically developed for its improved bioavailability. Secondly, we aimed to 
study the bioavailability of this hesperidin extract in more detail by conducting a placebo 
controlled trial in which participants received products for 5 consecutive days. Chapter 6 
investigates the potential role of hesperidin 2S in the regulation of endothelial function and 
blood pressure, while Chapter 7 reveals whether it has a role in glucose and insulin 
metabolism. Furthermore, local effects of hesperidin 2S on gastrointestinal environment were 
assessed. The last nutritional intervention we performed relates to PD01, a Bacillus indicus 
strain known to produce in vitro high amounts of carotenoids. Carotenoids are lipophilic 
antioxidants, and a potential preventive role of these antioxidants in the development of 
CVD has been proposed. Furthermore, in vitro data indicate that PD01 itself is able to 
modulate composition of gut microbiota. Hence, both the effects of the bacillus strain on 
microbiota composition and functioning and the effects of the carotenoids on CVD risk 
markers were explored (Chapter 8). 
Finally, Chapter 9 summarizes the main findings of all studies presented in this thesis, and 
discusses the new insights, future perspectives and potential implications for further research 
and future applications. 
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Abstract 
Background 
Aspergillus niger prolyl endoprotease (AN-PEP) efficiently degrades gluten molecules into non-
immunogenic peptides in vitro. 
 
Aim 
To assess the efficacy of AN-PEP on gluten degradation in a low and high calorie meal in healthy 
subjects. 
 
Methods 
In this randomised, double-blind, placebo-controlled, cross-over study 12 healthy volunteers attended 
to four test days. A liquid low or high calorie meal (4 g gluten) with AN-PEP or placebo was 
administered into the stomach. Via a triple-lumen catheter gastric and duodenal aspirates were 
sampled, and polyethylene glycol (PEG)-3350 was continuously infused. Acetaminophen in the meals 
tracked gastric emptying time. Gastric and duodenal samples were used to calculate 240-min area 
under the curve (AUC0-240min) of α-gliadin concentrations. Absolute α-gliadin AUC0-240min was 
calculated using duodenal PEG-3350 concentrations. 
 
Results 
AN-PEP lowered α-gliadin concentration AUC0-240min compared to placebo, from low and high calorie 
meals in stomach (low: 35 vs. 389 μg*min/ml; high: 53 vs. 386 μg*min/ml; P < 0.001) and duodenum 
(low: 7 vs. 168 μg*min/m.; high: 4 vs. 32 μg*min/ml; P < 0.001) and absolute α-gliadin AUC0-240min in 
duodenum from low (2,813 vs. 31,952 μg*min; P < 0.001) and high (2,553 vs. 13,095 μg*min; 
P = 0.013) calorie meals. In the placebo group, high compared to low calorie meal slowed gastric 
emptying and lowered duodenal α-gliadin concentration AUC0-240min (32 vs. 168 μg*min/ml; 
P = 0.001). 
 
Conclusions 
AN-PEP significantly enhanced gluten digestion in the stomach of healthy volunteers. Increasing caloric 
density prolonged gastric residence time of the meal. Since AN-PEP already degraded most gluten 
from low calorie meals, no incremental effect was observed by increasing meal caloric density. 
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Introduction 
Gluten is a storage protein present in wheat, barley and rye and is exceptionally rich in 
proline, rendering gluten peptides resistant to gastrointestinal digestion. Proline-cleaving 
proteases are absent in the human gastrointestinal tract. Therefore, long proline-rich gluten 
peptides reach the small intestine intact after ingestion.1 About 1% of the western population 
is suffering from celiac disease.2-5 In these patients, exposure of duodenum and proximal 
small intestine to the specific amino acid sequences of such poorly digested proline-rich 
gluten peptides triggers an abnormal immune response. This causes inflammation with 
infiltration of lymphocytes in the intestinal mucosa and ultimately villous atrophy and crypt 
hyperplasia.6 Adverse reactions to gluten consumption are not limited to subjects suffering 
from celiac disease. Presently non-celiac gluten sensitivity has been clinically recognized as 
a separate condition in which neither allergic nor autoimmune mechanisms are involved.7,8 
The symptoms experienced by these subjects are often identical to those seen in celiac 
disease.9,10 
A lifelong gluten-free diet is the only treatment for individuals who cannot tolerate gluten. 
However, a gluten-free diet is hard to comply with as gluten-free products may not always 
be labelled, and may not always be at hand during social events or travelling.11-13  
Prolyl endopeptidases belong to a family of enzymes with the ability to cleave at internal 
proline residues within a peptide.14 Early investigations on oral protease therapy as 
approach to degrade gluten have focused on bacterial prolyl oligopeptidases.15-18 
However, several in vitro studies conducted with such enzymes revealed only low 
enzymatic activity at acidic stomach pH and rapid degradation of these enzymes by 
pepsin.16 Moreover, these enzymes were not able to prevent passage of potentially harmful 
gluten fragments into the small intestine.16,19 But, other enzymatic preparations have shown 
to be capable of degrading complex gluten proteins both in vitro and in vivo.20-23 
In this respect, the Aspergillus niger-derived prolyl endoprotease (AN-PEP) also presents a 
promising option to degrade inadvertent dietary gluten. The use of the enzyme as food 
supplement has undergone successful evaluation by the French Agency for Food, 
Environmental and Occupational Health & Safety.24 AN-PEP is active between pH 2 and 6, 
with optimum activity at gastric pH between 3 and 5.19 In a dynamic, multi-compartmental 
gastrointestinal in vitro model, AN-PEP was shown to degrade almost all immunogenic 
gluten epitopes from gluten-containing meals into non-immunogenic fragments during 
passage through the stomach compartment.25 A pilot study in celiac patients showed that a 
combination of AN-PEP and gluten was safe and well tolerated.26 Before AN-PEP can be 
used as a future digestive aid for subjects intolerant to gluten, it is essential that the 
promising in vitro results are confirmed in a human in vivo study, focussing on duodenal 
gluten delivery after intake of gluten-containing meals with and without AN-PEP. Thereafter 
the efficacy and safety of AN-PEP should be evaluated in target populations.  
 Enzyme-mediated gluten digestion in humans 
35 
Our aim was to investigate the efficacy of AN-PEP on gluten degradation in an 
intragastrically delivered gluten-containing meal in healthy volunteers. To standardize meal 
intake, we administrated the meal intragastrically at a fixed rate instead of by oral ingestion. 
Secondly, we hypothesized that increasing the caloric density of a meal enhances gluten 
degradation by delaying gastric emptying and thereby prolonging gastric residence time of 
the meal. 
Materials and methods 
The study was approved by the Medical Ethics Committee of the Maastricht University 
Medical Center (MUMC+) and conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as revised in 2008 and with the Dutch Regulations on 
Medical Research involving Human Subjects (WMO, 1998). The study was performed at 
the MUMC+ from December 2011 to May 2012. All participants gave their written 
informed consent before participation. The trial has been registered in the Clinical Trials 
register (NCT01335503) and the Dutch trial register (NTR2780). 
Subjects 
Healthy volunteers aged 18-45 years were recruited by advertisement. All subjects were 
screened by means of a standardized general physical examination. Reasons for exclusion 
included: history of gastrointestinal disorders or gastrointestinal surgery interfering with 
gastrointestinal function; history of major disease, use of medication (except oral 
contraceptives) within 14 days before testing; dieting; pregnancy; lactation; excessive 
alcohol consumption (>20 alcoholic consumptions/week); and smoking. 
Design and intervention 
In this double-blind, randomized, placebo-controlled, crossover study, participants attended 
to four test days with at least 1 week washout period between two test days. At test days, 
participants were randomized in a double-blind fashion to 1 of the 24 possible orders of 
the four interventions; a low calorie gluten meal with AN-PEP or placebo, or a high calorie 
gluten meal with AN-PEP or placebo. The randomization list was generated by an 
independent and blinded statistician using a computerised procedure. All participants and 
investigators remained blinded to treatment until the analyses were completed. After an 
overnight fast, a triple-lumen catheter (adapted from Freka® Trelumina, Fresenius Kabi 
Nederland B.V., Zeist, The Netherlands) was introduced trans-nasally via the stomach into 
the duodenum, under fluoroscopic guidance. The proximal lumen, with an infusion port 
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positioned in the stomach, was used for administration of the test meal and aspiration of 
gastric contents. The second lumen, positioned 5 cm distal to the pylorus, was used for 
continuous perfusion of the inert dilution marker polyethylene glycol (PEG)-3350. The third 
and distal lumen (positioned at tip and located 15 cm distal to the pylorus) was used for 
aspiration of duodenal contents. The catheter position was secured by radiology and 
regularly checked during the tests by measuring pH of each aspirate. Meals, mixed with 
acetaminophen (Centrafarm B.V., Etten-Leur, The Netherlands), and either AN-PEP or 
placebo, were infused into the stomach over a 5-min period, at a rate of 80 ml/min. A PEG-
3350 (Norgine B.V., Amsterdam, The Netherlands) solution (15 mg/ml in 0.9% saline) was 
continuously infused into the proximal part of the duodenum at 3 ml/min to calculate the 
gluten amount corrected for dilution of duodenal content by endogenous secretions.27-30 
Infusion started 60 min prior to meal infusion, to achieve steady state conditions in fluid 
secretion and absorption at the start of meal infusion, and continued until 240 min. Gastric 
and duodenal content was sampled at baseline (t=0 min), and after start of meal infusion at 
t=15, 30, 45, 60, 75, 90, 120, 150, 180, 210 and 240 min. Gastric content was also 
aspirated at t=5 and t=10 min. Mixing of the meal with AN-PEP or placebo and 
acetaminophen was performed immediately prior to the start of infusion. Approximately 3 ml 
and 2 ml were aspirated from the gastric and duodenal port, respectively, for pH and 
gluten epitope measurements. Also, acetaminophen concentrations in gastric samples were 
measured. The samples were immediately frozen in liquid nitrogen to stop enzyme activity 
and were subsequently stored at -80°C until analysis.  
Gluten meals 
Dry meals were packaged in sachets of airtight tinfoil and stored at room temperature. On 
test days, meals were prepared at a food-grade kitchen facility. During preparation of the 
test meal, 1 g acetaminophen was added. Table 2.1 shows the composition of the meals. All 
test meals contained 5.2 g of gluten powder, of which 4.0 g was gluten protein (Syral, Aalst, 
Belgium). Encapsulated refined olive oil powder (Vana Grasa 80B, FrieslandCampina, Kievit 
B.V., Meppel, The Netherlands) was used as fat source for the meals and together with 
maltodextrin as additional energy source for the high calorie meal, and sodium caseinate 
(DMV, Veghel, The Netherlands) was used to match both meals for protein content. The dry 
meal powders were dissolved in a total volume of 300 ml tap water of 40°C by stirring with 
a spoon and subsequently mixing with a Turrax (IKA, Ultra Turrax® T25, Staufen, Germany). 
Low and high caloric meals were not blinded to the investigator. 
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Table 2.1 Recipe and nutritional composition of the low and high calorie test meal per 300 g portion. 
 Low calorie meal High calorie meal 
Vana Grasa (g)     7.0   22.0 
Sucrose (g)   17.0   16.9 
Maltodextrin (g)     0.0   36.3 
Caseinate (g)     0.7     0.3 
Gluten powder (g)     5.2     5.2 
Citric acid (g)     0.1     0.1 
Water (g) 270.9 245.1 
Protein (g)     4.9     4.9 
Fat (g)     5.7   17.7 
Carbohydrate (g)   18.0   56.5 
Ash (g)     0.2     0.5 
Protein (kcal)   19.6   19.6 
Fat (kcal)   51.6 159.6 
Carbohydrate (kcal)   71.9 225.8 
Total (kcal) 143.1 405.1 
Caloric density (kcal/g)     0.5     1.4 
Osmolarity (mOsm/kg) 194.8 373.6 
pH     6.0     6.0 
 
AN-PEP enzyme and placebo 
The AN-PEP enzyme was obtained from DSM Food Specialties (Delft, The Netherlands). A 
total of 6.1 ml of AN-PEP corresponding with 1.600.000 Protease Picomol International 
(1 Protease Picomol International is the amount of enzyme that releases one picomole of 
p-nitroaniline per second under defined assay conditions) in a total of 100 ml water was 
added to the 300 mL test meals. A 6.1 ml solution consisting of 4.8 g water, 1.3 g 
maltodextrin, 0.01 g caramel liquid (Brenntag, Deerlijk, Belgium), 0.03 g citric acid, and 
0.02 g sodium benzoate (Wuhan Youji, Wuhan, China) at pH 4.2, with a similar appearance 
to AN-PEP, served as placebo. 
Sample pre-treatment 
Upon thawing, the enzyme in the gastric and duodenal samples was immediately 
inactivated by increasing the pH of the sample to 11–12 using 1 M NaOH, heating at 
85°C for 10 min and neutralizing the pH with 1 M HCl. For the gluten content analysis, 
100 μl from each sample was frozen again at -80°C for further analysis by ELISA, or mixed 
with loading buffer (60% glycerol, 300 mM Tris, pH 6.8, 12 mM EDTA, pH 8.0, 12% sodium 
dodecylsulphate, 864 mM 2-mercaptoethanol, 0.05% bromophenol blue), boiled for 5 min 
for further analysis by Coomassie Blue staining and western blot.  
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Gluten monitoring by ELISA analyses   
The sample was diluted 40-5000 times in phosphate-buffered saline and the presence of 
the DQ2.5-glia-α3 epitope was quantified using the Gluten-Tec ELISA assay (EuroProxima 
B.V., Arnhem, The Netherlands) according to the manufacturer’s instructions.31 The DQ2.5- 
glia-α3 epitope is directly adjacent to the 33-mer that contains the immunodominant 
DQ2.5-glia-α1 and DQ2.5-glia-α2 epitopes. As the α-gliadins contain only a single copy of 
the DQ2.5-glia-α3 epitope, the measurement of this epitope provides an accurate estimate 
of the actual α-gliadin content of the samples.32  
Volume marker 
PEG-3350 concentrations were determined in samples obtained from the distal aspiration 
port in the duodenum, using reversed-phase HPLC in combination with evaporative light 
scatter detection. The analysis was based on PEG analysis as described by van Wijck et 
al.33 PEG-3350 concentrations were used to calculate the dilution of duodenal samples by 
endogenous secretions, using the formula described by Beglinger et al.27  
 
V = (F x [PEG]perfused x 15) / (PEGmeasured) 
 
V represents the calculated duodenal volume (ml per 15 or 30 min); F the flow rate of PEG 
solution perfused (3 ml/min); [PEG]perfused the concentration of PEG in the perfusate; 
PEGmeasured the concentration of PEG in the duodenal juice collected for 15 or 30 min. The 
number ‘15’ has to be replaced by ‘30’ if the time interval between two samples was 
30 min.  
To calculate the absolute duodenal gluten amount at a certain time point, the calculated 
duodenal volume was multiplied with the gluten concentration at that time point. 
Gluten monitoring by western blot 
Measurement of gluten epitopes by ELISA is an indirect method of gluten analysis. To 
confirm the presence of intact gluten proteins and relatively large fragments thereof we 
also performed Western blot analysis. The proteins present in samples isolated from the 
stomach were separated on SDS-PAGE, blotted onto polyvinylidenefluoride membrane and 
the gliadin proteins were visualized with a monoclonal antibody specific for the 
immunodominant DQ2.5-glia-α1 epitope.34 
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Presence of AN-PEP in gastric and duodenal samples 
To assess the presence of AN-PEP protein in gastric and duodenal samples, the protein in 
the samples was separated on SDS-PAGE followed by Coomassie Blue staining. 
Assessment of gastric emptying 
Gastric emptying rate was measured at all test days of 6 of the 12 participants who 
completed the study, randomly chosen. Gastric emptying rate was determined according to 
the changes of the acetaminophen concentration over time in the stomach, with stomach 
samples taken at predetermined time points. Gastric fluid samples were first deproteinated 
by adding a 10% solution of trichloroacetic acid. After centrifugation (800 g, 5 min) the 
supernatant was injected into an HPLC using a reversed-phase method with UV detection at 
250 nm (Agilent 1100 series HPLC Value System, Waldbronn, Germany). A composition of 
MilliQ and acetonitrile (97: 3%v/v) was used to elute the samples. As the total gastric 
volume changes constantly after meal ingestion, it was difficult to calculate the 
concentration via a formula. A calibration curve of acetaminophen was used to calculate 
the acetaminophen concentration in the samples. As a pragmatic approach, the total gastric 
emptying time (in minutes) was derived from this acetaminophen concentration-time curve. 
The time point when the acetaminophen concentration in a gastric sample is zero indicates 
the complete passage of the test meal into the duodenum and is thus considered to 
represent total gastric emptying time. 
Gastrointestinal symptoms questionnaire 
At the end of each test day, participants were requested to complete a ‘Symptoms Diary’, 
to ensure that all gastrointestinal complaints of the test day, caused by the intervention, 
were reported to the investigator. This questionnaire included 8 items, each rated on a five-
point Likert scale. The lowest score, 1, denotes no symptoms and 5 denotes the most 
pronounced symptoms. Items that were included in the ‘Symptoms Diary’ were: abdominal 
discomfort, abdominal pain, abdominal distension, constipation, diarrhoea, flatus, eructation 
and nausea. 
Statistics 
The primary outcome of this study was the effect of AN-PEP on gluten degradation, 
measured by the difference in the 240-min AUC (AUC0-240min) of duodenal gluten epitope 
concentration between AN-PEP and placebo. Secondly, we investigated the effect of AN-
PEP on gluten degradation, measured by the difference in AUC0-240min of absolute amounts 
of gluten epitopes in the duodenum between both interventions. The AUC0-240min was 
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calculated by using the trapezoidal equation. We calculated that a sample size of 
12 subjects would be required based on a standardized effect-size of 1.3, a power of 90%, 
and alpha = 0.05 (one sided). Seventeen subjects were recruited taking into account a drop-
out of 5 subjects. Baseline characteristics are presented as mean (SD) for numerical 
variables and number (%) for categorical variables. Differences in AUCs, gastric emptying 
rate and ‘Symptom Diary’ scores between combinations of treatment (AN-PEP or placebo) 
and meal (high or low calorie) were assessed using linear mixed models based on restricted 
maximum likelihood, where the natural logarithm of the AUCs was taken to account for the 
expected non-normality. The linear mixed model accounts for the correlation between 
repeated measures within a person (cross-over design) and missing data, where a likelihood 
approach was used assuming data missing at random. Fixed factors were treatment, meal, 
treatment*meal, and test-day. The best fitting covariance structure, i.e. structure of variances 
over different test-days and correlations between test-days, was based on Akaike’s 
Information Criterion. All statistical analyses were performed using IBM SPSS Statistics for 
Windows (Version 20.0, IBM Corp, Armonk, NY, USA). Two-sided P ≤ 0.05 were considered 
statistically significant. 
Results 
Study subjects 
A total of 12 healthy volunteers [67% male; age 26 ± 6 years; BMI (in kg/m2) = 22 ± 3] were 
included in the study. One of these subjects did not complete the fourth test day and only 
the results of the two high calorie meal test days were available for inclusion in the analyses. 
In two other subjects the catheter progressed more distally into the small intestine at one 
occasion, causing administration of (part of) the meal directly into the duodenum. Data of 
these experiments were omitted, but data from their remaining test days were still included 
in the analysis as the linear mixed model accounts for missing data. Initially 17 subjects were 
enrolled in the study, but 5 subjects dropped out due to discomfort related to the 
nasoduodenal tube. Data of drop-outs were omitted from analyses. 
pH of gastric samples 
The mean gastric pH of gastric samples, taken during test days when low and high calorie 
meals combined with AN-PEP were infused, ranged between 2.3 and 5.3 and was similar to 
the pH range of the samples of placebo-containing meals (data not shown). 
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DQ2.5-glia-α3 concentrations in stomach and duodenum and absolute 
amount in duodenum  
The mean DQ2.5-glia-α3 concentrations in stomach and duodenum samples after ingestion 
of low and high calorie meals with and without AN-PEP are shown in Figure 2.1 and the 
AUC0-240min in Table 2.2. The mean duodenal DQ2.5-glia-α3 concentrations per participant 
are shown in Figure 2.2. Over a 240-min period, AN-PEP reduced the gastric DQ2.5-glia-
α3 concentrations, compared to placebo, both after ingestion of the low (35 vs 389 
μg*min/ml; P < 0.001) and the high (53 vs 386 μg*min/ml; P < 0.001; Figure 2.1A and B; 
Table 2.2) calorie meals. This was also observed for duodenal DQ2.5-glia-α3 
concentrations (low calorie: 7 vs. 168 μg*min/ml; high calorie: 4 vs. 32 μg*min/ml; P < 0.001; 
Figure 2.1C and D; Table 2.2). In the placebo intervention, the duodenal DQ2.5-glia-α3 
concentrations were significantly lower after intake of a high compared to a low calorie 
meal (32 vs. 168 μg*min/ml; P = 0.001; Figure 2.1C and D; Table 2.2). In the presence of 
AN-PEP this difference was not present (4 vs. 7 μg*min/ml; P > 0.05; Figure 2.1C and D; 
Table 2.2) and low duodenal DQ2.5-glia-α3 concentrations were observed after intake of 
both a high and low calorie meal. The AUC0-240min of DQ2.5-glia-α3 concentrations in the 
duodenum of AN-PEP-receiving subjects was around or lower than the limit of detection 
(26.7 μg/l * 240 min= 7 μg*min/ml) and lower than the limit of quantification (89 μg/l * 240 
min= 21 μg*min/l) of the ELISA assay. The pattern for the duodenal DQ2.5-glia-α3 
concentrations corresponds with the data for absolute duodenal DQ2.5-glia-α3 amount, 
which is corrected for the dilution during the digestion process. AN-PEP lowered the 
calculated absolute duodenal α-gliadin compared to placebo in both low (2,813 vs. 31,952 
μg*min; P < 0.001) and high (2,553 vs. 13,095 μg*min; P = 0.013; Figure 2.1E and F; Table 
2.2) calorie meals. 
Gluten monitoring by western blot 
Western blot analysis of stomach samples indicated that gluten degradation 
was accelerated by the addition of AN-PEP. Compared to samples of placebo-containing 
meals, samples of AN-PEP-containing meals showed generally a markedly faster 
degradation of DQ2.5-glia-α1. In many cases, very little or even no gluten protein could be 
detected when AN-PEP was taken with the meal. In contrast, in gastric samples of placebo-
containing meals, in some cases DQ2.5-glia-α1 was still detectable up to 2 h after meal 
infusion. In duodenal samples, the Western blots were unable to detect significant amounts 
of intact gluten proteins, neither with AN-PEP, nor with placebo (Figure 2.3). This finding 
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suggests that in both cases little or no intact water insoluble gluten protein reaches the 
duodenum.  
Overall, for the majority of the meals analysed, the pattern on gluten degradation by both 
ELISA and Western blot showed a correlation, demonstrating the robustness of the study 
results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 A: DQ2.5-glia-α3 concentration (mean ± SEM) over time in the stomach in low calorie meals; 
B: DQ2.5-glia-α3 concentration (mean ± SEM) over time in the stomach in high calorie meals; 
C: DQ2.5-glia-α3 concentration (mean ± SEM) over time in the duodenum in low calorie meals; 
D: DQ2.5-glia-α3 concentration (mean ± SEM) over time in the duodenum in high calorie meals; 
 E: Absolute DQ2.5-glia-α3 output (mean ± SEM) over time in the duodenum in low calorie meals; 
 F: Absolute DQ2.5-glia-α3 output (mean ± SEM) over time in the duodenum in high calorie meals. 
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Figure 2.2 DQ2.5-glia-α3 concentration over time in the duodenum of the individual subjects in low calorie meals 
(LCM) and high calorie meals (HCM). (a) + (b): subject 5. (c) + (d): subject 6. (e) + (f): subject 7. (g) + (h): 
subject 10. (i) + (j): subject 11. (k) + (l): subject 12. (m) + (n): subject 13. (o) + (p): subject 14. (q) + (r): subject 
15. (s) + (t): subject 16. (u): subject 17. (v) + (w): subject 19. 
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Table 2.2 AUC0-240min of DQ2.5-glia-α3 concentrations in stomach and duodenum and the AUC0-240min of 
absolute DQ2.5-glia-α3 amount in duodenum. 
  Low calorie meal High calorie meal 
  Placebo AN-PEP Placebo AN-PEP 
AUC0-240min DQ2.5-glia-α3, μg*min/ml 
Stomach Mean 389 35 a 386 53 a 
 95% CI 180-840 17-73 192-775 25-113 
Duodenum Mean 168 7 a, d 32 b 4 a, e 
 95% CI 80-352 3-14 16-63 2-9 
AUC0-240min DQ2.5-glia-α3, μg*min/ml 
Duodenum Mean 31,952 2,813 a 13,095 2,553 c 
 95% CI 12,670-80,579 1,206-6,555 5,967-28,730 884-7,369 
a P < 0.001 compared to placebo; b P = 0.001 compared to low calorie placebo meal; c P < 0.05 compared to 
placebo; d Below the level of quantitation 21 μg*min/ml; e Below the level of detection 7 μg*min/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Representative Western blot showing degradation of water-insoluble DQ2.5-glia-α1 over time in 
the stomach and duodenum in low and high calorie meals with and without AN-PEP. 
 
Presence of AN-PEP in gastric and duodenal samples 
After administration of AN-PEP-containing meals, a band with AN-PEP’s characteristic 
molecular weight (66 kD) was visible in the gastric samples of 14 different test days 
(Figure 2.4). In the other test days, the AN-PEP signal was either too weak to be detected or 
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masked by other proteins with a similar electrophoretic mobility. In the placebo-containing 
meals, a band with this particular molecular weight was always absent (data not shown). 
With high calorie meals, AN-PEP was detectable for a longer period than with low calorie 
meals. AN-PEP was not found in the duodenal samples of any test day (Figure 2.4), possibly 
due to degradation of the enzyme by trypsin or chymotrypsin under conditions of high pH in 
the duodenum. 
 
 
 
 
 
 
 
 
 
 
Figure 2.4 Representative SDS-PAGE gel showing the presence of AN-PEP protein in gastric and duodenal 
aspirates. 
 
Gastric emptying 
The mean of total gastric emptying time of the high calorie meals was approximately twice 
as long as compared to the low calorie meals, being significantly different in the presence 
of placebo (172 vs. 88 min; P = 0.014) but not in the presence of AN-PEP (154 vs. 100 min; 
P = 0.100). 
Gastrointestinal symptoms questionnaire 
Mild gastrointestinal symptoms were reported on some occasions during low and high 
calorie meal intervention. Overall, discomfort was low for each different intervention. No 
significant differences were observed in reported gastrointestinal symptoms between meal 
types in combination with AN-PEP or placebo (data not shown). 
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Discussion 
In the current placebo-controlled intervention study, AN-PEP-mediated gluten digestion was 
studied in the stomach and duodenum of healthy volunteers. This is the first study showing 
that the AN-PEP enzyme efficiently degrades gluten from a meal in the stomach of human 
subjects.  
Considering the enzyme’s optimum pH range between 3 and 5, and the mean pH of the 
gastric samples ranged between 2.3 and 5.3 with both low and high calorie meals, this 
points to optimal enzyme activity during the entire digestive process in the stomach.19 
Irrespective of the caloric density of the meal, the enzyme degraded almost all gluten 
present in the stomach within a period of 1 hour whereas with placebo, gluten were 
present for 3 hours. Furthermore, the addition of AN-PEP did not result in differences in 
gastrointestinal-related symptoms compared to placebo, confirming that intake of the 
enzyme is safe and well tolerated by human subjects.26 
We also tested whether increasing meal caloric density would improve gluten degradation 
by delaying gastric emptying and thus prolonging exposure time of gluten proteins to AN-
PEP and endogenous gastric proteases. Whereas the low calorie meal in the stomach was 
emptied within about 1.5 hour, the gastric emptying of the high calorie meal took about 
twice as long. Delayed gastric emptying also resulted in longer gastric residence time of 
AN-PEP. These findings are in line with a previously reported delay in gastric emptying rate 
with increased meal caloric density in human subjects.35 Within 1 hour, AN-PEP degraded 
gluten to concentrations around or below reliably detectable levels, irrespective of meal 
caloric density. Without AN-PEP enzyme, high gluten concentrations were present in the 
stomach when given with a low or high calorie meal, supporting the notion that pepsin 
exerts only minimal proteolytic action on dietary gluten.36 Interestingly, in absence of the 
enzyme, less gluten reached the duodenum with high than with low calorie meals. Possibly, 
the fat content of the high calorie meals supported gluten digestion in the duodenum by 
increasing pancreatic enzyme outputs which has been described for high-fat as compared 
to low-fat diets.37 
We used a marker infusion technique to correct for dilutions resulting from biliary and 
pancreatic secretions that might have influenced the gluten concentrations measured in the 
duodenum. The absolute gluten values obtained, therefore, represent a better measure of 
true gluten exposure than the gluten concentrations. The absolute amount of gluten reaching 
the duodenum was significantly reduced with AN-PEP irrespective of meal caloric density, in 
line with the findings for gluten concentrations. The duodenal gluten degradation pattern 
was comparable between concentrations and absolute amounts suggesting little influence of 
duodenal dilutions. Insoluble gluten measurements confirmed that AN-PEP is able to 
significantly reduce gluten before entering the duodenum. 
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A band on SDS-PAGE with AN-PEPs characteristic molecular weight was observed in 
gastric, but not in duodenal aspirates, indicating AN-PEP is present and active in the 
stomach but not in the duodenum. Possibly, under duodenal neutral pH conditions, bile and 
pancreatic enzymes may have degraded the enzyme. 
Apart from AN-PEP, other enzymes detoxifying gluten are currently under investigation. A 
mixture of two proteases, namely PEP derived from Sphingomonas capsulate and a barley 
protease (EP-B2), termed ALV003 has previously been shown to be capable of degrading 
complex gluten proteins in vitro.20,23 In a human setting, ALV003 was well tolerated and 
effective in detoxifying 1 g of gluten.21 A recent study in celiac patients showed that 
ALV003 attenuated small intestinal mucosal injury induced by 6 weeks ingestion of 2 g 
gluten daily.22 Another protease mix, STAN-1, showed effective in vitro gluten-degrading 
properties.38 These enzymes have been investigated for their applicability as a future celiac 
disease drug therapy. 
This study made use of a triple lumen nasogastroduodenal catheter. This enabled the 
simultaneous administration of a test meal, infusion of a dilution marker, and aspiration of 
gastric and duodenal contents. Clear benefit of this approach is that it allowed us to 
measure the actual gluten concentration present in duodenum samples. This information is 
important for safe use in subjects intolerant to gluten. Further, by infusion of the dilution 
marker we could calculate the absolute intraduodenal gluten appearance. In none of 
previous mentioned studies, investigating other gluten-detoxifying enzymes, true gluten 
presence in the duodenum has been measured. To standardize each meal intake, AN-PEP 
was added to the meal and thereafter immediately infused intragastrically at a 
standardized rate, to avoid differences in gluten degradation during meal consumption 
between interventions, caused by variable meal ingestion rates. We acknowledge that this 
does not represent a fully physiological meal setting, in which solid food and AN-PEP are 
ingested separately and undergo the normal physiologic processes of mixing in the stomach. 
A randomized placebo-controlled trial is underway in which the efficacy of AN-PEP in an 
actual meal setting will be investigated. Furthermore, this technique also has another 
drawback. Migration of the catheter, due to gastrointestinal peristalsis, caused erroneous 
infusion of the meal into the duodenum in two subjects at one occasion, as was noted based 
on pH profiles. These data were excluded from analysis. 
The AN-PEP enzyme has been developed as a dietary supplement that in conjunction with 
a gluten-free diet may help subjects intolerant to gluten to digest unintended dietary gluten. 
Despite these promising results, the data do not prove that AN-PEP allows subjects 
intolerant to gluten to ingest gluten safely. Oral enzymes cannot replace a gluten-free diet, 
yet our observations suggest that AN-PEP may be useful as a digestive aid to help digest 
hidden gluten. The enzyme may protect against unintentional ingestion of gluten on a daily 
basis, during social events or travelling. A randomized placebo-controlled trial is underway 
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to address AN-PEP’s efficacy in the target population which is necessary prior to AN-PEP’s 
use to be considered safe and effective.  
In conclusion, AN-PEP efficiently degrades gluten from a meal in the stomach of healthy 
volunteers before entering the duodenum. Increasing the caloric density of a gluten meal 
slowed gastric emptying rate and prolonged gastric residence time of the enzyme. Since 
AN-PEP with a low calorie meal already degraded almost all gluten, a high calorie meal 
could not further increase the efficacy of the enzyme to digest gluten. 
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Abstract 
The use of paracetamol as tool to determine gastric emptying was evaluated in a cross-over study. 
Twelve healthy volunteers were included and each of them consumed two low and two high caloric 
meals. Paracetamol was mixed with a liquid meal and administered by a nasogastric feeding tube. The 
post prandial paracetamol plasma concentration time curve in all participants and the paracetamol 
concentration in the stomach content in six participants were determined. It was found that after 
paracetamol has left the stomach, based on analysis of the stomach content, there was still a 
substantial rise in the plasma paracetamol concentration time curve. Moreover, the difference in 
gastric emptying between high and low caloric meals was missed using the plasma paracetamol 
concentration time curve. The latter curves indicate that (i) part of the paracetamol may leave the 
stomach much quicker than the meal and (ii) part of the paracetamol may be relatively slowly 
absorbed in the duodenum. This can be explained by the partition of the homogenous paracetamol-
meal mixture in the stomach in an aqueous phase and a solid bolus. The aqueous phase leaves the 
stomach quickly and the paracetamol in this phase is quickly absorbed in the duodenum, giving rise to 
the relatively steep increase of the paracetamol concentration in the plasma. The bolus leaves the 
stomach relatively slowly, and encapsulation by the bolus results in relatively slow uptake of 
paracetamol from the bolus in the duodenum.  
These findings implicate that paracetamol is not an accurate post prandial marker for gastric 
emptying. The paracetamol concentration time curve rather illustrates the food-drug interaction on 
absorption, which is not only governed by gastric emptying. 
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Introduction 
In order to display a systemic biological effect most compounds first have to be absorbed 
from the gastro-intestinal tract. The onset of the effect depends heavily on the rate of 
absorption. Absorption mainly takes place once the compound has reached the intestine. 
Gastric emptying is considered to be the bottleneck in uptake, and numerous studies have 
been conducted on the effect of nutrition and disease on this process. 
Paracetamol is the number one tool for monitoring gastric emptying.1 To assess gastric 
emptying, paracetamol is mixed through a meal. After ingestion, the meal containing 
paracetamol will enter the stomach, and the meal is digested. Gradually the meal-
paracetamol mixture passes through the pyloric sphincter into the duodenum. The large 
surface area, the peristaltic movement, the relatively thin membrane and the rich blood 
supply of the intestine enable rapid uptake in the duodenum. It is assumed that paracetamol 
will be absorbed almost immediately after leaving the stomach. Moreover, it is assumed that 
the passage time of paracetamol through the stomach is identical to that of the meal. Based 
on these assumptions, the rate of paracetamol uptake into the plasma would be governed 
by gastric emptying and consequently gastric emptying might be deduced from the time 
course of the plasma concentration of paracetamol.2-5 
This approach with paracetamol as marker molecule is regarded as an established and well 
validated method and is extensively applied. The wide application and acceptance of the 
procedure, might explain why a critical attitude is lacking. Often, only a small number of 
samples (sometimes even only one) is taken which will give only a rudimentary kinetic profile. 
Surprisingly, only a few studies addressed the validity of the method.6,7 In the most extensive 
literature review on the subject is was stated that “it is a simple, noninvasive, and 
economical method, making it suitable for application on a larger scale but further research 
should be performed under standardized conditions to allow wide scale clinical use”.6 
Moreover, in a recent study, we obtained data which are in conflict with the widely 
accepted model which prompted us to carefully evaluate the use of paracetamol as post 
prandial marker for gastric emptying. This revealed two major pitfalls, i.e. (i) part of the 
paracetamol may leave the stomach much quicker than the meal and (ii) part of the 
paracetamol may be relatively slowly absorbed after entering the duodenum. 
Materials and methods 
Clinical study 
In the randomized cross-over study “Aspergillus niger-derived enzyme effectively digests 
gluten in the stomach of healthy volunteers”8 (December 2011 to May 2012) gastric 
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emptying was assessed with the use of paracetamol. The healthy volunteers attended four 
test days with at least one week washout period between two test days. On two test days 
the volunteers were given a low caloric meal (143 kcal), administered via a nasogastric 
feeding tube (Freka® Trelumina, Fresenius Kabi Nederland b.v., Zeist, The Netherlands). One 
of the two low caloric meals given to each of the volunteers was mixed with Aspergillus 
niger-derived prolyl endoprotease (AN-PEP). On the other two test days a high caloric meal 
(405 kcal) was administered. Also one of the two high caloric meals given to each of the 
volunteers was mixed with AN-PEP. The AN-PEP treatment had no effect on the 
paracetamol data and therefore the results of the meal treated with AN-PEP were 
combined with that of the meal that was not treated.  
Prior to administration, 1000 mg paracetamol was added to the meals and the meal was 
thoroughly mixed. The rate of gastric emptying was determined using two different 
strategies. The common strategy is based on the paracetamol plasma concentration. Blood 
samples were taken 0, 10, 15, 30, 60, 90, 120, 150, 180, 210 and 240 minutes after 
administration of the meal. Further details regarding materials and methods are described 
earlier by Salden et al..8 The flow diagram of the study is presented in Figure 3.1.  
A total of 12 (8 male and 4 female) healthy volunteers (average age 26 ± 6 years, average 
BMI 22 ± 3 kg/m2) were included in the study. One of these subjects did not complete the 
fourth test day. In two other subjects the catheter progressed more distally into the small 
intestine on one occasion (based on the high pH of the sample), indicating that (part of) the 
meal was directly administered into the duodenum. These experiments were omitted, but the 
other experiments of these subjects were included in the data analysis. Initially 17 subjects 
were enrolled in the study, but 5 subjects dropped out due to discomfort related to the 
nasoduodenal tube. Data of dropouts were omitted from analyses. 
The amount of paracetamol taken up on 10 and 240 minutes after intake was derived from 
the area under concentration-time curve in all subjects. The second strategy to determine 
gastric emptying was based on the paracetamol concentration in the content of the 
stomach. Samples were aspirated from the stomach on 15, 30, 45, 60, 75, 90, 120, 150, 
180, 210 and 240 minutes after intake. In 6 subjects a complete set of stomach samples 
could be obtained, and the paracetamol content of the stomach samples of these subjects 
was determined. Paracetamol metabolites were not determined, because the aim of the 
study was to evaluate the use of paracetamol as tool for gastric emptying. The paracetamol 
concentration-time curve derived from the HPLC analysis of the sample was used to 
determine gastric emptying.9  
The fractionation of paracetamol in the stomach was mimicked by adding 100 μl HCl-
solution (0.01 M) to 400 μl of the meal to obtain a pH of 2. After centrifugation the pellet 
was resuspended in a sodium-phosphate buffer of pH 7.4 and centrifuged again. In both 
supernatants the paracetamol concentration was determined using HPLC.  
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The study has been approved by the Institutional Review Board of Maastricht University, 
and all clinical investigations have been conducted according to the principles expressed in 
the Declaration of Helsinki. Written informed consent has been obtained from the 
participants. The study has been registered as NTR2780 in the Dutch trialregister 
(Nederlands Trialregister). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1 Consort Flow Diagram of the study. 
Determination of paracetamol 
For the determination of the paracetamol concentration, the samples were deproteinated 
by adding trichloroacetic acid. After centrifugation (800 x g, 5 minutes) the supernatant was 
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analyzed using reversed phase HPLC with UV detection at 250 nm. The eluent was a 
mixture of MilliQ and Acetonitrile (97: 3% v/v). The quality control samples as well as the 
calibration curves were well within the specifications for pharmacokinetic studies.10 For each 
subject and each treatment, an extra control sample taken before the administration of 
Paracetamol was taken. In none of these control samples interfering peaks were observed. 
The analyses were performed blinded to the study. 
Statistics 
The concentration time curve was statistically evaluated in Prism 6 (GraphPad Software, La 
Jolla, USA). Differences in pharmacokinetic parameters between groups were analyzed 
using ANOVA. Post-hoc testing was performed using a paired t-test with Bonferroni 
correction. A P < 0.05 was considered to be statistically significant. 
Results 
A liquid meal was administered as a slurry by a nasogastric feeding tube. Paracetamol was 
mixed through the meal prior to administration for monitoring gastric emptying. 
Subsequently, the concentration of paracetamol in plasma was determined post prandial. In 
six volunteers, also the concentration of paracetamol in the content of the stomach was 
determined. 
Partition of the paracetamol 
The paracetamol level in plasma rose after administration of the meal, until it reached a 
maximum concentration (Cmax) relatively quickly with the low caloric meals. After reaching 
Cmax, the concentration time curve of paracetamol in plasma showed a biphasic exponential 
decay. Surprisingly, the exponential decay immediately after reaching Cmax was higher 
compared to that at a later stage (P < 0.05). An illustration of this kinetic profile is given in 
Figure 3.2A. 
From the plasma paracetamol data the amount of paracetamol which was taken up was 
calculated. It appeared that in most subjects, already within 15 minutes, an unexpected high 
amount of paracetamol was absorbed, even up to 70% of the total dose (Figure 3.2). The 
uptake in two phases indicates that paracetamol, administered mixed with the meal, is 
divided into two fractions. One fraction enters quickly the duodenum and is responsible for 
the fast uptake. The other fraction apparently stays relatively long in the stomach and is 
responsible for the relatively slow uptake.  
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Figure 3.2 The plasma paracetamol concentration in time after administration of a low or high caloric meal 
containing 1 g paracetamol via a nasogastric tube. (● ) (Panel A, low caloric meal; panel B, high 
caloric meal). A typical example is shown. The inserts show the uptake of paracetamol based on the 
plasma concentration curve (● ) and the concentration of paracetamol detected in the stomach 
content (● ) (panel A, low caloric meal; panel B, high caloric meal). 
Encapsulation of part of the paracetamol by the meal 
To further investigate the fractionation of paracetamol, a hydrochloric acid solution (to 
obtain a pH of 2) was added to the low caloric meal containing paracetamol in a test tube 
to mimic the condition in the stomach. The obtained mixture was centrifuged and two thirds 
of the paracetamol was retrieved in the supernatant. The pellet was mixed with buffer 
(150 mM sodium phosphate buffer, pH 7.4) and centrifuged again. This extract of the pellet 
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appeared to comprise approximately one tenth of the original amount of paracetamol 
(Figure 3.3). Similar results were obtained with the high caloric meal instead of the low 
caloric meal (data not shown). These experiments substantiate that in the stomach the 
paracetamol is divided into two fractions, which are (i) a fraction in which paracetamol is 
dissolved in the liquid content of the stomach and (ii) a fraction in which paracetamol is 
encapsulated by the contents of the meal that precipitate in the acid environment of the 
stomach. 
The conclusion is corroborated when the plasma concentration in time is compared to the 
level of paracetamol detected in the content of the stomach. A slow, but substantial 
paracetamol uptake in the plasma occurs even when the paracetamol has left the stomach, 
as shown in Figure 3.2. This indicates that slow release in the intestine of the paracetamol 
that is encapsulated by a meal, is a rate-limiting process in the uptake. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3 Encapsulation of paracetamol by the meal. The meal containing paracetamol was mixed with a 
hydrochloric acid solution (pH 2) in a test tube to mimic the conditions in the stomach. After 
centrifugation two thirds of the paracetamol was retrieved in the supernatant. Extraction of the 
pellet with buffer (150 mM sodium phosphate buffer, pH 7.4) released one tenth of the 
paracetamol. 
 
High and low caloric meals 
In our study, high and low caloric meals were given to the volunteers. The rate of gastric 
emptying of these meals was estimated from the plasma paracetamol concentration and the 
concentration of the first time point (10 minutes) was used for this. After 10 minutes a 
substantial amount of paracetamol, on average 35%, was taken up. No difference was 
found in the 10 minutes paracetamol concentrations between the low and high caloric 
meal, suggesting that gastric emptying did not differ between both types of meal (Figure 
3.4A). Also after 240 minutes, the plasma paracetamol data indicate that there is no 
difference in gastric emptying between the low and high caloric meals (Figure 3.4B). 
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The time at which no paracetamol was detected in the stomach content is a direct measure 
for gastric emptying. These stomach data show that gastric emptying was statistically longer 
with the high caloric meal compared to the low caloric meal (Figure 3.4C). The lower gastric 
emptying of a high caloric meal compared to that of a low caloric meal is well documented, 
and this difference is confirmed by the longer retention of paracetamol in the stomach 
samples after the high caloric meal compared to that after the low caloric meal. The 
difference between the low and high caloric meal is not observed in the gastric emptying 
determined using the plasma paracetamol concentration (Figure 3.4).11  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Discrepancy in gastric emptying deduced from the paracetamol plasma data and deduced from 
content in the stomach. The amount of paracetamol  taken up after 10 min (panel A) and 240 min 
(panel B) calculated form the concentration time curve of paracetamol in plasma do not show a 
difference between the high and low caloric meals. However, the time needed for gastric emptying 
determinded by the paracetamol content of the stomac (panel C), show a clear difference in gastric 
emptying between the high and low caloric meals. * different form the high caloric value (P < 0.05). 
Discussion 
In the present study, the use of paracetamol as tool for gastric emptying is evaluated. The 
nasogastric feeding tube which was used in our experimental set up, assured that the 
complete and homogeneous meal/paracetamol mixture was in the stomach at the start of 
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the experiment. After administering the meal, a relatively steep initial increase in the plasma 
concentration of paracetamol was seen, indicative for a relatively quick uptake. After the 
quick initial rise, the plasma paracetamol concentration demonstrated a more prolonged, 
gradual uptake of paracetamol in the blood. Even when all paracetamol has left the 
stomach, based on analysis of the stomach content, there was still a slow but substantial rise 
uptake with all meals and in all volunteers. That there still is a substantial uptake of 
paracetamol when all of the paracetamol has left the stomach, already indicates that the 
plasma paracetamol levels do not only reflect gastric emptying. 
The biphasic time course of the paracetamol curve can be explained by the division of 
paracetamol into two fractions after entering the stomach, a fraction that is encapsulated 
by the meal and a fraction that is dissolved in the liquid content of the stomach. The 
aqueous phase is expected to leave the stomach quickly and paracetamol in an aqueous 
phase is readily absorbed in the duodenum. Deduced from the relatively high and early 
peak in the plasma paracetamol time course, most paracetamol is in this aqueous phase. This 
is corroborated by the test tube experiment, whereby acid is added to the meal and only a 
small part of the paracetamol remains in the solid content of the meal that precipitates. 
Apparently, the steep initial increase of paracetamol plasma concentration should not be 
mistaken for a rapid gastric emptying which would give an overestimation of the rate of 
gastric emptying.  
Part of the paracetamol is encapsulated by the meal and this fraction might be used to 
determine the gastric emptying. However, after all paracetamol has passed the stomach, still 
a slow uptake of paracetamol in the plasma is detectable. This indicates that the 
paracetamol is not instantaneously taken up once the meal containing paracetamol reaches 
the duodenum. Apparently, paracetamol encapsulated by the meal is only slowly released 
from the bolus and this slow release appears to be the bottleneck in paracetamol uptake in 
our experiment. This is also corroborated by the test tube experiment, paracetamol 
encapsulated by the meal after acid precipitation is only partial released by an extraction. 
The slow release of the encapsulated paracetamol is probably also the result of the 
relatively high viscosity of the bolus, which reduces the rate of absorption in the intestine.3, 11-
13 In fact, the bioaccessibility, i.e. the release of the compound from the matrix in the 
intestine, is the rate limiting factor for absorption. This was previously also observed for 
phenolic compounds in bread.14  
It is well established that the rate of gastric emptying of high caloric meals is slower than 
that of low caloric meals.15 This is confirmed by the paracetamol concentration time course 
in the stomach in our study that does demonstrate a slower rate of gastric emptying for the 
high caloric meals. However, the plasma paracetamol data fail to reflect this difference in 
gastric emptying of low and high caloric meals. This confirms that for the meals studied, the 
plasma paracetamol concentration time curve is not a valid marker for gastric emptying.  
Chapter 3 
64 
Although plasma paracetamol concentrations are an inappropriate measure of the gastric 
emptying, by definition the paracetamol concentration time curve does reflect the 
absorption of paracetamol. Actually, our study shows the effect of food on the rate of 
absorption of paracetamol. The absorption of a drug in the gastrointestinal tract bears 
major clinical relevance. Often it is advised to take medication in combination with or after 
a meal to avoid a peak concentration which would prevent side effects and possible 
toxicity. Our study shows that this is not necessarily the case. In case of enteral feeding still a 
relatively high peak concentration can arise. Moreover, the duration of the effect might be 
extended by encapsulation of the drug by the meal and the slow release of the drug from 
the drug-meal bolus. 
Food-drug interactions are not limited to an effect of food on gastric emptying; apparently, 
it also includes separation of the drug into different fractions, which has an impact on both 
the onset and duration of the pharmacotherapeutic effect. However, in studying food-drug 
interactions, it is important to realize that a drug might be separated in two fractions which 
have a large difference in their rate of absorption. In the use of paracetamol plasma levels 
as a post prandial marker for gastric emptying, the food-drug interaction on absorption may 
lead to incorrect conclusions. 
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Abstract 
Background & aims 
Obesity and metabolic diseases are associated with alterations in microbial composition and impaired 
gut barrier. Previous in vitro and animal studies have shown that arabinoxylans (AX) have the potential 
to modulate gut microbiota and gut barrier and therefore could have a protective role. Primary aim of 
the study was to investigate the effect of AX on intestinal permeability. Secondary aims included the 
effect of AX on gene transcription and protein expression of tight junctions (TJ), intestinal microbiota 
composition and activity, immune response and metabolic markers in overweight and obese 
individuals. 
 
Methods 
In this randomized, double-blind, placebo-controlled trial, 47 overweight subjects were randomly 
assigned to groups receiving 7.5 g/d AX (n = 16), 15 g/d AX (n = 17) or 15 g/d placebo (n = 14) for 
6 wks. Intestinal permeability was investigated using a multi-sugar test. Sigmoid colon tissue was 
obtained from a subgroup (n = 26) for analyzing gene transcription and mucosal expression of TJ 
proteins. Fecal samples were collected to assess microbial composition and activity. Furthermore, the 
production of cytokines by stimulated peripheral blood mononuclear cells (PBMCs) was examined. 
Blood was also sampled for measuring metabolic markers. 
 
Results 
No significant changes in gastrointestinal permeability and TJ protein expression were observed after 
6 wks AX supplementation compared to placebo. However, gene transcription of occludin was 
upregulated in the 7.5 g AX group, and transcription of claudin-3 and claudin-4 were upregulated in 
the 15 g AX group compared to placebo. Furthermore, fecal microbiota diversity was decreased 
after 6 wks 15 g AX treatment, but no change in relative abundance of dominant phyla was 
observed. AX intake significantly decreased fecal pH and increased fecal concentrations of total 
SCFAs, acetate, propionate and butyrate, compared to placebo. Additionally, a decreased TNFα 
production by stimulated PBMCs was observed after 15 g AX treatment. No changes in metabolic 
markers were detected. 
 
Conclusions 
Regular consumption of AX resulted in a more beneficial fermentation profile in overweight and obese 
individuals. Further studies are required to assess whether such fermentation profile will translate into 
improved gut barrier function and immune health. 
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Introduction 
The gastrointestinal (GI) epithelial barrier is a complex system that includes an active local 
immune defense, a physical barrier comprised of a network of epithelial cells which are 
connected by tight junction (TJ) proteins to control permeability, a mucus layer, secretion of 
antimicrobial peptides, intestinal microbiota and luminal microbial metabolism.1 Recent 
research has focused on intestinal microbiota and their effects on intestinal physiology, 
nutrient digestion, luminal metabolism and immune function.2 Short-chain fatty acids (SCFA) 
are the end products of fermentation of non-digestible carbohydrates by intestinal 
microbiota and have an important role in maintenance of intestinal homeostasis. Changes in 
gut microbiota composition may affect gut barrier function via changes in expression, 
localization and distribution of TJ proteins, thereby influencing gut permeability.3 Changes in 
gut barrier function are regarded as early events or triggers in the development of various 
intestinal diseases, and also in the development of systemic metabolic diseases, such as 
diabetes mellitus type 2 (DM2) and cardiovascular diseases (CVD).4 
Modulation of gut microbial communities by prebiotics appears to be an interesting concept 
to enhance the gut barrier, to treat or even prevent the onset or aggravation of chronic 
diseases. Prebiotics are non-digestible food ingredients selectively stimulating growth and/or 
activity in the GI microflora conferring potential health benefits to the host.5 A limitation of 
most prebiotics is their rapid fermentation in the proximal colon. Arabinoxylans (AX), the most 
abundant non-digestible carbohydrates present in wheat, form a novel class of potential 
prebiotics.6 Due to their structure, AX rely on a whole spectrum of (microbial) enzymes for 
degradation. They are more gradually fermented along the colon, resulting in more distal 
fermentation.6,7 AX exist in different forms, ranging from long-chains to enzymatically 
modified short-chain fractions. In vitro research has shown that the AX form affects the 
fermentation pattern and immune function, high-molecular weight AX being most active.7,8 
Promising outcomes of high-molecular weight AX on the gut barrier,9,10 gut microbiota,9,11,12 
immune system9 and metabolic markers9 have been shown both in in vitro and in animal 
studies. To date, no human data are available on the combined effect of such AX on 
intestinal environment, gut barrier and immune system.  
Therefore, the purpose of this study was to investigate the effects of a high-molecular 
weight AX concentrate on the gut barrier, intestinal microbiota, immune system and 
metabolic control in humans in overweight and obese individuals. We hypothesized that 6 
wks AX supplementation ameliorates the gut barrier, improves colonic microbiota 
composition and its metabolic activities, improves the immune system, enhances metabolic 
control and is well-tolerated in overweight and obese individuals. We specifically chose to 
study an overweight and obese population, as overweight and obesity are associated with 
an impaired gut barrier function. Primary aim of this study was to investigate the effect of 
AX on intestinal permeability, measured by a multi-sugar test. Secondary, we aimed to 
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investigate the effect of AX intake on gene transcription and protein expression of TJ, on 
fecal microbiota composition and fecal pH, ammonium and SCFA concentrations, on 
cytokine production by stimulated peripheral blood mononuclear cells (PBMCs), on blood 
concentrations of glucose, insulin and lipids, and on GI tolerance. 
Materials and methods 
The Medical Ethics Committee of the Maastricht University Medical Center (MUMC+) 
approved the trial and the study was performed at the MUMC+ from March 2012 to 
December 2012 in full accordance with the principles of the Declaration of Helsinki of 
1964 as amended in 2013 and with the Dutch Regulations on Medical Research involving 
Human Subjects (WMO, 1998). Before participation all participants provided written 
informed consent. 
Subjects 
Healthy overweight and obese volunteers aged 18-70 y with a BMI between 28-35 kg/m2 
were recruited by local advertisement. Key exclusion criteria were: any medical condition 
that might interfere with the study and might jeopardise the health status of the participant; 
smoking; abuse of alcohol (>20 consumptions/wk) and drugs; no consistently stable body 
weight for at least 6 months (± 2 kg); plans to lose weight or following an energy restriction 
diet during study period; use of medication, vitamin- or mineral supplements, consumption of 
pro-, pre- or synbiotics during study period; use of antibiotics in the 90 days prior to start of 
the study; pregnancy and lactation; history of any side effects towards the intake of pro-, 
pre-, or synbiotic supplements of any kind. Throughout the trial, subjects consumed their 
habitual diet. Before start of the study, subjects were informed about the prohibited pre-, 
pro- and synbiotics and the food products containing them. 
To assess the difference in GI permeability between this study population and a group of 
age and sex matched healthy lean subjects, we used the GI permeability data obtained 
with exactly the same protocol in healthy controls. These data have recently been published 
by our group.13 
Design and intervention 
This study was set up as a randomized, placebo-controlled, double-blind, parallel group 
study. Each subject was tested on three occasions, while a subset of these subjects 
additionally provided sigmoid mucosal tissue samples on two separate occasions. 
Participants were randomly assigned in a double-blind fashion to one of the three 
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intervention arms: 7.5 g AX, 15 g AX or a placebo (15 g maltodextrin). An independent and 
blinded person generated the randomization list, using a computerized method. All 
participants and investigators remained blind to intervention until all analyses were finalized.  
Participants were instructed to refrain from consumption of alcohol and strenuous physical 
exercise on the day before each test day. After an overnight fast, subjects handed in a 
fecal sample on the first test day. Fecal samples were collected one day before or on a test 
day, and stored at -20°C until arrival at the study site. Subsequently, venous blood samples 
were collected from an antecubital vein in the fore-arm. Then, subjects ingested a multi-
sugar drink, to assess gastrointestinal permeability, and collected full urine output for 24 h. A 
subset of the participants underwent a standard flexible sigmoidoscopy without bowel 
preparation on the second test day. Seven mucosal tissue samples of approximately 5 mg 
each were obtained from the sigmoid colon by using a standard forceps (diameter: 2.8 mm) 
and directly after collection frozen in liquid nitrogen. Two tissue samples were embedded in 
Tissue-tek (Sakura Finetek, Tokio, Japan) prior to freezing for immunohistochemical analyses. 
After completion of the baseline measurements, participants received the study product for 
the first 3 wks. After 3 wks of daily supplementation, the third test day was organized. 
Again, a fecal sample was handed in, blood samples were taken and study products for 
another 3 wks were provided. After 6 wks of daily administration of the study product, the 
fourth and fifth test days took place. Measurements were identical to the baseline 
measurements performed during the first and second test days, respectively. The same 
subgroup of subjects underwent again a sigmoidoscopy. Also, all participants had to 
complete a questionnaire at weekly intervals, to assess the presence of GI symptoms, stool 
frequency and stool consistency. To assess compliance, participants were asked to collect 
the empty sachets and to return these at the last visit.  
AX concentrate and placebo 
BioActor BV (Maastricht, The Netherlands) supplied AX with a purity of 62%, degree of 
substitution of 0.7, and a varying degree of polymerization, with an average above 60; the 
composition of the batch used for the study was 67% non-starch polysaccharides (62% AX), 
18% protein, 0.5% lipids, 3.8% ash. Maltodextrin (Glucidex IT 19; Roqette Frères, Lestrem 
Cedex, France) served as placebo. The study products were provided to subjects as a 
powder in sachets. The placebo group received per day two sachets, each containing 7.5 g 
Maltodextrin, the 7.5 g AX group received per day two sachets, each containing 3.75 g AX 
combined with 3.75 g Maltodextrin and the 15 g AX group received per day two sachets, 
each containing 7.5 g AX. Subjects were asked to stir the content of one sachet in 200 ml 
liquid (e.g. juice, water, milk) and ingest the solution twice daily (every morning and every 
evening) for 6 wks. 
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Gastrointestinal permeability 
GI permeability was investigated using a validated multi-sugar test, quantifying 24-h urinary 
excretion of five different ingested sugars reflecting the permeability of 4 segments of the 
GI tract. Firstly, fasted volunteers emptied their bladder and drank the multi-sugar drink, 
consisting of 1 g lactulose (Centrafarm, Etten-Leur, the Netherlands), 0.5 g L-rhamnose 
(Danisco, Copenhangen, Denmark), 1 g erythritol (Now Foods, Bloomindale, IL, USA), 1 g 
sucralose (Brenntag, Sittard, the Netherlands) and 1 g sucrose (Van Gilse, Dinteloord, the 
Netherlands) dissolved in 150 mL tap water. Participants were instructed to collect their 24 
h urine output in two different fractions; one fraction containing the 0–5 h urine output and a 
second fraction containing the 5–24 h urine output. It was not allowed to ingest any foods 
or drinks, except for water, throughout the first urine fraction (0-5 h) collection. 
Gastroduodenal and small intestinal permeability were reflected by the 0-5 h urinary 
sucrose excretion and the lactulose and L-rhamnose (L/R) ratio, respectively. In the 5-24 h 
urine, the sucralose to erythritol (S/E) ratio represented colonic permeability, while in the 0-
24 h urine it indicated whole gut permeability. After collection of the 24 h urine output, total 
volume was quantified and urine aliquots were frozen at -80°C. Urinary sugars were 
analysed using HPLC-MS as reported earlier.14 The intestinal permeability test and the 
analysis of urine samples in the study of Mujagic et al.13 was performed in exactly the same 
way and done by the same research group as in our study. 
Gene transcription of TJ and associated proteins 
Gene transcription of TJ and associated proteins (claudin-3, claudin-4, occludin, myosin 
light-chain kinase (MLCK) and zonula occludens-1 (ZO-1)) in sigmoid colon tissue samples 
was determined by quantitative real-time polymerase chain reaction, as earlier presented 
by Pijls et al.15 Housekeeping genes included GAPDH and 18S RNA. Data are shown as 
normalized expression ratios. 
Protein concentrations of claudin-3 
Sigmoid mucosal tissue was used for the determination of claudin-3 protein concentrations. 
Biopsy specimens were kept in liquid nitrogen and ground in a nitrogen cold mortar. The 
powder was gently scraped with a spatula of the auger and dissolved in 150 μl phosphate-
buffered saline (PBS) (Invitrogen 10010, pH 7.4) containing protease inhibitor cocktail 
(Sigma P8340) with a concentration from 10 μl PI/ml PBS and centrifuged for 20 min at 
10,000 rpm at 4°C. Supernatant was stored at -80°C. The concentration of claudin-3 was 
determined with the sandwich ELISA kit for human claudin-3 (CloudClone Corp., Houston 
USA Kit: SEF293Hu). The microtitre plate provided in this kit was precoated with an 
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antibody specific to claudin-3. Standards of samples (samples were 1 to 5 diluted) were 
added to the suitable microtitre plate wells together with a claudin-3 specific 
biotin-conjugated antibody. Then, avidin conjugated to horseradish peroxidase was applied 
on each microplate well and incubated. Subsequently tetramethylbenzidine substrate 
solution was added, and only the wells containing claudin-3, biotin-conjugated antibody 
and enzyme-conjugated avidin exhibited a color change. Addition of sulphuric acid solution 
ended the enzyme-substrate reaction. The change in color was quantified using 
spectrophotometry (wavelength: 450 nm ± 10 nm). The concentrations of claudin-3 in the 
tissue was defined by comparison of the O.D. of the tissue sample to that of the standard 
curve. Total protein determination in the sigmoid tissue was done using Pierce® BCA Protein 
Assay Kit (ThermoFisher, Waltham, MA USA). Samples were 1 to 15 diluted. Data are 
presented as pg claudin-3 per ug total protein. 
Immunofluorescence staining of ZO-1 and occludin 
Immunofluorescent staining of ZO-1 and occludin was done as presented earlier.16 Leica 
TCS SPE confocal microscopy (Leica Micro systems GmbH, Mannheim, Germany) was used 
to analyse images. Obtained images were quantified by calculating the AUC. Briefly, to 
assess the fluorescent staining of both TJ proteins in the TJ region, mucosal tissue was 
exposed to confocal analysis of Z regions perpendicular to the apical cell surface of the 
epithelium. Three randomly selected areas within 3 different Z regions were analyzed. The 
middle part of the villi was used for analyzing the staining. Image J software created the 
plot profiles reflecting staining intensity and AUC was calculated using Matlab R2013a 
software (Natick, MA, USA). 
Microbiota composition and activity 
DNA extraction 
To extract DNA from fecal samples (100 mg) samples were resuspended in 1 mL of lysis 
buffer (Tris/HCl (100 mM pH 8.0), 100 mM EDTA, 100 mM NaCl, 1% (wt/vol) 
polyvinylpyrrolidone and 2% (wt/vol) SDS). Cells were lysed in a Fast Prep®-24 instrument 
(MP Biomedicals, Solon, OH, USA) for 30 s at 1800 rpm and extractions were performed 
using phenol-chloroform-isoamyl alcohol (25:24:1). DNA was precipitated with ice-cold 
isopropanol and resuspended in 100 μl of TE buffer (10 mM Tris-HCl, 1 mM EDTA [pH 
8.0]). The amount and quality of DNA was measured using an ND 1000 spectrophotometer 
(ThermoFisher, Waltham, MA, USA). 
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Gut microbiota composition 
We used 16S targeted DNA-based Illumina with MiSeq platform to assess the gut 
microbiome structure in the fecal samples. Primers for the 16S rRNA gene amplified the 
hypervariable region V1-V2. After sequencing, quality filtering was performed as previously 
described and sequences were taxonomically annotated using RDP database with 80% 
threshold.17 Sequencing depth was normalized to the minimum reads per sample, using the 
Phyloseq package from R. Rarefaction curves and biodiversity indices were calculated using 
the vegan package from R. Rarefaction curve analysis showed that the use of at least 
10.000 reads was sufficient to sample the complete diversity of the library. 
The following metrics of alpha diversity were determined: observed richness, Shannon 
diversity index and Simpson evenness. Beta diversity was assessed by Bray-Curtis (BC) 
dissimilarity. BC is an ecological diversity index representing the extent of change in 
microbiota composition. This index takes into consideration both the bacterial taxa detected 
in a specimen, and their relative presence. 
Fecal pH, ammonium and SCFA determination 
Fecal samples were collected by the participants and stored at -20°C until handed in at the 
study site. For SCFA and ammonium analyses, aliquots of approximately 1 g of fecal 
samples were diluted and homogenized with 6 mL demineralized water. After removal of 
the particulate material by centrifugation (10 min, 500 x g), the supernatants were stored at 
-20°C prior to analysis. SCFA concentrations in the supernatants were determined using gas 
chromatography with flame ionization detector, based on the SCFA concentration analysis 
described by Possemiers et al..18 The sum of acetate, propionate, butyrate, isobutyrate, 
valerate, isovalerate, caproate and isocaproate represent total SCFA. Ammonia 
concentrations in the supernatants were measured using the method previously presented.19 
To determine fecal pH, an aliquot of approximately 1 g feces was homogenized by mixing 
into 10% (w/w) demineralized water. Directly after homogenization pH was assessed. 
Production of cytokines by stimulated peripheral blood mononuclear cells 
Blood was collected in sodium heparine tubes (Becton & Dickinson, Franklin Lakes, NJ, USA) 
and used within 1 h for the isolation of PBMCs. To examine ex vivo cytokine production by 
PBMCs, cells were isolated from whole blood and stimulated with Phytohemagglutinin-M 
(PHA). PHA-stimulation is used to bind antigen-presenting cells and T-cells and thereby PHA 
induces T-cell proliferation. This technique is used to enlarge the current activities of the 
T-cells present in the culture. Lymphoprep gradient centrifugation was performed according 
to the manufacturer’s instructions (Takeda Nederland B.V., Hoofddorp, The Netherlands). 
Freshly isolated cells were diluted in RPMI 1640 culture medium containing HEPES and 
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L-glutamine (ThermoFisher, Waltham, MA USA), with 1% added Penicillin/Streptomycin, 
Sodium Pyruvate, and heat inactivated human serum pool. Cells were seeded 1*106 in 
24-well flat bottom culture plates (Greiner Bio-One B.V., Alphen a/d Rijn, The Netherlands) 
and T-cell proliferation was stimulated with PHA (Roche Diagnostics Nederland B.V., 
Almere, The Netherlands). After 48 h, the culture medium was harvested and stored at 
-80°C until further analysis. Interferon-gamma (IFNγ) was measured using a sandwich ELISA 
according to the manufacturer’s instructions (eBioscience, Vienna, Austria). IL-2, IL-10, 
IL-12p40 and TNFα were measured with a multiplex chemoluminescence assay (Meso 
Scale Diagnostics, Rockville, Maryland USA). 
Blood lipids, glucose and insulin 
Blood samples were collected at baseline, after 3 wks of supplementation and at the end of 
the supplementation period. Serum concentrations of glucose, total cholesterol, LDL- and 
HDL-cholesterol and triglycerides were measured using spectrophotometry. Plasma insulin 
was determined using a luminescence-enhanced immunoenzymatic assay. Insulin sensitivity 
was estimated by the quantitative insulin sensitivity check index (QUICKI) index as: 1 / (log 
insulin 0 h + log glucose 0 h). 
Gastrointestinal tolerance 
The gastrointestinal symptom rating scale (GSRS) was used to assess the presence of GI 
symptoms. This questionnaire consists of 15 seven-point graded items that can be combined 
into 5 symptom clusters reflecting reflux, abdominal pain, indigestion, diarrhea, and 
constipation. The absence of troublesome symptoms is represented by a score of 1, while a 
score of 7 reflects very inconvenient GI symptoms.20 Defecation frequency and stool 
consistency were assessed using the Bristol stool chart. Subjects completed these 
questionnaires at weekly intervals during the study period. 
Statistical analyses 
The primary outcome of the study was the effect of 6 wks 7.5 g AX and 15 g AX 
supplementation on GI permeability, compared to placebo. Secondary outcomes include 
the effect of 6 wks AX supplementation versus placebo on gene transcription and protein 
expression of TJ, fecal microbiota composition and activity, cytokine production by PBMCs, 
metabolic markers and on GI tolerance. Sample size was determined for the primary 
outcome of the study, using a significance level alpha = 0.017 and a power of 80%. A study 
in diet-induced obese mice, investigating the effect of a dietary fiber on GI permeability,21 
was used for calculating the sample size. To detect a difference in intestinal permeability of 
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0.3 ± 0.25 μg/ml (mean ± SD) a total of 45 subjects would be required. Baseline 
characteristics are displayed as mean (SD) for numerical variables. Baseline values in age 
and BMI between overweight and obese individuals and lean controls were compared 
using independent t-test, and baseline numbers in sex were evaluated with chi-square test. 
Differences in gut barrier (function), fecal pH, relative abundance of main phyla of the fecal 
microbiota, alpha diversity metrics, fecal SCFA concentrations, immune response, blood 
parameters and digestive tolerance between placebo and 7.5 g AX and placebo and 15 g 
AX were assessed using linear mixed models with group (placebo, 7.5 g AX and 15 g AX), 
time (0, 3 and 6 wks for AX effect) and group*time as fixed factors, where an unstructured 
covariance structure was used for repeated measures. The linear mixed model accounts for 
the correlation between repeated measures and missing data, where a likelihood approach 
was used assuming data missing at random. 
GI permeability data were not normally distributed, as assessed by Shapiro-Wilk Test. 
Mann-Whitney U test was used to evaluate the difference in baseline GI permeability 
between healthy lean and overweight and obese individuals. Statistical analysis was 
performed using IBM SPSS Statistics for Windows (version 21.0, Armonk, NY, USA).  
R language for statistical computing [http://www.R-project.org] was used for normalizing 
sequencing depth, calculating rarefaction curves and biodiversity indices. It was also used to 
generate exploratory heat maps, using the heatmap.2 function from the R package gplots 
on logarithmic transformed data. To determine the effect of intervention on the shared 
diversity between samples, beta diversity metrics (BC dissimilarity) were calculated for 
placebo versus 7.5 g AX and placebo versus 15 g AX. A Principal coordinate analysis 
(PCoA), based on the BC similarity distances, was used in order to visualize the microbial 
variation among placebo, 7.5 g AX and 15 g AX. A two-way crossed analysis of similarity 
(ANOSIM) was used to determine if the microbial communities were significantly different 
between treatment groups. These analyses were performed using PAleontological STatistics 
version 3.11 (PAST, Øyvind Hammer, Natural History Museum, University of Oslo). For all 
comparisons, two-sided p-values ≤ 0.05 were considered statistically significant. 
Results 
Study subjects 
A total of 47 healthy volunteers were enrolled in the study; 14 subjects were assigned to 
the placebo group, 16 subjects to the AX 7.5 g group and 17 subjects to the AX 15 g 
group. Forty-five volunteers completed the entire study protocol. One participant dropped 
out during the intervention period because of a pneumonia and consequent antibiotic 
treatment. The second dropout developed gallstones during the study period and had to 
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undergo surgery. From these participants only baseline characteristics were available 
(Online Supplemental Material Figure S4.1). Sigmoidoscopy was performed in 9 
participants in the placebo group, 9 participants in the 7.5 g AX group and 8 participants in 
the 15 g AX group. Baseline characteristics are presented in Table 4.1. 
Data of a group of 33 lean age and sex matched controls, derived from Mujagic et al.,13 
were used to evaluate differences in GI permeability between lean and overweight/obese 
subjects. 
 
Table 4.1 Baseline characteristics in the overweight and obese study population, and lean controls. 
 Overall cohort  
(n = 47) 
Placebo  
(n = 14) 
AX 7.5 g  
(n = 16) 
AX 15 g 
(n = 17) 
Lean controls 
(n = 33) 
Age (y) 48 ± 16 49 ± 17 49 ± 17 47 ± 15 42 ± 3 
Sex (M/F) 25/22 8/6 10/6 7/10 13/20 
BMI (kg/m2) 31.0 ± 2.4 31.4 ± 3.1 30.2 ± 1.9 31.5 ± 2.2 22.0 ± 0.31 
Sigmoidoscopy (n) 26 9 9 8 n/a 
Differences in age and BMI between overall cohort and lean controls tested with independent t-test, differences in 
sex between overall cohort and lean controls tested with chi-square test. Data are given as mean ± SD. P < 0.001 
overall cohort vs. lean controls. AX, arabinoxylans. 
 
Gastrointestinal permeability 
Baseline GI permeability was significantly increased in our healthy, but overweight 
population, compared to an age and sex matched healthy, lean population (all P < 0.001, 
Table 4.2). 
 
Table 4.2 Gastrointestinal permeability, reflected by urinary sugar excretion (μmol) and ratios of excreted 
sugars (in 0-5, 5-24 and 0-24 h fraction) for lean, and overweight and obese subjects. 
Sugar excretion Lean (n = 33) Overweight & obese (n = 45) P value 
0-5 h sucrose 2.06 [0.51; 6.91] 7.75 [4.68; 13.91] <0.001 
0-5 h L/R ratio 0.016 [0.009; 0.036] 0.050 [0.030; 0.108] <0.001 
5-24 h S/E ratio 0.009 [0.006; 0.015] 0.018 [0.014; 0.023] <0.001 
0-24 h S/E ratio 0.010 [0.005; 0.014] 0.020 [0.014; 0.024] <0.001 
Differences between lean subjects and overweight and obese subjects tested with Mann-Whitney U test. Data are 
given as median [IQR, i.e. Q1; Q3]. L/R, lactulose/l-rhamnose. S/E, sucralose/erythritol. 
 
Six weeks effect 
Table 4.3 presents the effect of 6 wks intervention on GI permeability. Gastroduodenal 
permeability, as indicated by the sucrose excretion in the 0-5 h urine fraction, did not 
significantly change after both 7.5 g AX and 15 g AX supplementation compared to 
placebo (all P ≥ 0.224). Neither was the 0-5 h urinary L/R ratio, reflecting small intestine 
permeability, altered after the AX interventions compared to placebo (all P ≥ 0.219). 
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Colonic and whole gut permeability, respectively reflected by the S/E ratio in 5-24 h and 
the 0-24 h urine fractions, did not show significant differences among AX and placebo 
groups after 6 wks supplementation (all P ≥ 0.257). 
 
Table 4.3 Gastrointestinal permeability, reflected by urinary sugar excretion (μmol) and ratios of excreted 
sugars (in 0-5, 5-24 and 0-24 h fraction) at baseline and after 6 wks supplementation. 
Sugar excretion  Intervention Baseline End P value 
Placebo 5.43 [3.97;8.74] 7.10 [4.99; 11.75]  
7.5 g AX 10.76 [8.39; 21.89] 12.52 [8.38; 17.55] 0.256 
0-5 h sucrose  
15 g AX 7.05 [3.38; 13.24] 7.88 [4.99; 9.29] 0.224 
Placebo 0.045 [0.030; 0.073] 0.065 [0.038; 0.170]  
7.5 g AX 0.070 [0.040; 0.120] 0.060 [0.048; 0.135] 0.464 
0-5 h L/R ratio 
15 g AX 0.050 [0.030; 0.115] 0.065 [0.040; 0.095] 0.219 
Placebo 0.020 [0.014; 0.025] 0.018 [0.016; 0.023]  
7.5 g AX 0.016 [0.012; 0.020] 0.020 [0.013;0.024] 0.766 
5-24 h S/E ratio 
15 g AX 0.020 [0.014; 0.026] 0.017 [0.013; 0.024] 0.810 
Placebo 0.020 [0.015; 0.025] 0.017 [0.015; 0.020]  
7.5 g AX 0.018 [0.014; 0.022] 0.018 [0.013; 0.025] 0.257 
0-24 h S/E ratio 
15 g AX 0.020 [0.014; 0.024] 0.016 [0.014; 0.024] 0.986 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model with correction for baseline 
values. Data are given as median [IQR, i.e. Q1; Q3]. AX, arabinoxylans. L/R, lactulose/l-rhamnose. S/E, 
sucralose/erythritol. 
 
Gene transcription of TJ and associated proteins  
Results regarding the effects of AX administration on gene transcription of TJ and 
associated proteins are given in Table 4.4. Transcription of claudin-3 and claudin-4 was 
significantly upregulated in participants receiving daily 15 g AX for 6 wks, compared to 
participants receiving placebo (P = 0.012 and P = 0.046 respectively). Furthermore, a trend 
towards upregulation of the TJ protein occludin was seen after 15 g AX intake compared to 
placebo (P = 0.057). In the 7.5 g AX group we observed a significant upregulation of 
occludin compared to placebo (P = 0.031). No significant changes in gene transcription for 
MLCK and ZO-1 between both AX groups and the placebo group were observed (all P ≥ 
0.087). 
Protein concentration of claudin-3, ZO-1 and occludin 
At baseline, protein concentrations of claudin-3 were 6.10 ± 0.61 (mean ± SEM), 4.92 ± 
0.41 and 7.02 ±1.49 pg claudin-3 per ug protein for placebo, 7.5 g AX and 15 g AX 
respectively. Protein concentration of ZO-1 and occludin in biopsies were quantified by 
calculating an AUC. At baseline, AUCs of ZO-1 were 159 ± 34 (mean ± SEM), 126 ± 33 
and 177 ± 41 and of occludin 112 ± 19, 142 ± 35 and 140 ± 29 for placebo, 7.5 g AX 
and 15 g AX respectively. No significant differences were observed in sigmoid protein 
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concentrations of claudin-3, ZO-1 and occludin between placebo and AX interventions 
after 6 wks supplementation (all P ≥ 0.144, data not shown). 
 
Table 4.4 Gene transcription of TJ and associated proteins (expressed as normalised expression ratios) at 
baseline and after 6 wks supplementation. 
Baseline End Gene 
transcription 
Intervention 
Mean SD Mean SD 
Difference 
in means 
95% CI P value 
Placebo 1.13 0.06 1.12 0.04    
7.5 g AX 1.09 0.04 1.13 0.03 0.02 -0.01, 0.05 0.225 
Claudin-3 
15 g AX 1.12 0.05 1.16 0.04 0.05 0.01, 0.08 0.012 
Placebo 1.13 0.04 1.11 0.03    
7.5 g AX 1.10 0.04 1.12 0.03 0.02 -0.01, 0.05 0.152 
Claudin-4 
15 g AX 1.10 0.05 1.13 0.04 0.03 0.00, 0.06 0.046 
Placebo 1.08 0.06 1.08 0.03    
7.5 g AX 1.06 0.03 1.10 0.03 0.03 0.00, 0.06 0.087 
MLCK 
15 g AX 1.06 0.06 1.09 0.05 0.02 -0.01, 0.05 0.236 
Placebo 1.14 0.05 1.14 0.02    
7.5 g AX 1.13 0.03 1.17 0.03 0.04 0.00, 0.07 0.031 
OCLN 
15 g AX 1.15 0.07 1.17 0.05 0.03 -0.01, 0.07 0.057 
Placebo 1.17 0.05 1.17 0.04    
7.5 g AX 1.15 0.04 1.19 0.04 0.02 -0.01, 0.05 0.197 
ZO-1 
15 g AX 1.14 0.05 1.17 0.04 0.01 -0.02, 0.05 0.516 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model. The presented difference in 
means is corrected for baseline differences. AX, arabinoxylans. MLCK, myosin light-chain kinase. OCLN, occludin. 
ZO-1, zonula occludens. 
 
Gut microbiota composition 
From 37 study participants (placebo: n=12; 7.5 g AX: n = 9; 15 g AX: n = 15) gut microbiota 
composition data were available. Data of 8 participants were not available because there 
was no amplification in sequencing or data were removed due to quality control issues. 
Phylum relative abundance 
16S targeted DNA-based Illumina with MiSeq platform allowed to obtain at least 30.000 
usable reads per sample. The dominant phyla across all baseline fecal samples were 
firmicutes (mean 52.5%, SD 10.5%) and bacteroidetes (mean 36.0%, SD 10.1%), followed by 
proteobacteria (mean 7.7%, SD 7.6%) and actinobacteria (mean 3.0%, SD 2.9%). The relative 
abundance of these four dominant phyla did not change significantly after 6 weeks intake 
of 7.5 g AX or 15 g AX, compared to placebo (all P ≥ 0.061; Figure 4.1). 
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Figure 4.1 Relative abundance of the main phyla according the 16S-targeted Illumina data for placebo, 7.5 g 
AX and 15 g AX at baseline (0), after 3 wks supplementation (3) and after 6 wks supplementation 
(6). No significant differences in relative abundance between placebo, 7.5 g AX and 15 g AX were 
during study period observed, as tested with linear mixed model with correction for baseline values. 
AX, arabinoxylans. 
 
Fecal samples alpha diversity 
Six wks treatment with the two dosages AX did not change the Simpson evenness index, 
compared to placebo (all P ≥ 0.063, Table 4.5). However, 6 wks intake of 15 g AX but not 
7.5 g AX significantly reduced the observed richness and lowered Shannon diversity, 
compared to placebo (P = 0.029 and P = 0.036 respectively, Table 4.5). Six wks treatment 
with 7.5 g AX or 15 g AX versus placebo did not change the Simpson evenness index.  
Microbiota composition and taxon distribution 
The PCoA analyses, based on the BC (dis)similarity matrix of the bacterial community 
sequence data, per test day are shown as Online Supplemental Material Figure S4.2, S4.3 
and S4.4. In order to see if treatment during study period significantly altered fecal 
microbial composition, a two-way ANOSIM was performed. Two-way ANOSIM applying 
the BC coefficient showed no significant differences for treatment (P = 0.746) using time as 
factor. The heat map analysis showed that variations observed were not linked to a specific 
dosage of the test product and were masked by the interindividual variability among 
subjects. The cluster dendrogram showed that, with a few exceptions mainly related to the 
15 g AX, samples from the same donor cluster together at baseline, after 3 wks intervention 
and end of the study, irrespective of the treatment received (data not shown). 
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Table 4.5 Observed richness, Shannon diversity and Simpson evenness indices at baseline and after 6 wks 
supplementation. 
Baseline End Indices 
 
Intervention 
Mean SD Mean SD 
Difference 
in means 
95% CI P value 
Placebo 295.3 21.4 285.2 44.9    
7.5 g AX 301.4 49.3 287.8 33.1 -1.9 -39.1, 35.3 0.918 
Observed richness 
15 g AX 272.4 40.3 235.8 62.5 -36.7 -69.3, -4.0 0.029 
Placebo 4.13 0.28 4.05 0.33    
7.5 g AX 4.28 0.37 4.03 0.31 -0.11 -0.41, 0.20 0.473 
Shannon diversity 
15 g AX 4.08 0.25 3.75 0.43 -0.29 -0.55 -0.02 0.036 
Placebo 0.96 0.02 0.96 0.02    
7.5 g AX 0.97 0.02 0.94 0.03 -0.01 -0.04, 0.01 0.278 
Simpson evenness 
 
15 g AX 0.96 0.01 0.94 0.03 -0.02 -0.04, 0.00 0.063 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model. The presented difference in 
means is corrected for baseline differences. AX, arabinoxylans. 
 
Fecal pH, ammonium and SCFA concentrations 
Data regarding fecal pH, ammonium and SCFA concentrations are depicted in Table 4.6. 
Fecal pH was significantly reduced after 6 wks 7.5 g AX supplementation, compared to 
placebo (P = 0.012). Six wks daily intake of both 7.5 g and 15 g AX increased the 
concentration of total SCFA, compared to a decrease in the placebo group, the difference 
being statistically significant (7.5 g AX: P = 0.012; 15 g AX: P = 0.006). The same was 
observed for fecal concentrations of acetate (7.5 g AX: P = 0.038; 15 g AX: P = 0.016) and 
butyrate (7.5 g AX: P = 0.001; 15 g AX: P = 0.030). Fecal propionate concentrations 
significantly increased in the 15 g AX group, compared to placebo (P = 0.026). AX intake 
versus placebo did not affect fecal ammonium concentrations (7.5 g AX: P = 0.111; 15 g AX: 
P = 0.370). No significant differences between interventions were seen in fecal pH, 
ammonium and SCFA concentrations after 3 wks supplementation (all P ≥ 0.082, data not 
shown). 
Production of cytokines by stimulated peripheral blood mononuclear cells 
Production of the pro-inflammatory cytokine TNFα by stimulated PBMCs was significantly 
reduced after 6 weeks 15 g AX intake (P = 0.035; Table 4.7) compared to placebo. No 
significant differences were found regarding the production of the other measured 
cytokines (all P ≥ 0.176; Table 4.7). 
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Table 4.6 Fecal pH, ammonium (mg/l) and short-chain fatty acid concentrations (μmol/g feces) at baseline and 
after 6 wks supplementation. 
 Intervention Baseline End P value 
Placebo 7.3 [7.0; 7.6] 7.7 [7.3; 8.1]  
7.5 g AX 7.1 [6.8; 7.5] 7.0 [6.9; 7.4] 0.013 
pH 
15 g AX 7.2 [6.9; 7.9] 7.4 [6.9; 7.7] 0.086 
Placebo 58.5 [46.1; 74.5] 44.8 [34.7; 59.9]  
7.5 g AX 53.8 [45.8; 69.7] 55.4 [41.9; 91.4] 0.111 
Ammonium 
15 g AX 43.4 [28.2; 60.8] 51.8 [31.5; 88.1] 0.370 
Placebo 67.4 [46.4; 97.0] 59.1 [31.7; 63.8]  
7.5 g AX 63.6 [50.0; 86.2] 71.6 [54.7; 88.3] 0.012 
SCFA: total 
15 g AX 49.3 [33.7; 72.5] 59.2 [41.8; 80.3] 0.006 
Placebo 34.8 [29.2; 49.9] 31.2 [17.4; 35.4]  
7.5 g AX 35.6 [28.6; 44.7] 35.0 [25.4; 53.3] 0.038 
SCFA: acetate 
15 g AX 27.8 [17.9; 40.1] 34.0 [23.0; 44.5] 0.016 
Placebo 11.1 [7.7; 18.4] 9.8 [6.1; 12.2]  
7.5 g AX 11.5 [8.7; 17.0] 12.5 [9.0; 15.5] 0.229 
SCFA: propionate 
15 g AX 10.2 [6.4; 17.0] 12.7 [8.4; 17.6] 0.026 
Placebo 9.0 [6.1; 27.4] 6.7 [3.7; 9.9]  
7.5 g AX 10.9 [8.7; 14.3] 11.9 [9.4; 17.0] 0.001 
SCFA: butyrate 
15 g AX 6.9 [4.5; 15.2] 7.4 [5.2; 14.6] 0.030 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model with correction for baseline 
values. Data are given as median [IQR, i.e. Q1; Q3]. AX, arabinoxylans. SCFA, short-chain fatty acids. 
 
 
Table 4.7 Cytokine production by stimulated PBMCs (ng/mL) at baseline and after 6 wks supplementation. 
Cytokine production  Intervention Baseline End P value 
Placebo 29.8 [5.0; 75.5] 48.8 [12.6; 419.2]  
7.5 g AX 14.2 [9.3; 59.3] 38.7 [2.5; 104.5] 0.176 
IFNγ 
15 g AX 54.9 [26.5; 85.3] 49.5 [10.7; 87.7] 0.211 
Placebo 15.2 [0.9; 38.2] 7.5 [1.2; 23.6]  
7.5 g AX 0.3 [0.1; 7.3] 5.3 [0.2; 41.1] 0.427 
Il-2 
15 g AX 10.7 [0.4; 53.4] 1.5 [0.2; 49.9] 0.489 
Placebo 6.7 [2.6; 18.6] 12.8 [11.4; 27.1]  
7.5 g AX 3.8 [1.5; 10.1] 5.3 [3.2; 18.4] 0.205 
Il-10 
15 g AX 8.3 [5.0; 18.3] 11.5 [5.6; 17.2] 0.402 
Placebo 0.02 [0.01; 0.16] 0.05 [0.02; 0.17]  
7.5 g AX 0.02 [0.01; 0.03] 0.04 [0.02; 0.06] 0.210 
Il-12p40 
15 g AX 0.02 [0.01; 0.07] 0.02 [0.00; 0.06] 0.861 
Placebo 72.9 [44.5; 147.6] 97.2 [52.4; 119.3]  
7.5 g AX 56.9 [28.6; 103.4] 61.9 [34.0; 138.7] 0.708 
TNFα 
15 g AX 83.0 [50.5; 96.0] 60.9 [27.4; 77.6] 0.035 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model with correction for baseline 
values. Data are given as median [IQR, i.e. Q1; Q3]. AX, arabinoxylans. IFN, interferon. TNF, tumor necrosis factor. 
 
Blood lipids, glucose and insulin 
At baseline, total cholesterol, LDL- and HDL-cholesterol, triglycerides, free fatty acids, 
glucose and insulin lied within normal blood value ranges. These parameters were not 
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significantly altered by either 3 wks or 6 wks supplementation with 7.5 g or 15 g AX 
compared to placebo (all P ≥ 0.083; Table 4.8). Subsequently, no change between 
intervention groups was observed regarding insulin sensitivity (all P ≥ 0.768, Table 4.8). 
 
Table 4.8 Blood lipids (mmol/l), glucose (mmol/l), insulin (pmol/l) and QUICKI at baseline and after 6 wks 
supplementation. 
Baseline End Metabolic markers Intervention 
Mean SD Mean SD 
Difference 
in means 
95% CI P value 
Placebo 5.39 1.00 5.37 1.24    
7.5 g AX 5.83 1.00 5.71 1.05 -0.11 -0.49, 0.27 0.563 
Total cholesterol 
15 g AX 5.59 0.80 5.46 0.99 -0.12 -0.49, 0.25 0.524 
Placebo 3.26 0.77 3.29 0.95    
7.5 g AX 3.67 0.83 3.56 0.99 -0.14 -0.52, 0.23 0.442 
LDL-C 
15 g AX 3.39 0.75 3.16 0.90 -0.26 -0.62, 0.10 0.148 
Placebo 1.42 0.31 1.46 0.35    
7.5 g AX 1.44 0.41 1.41 0.41 -0.06 -0.20, 0.08 0.357 
HDL-C 
15 g AX 1.60 0.36 1.64 0.45 0.00 -0.14, 0.13 0.972 
Placebo 1.57 0.58 1.37 0.51    
7.5 g AX 1.79 1.32 2.06 2.11 0.41 -0.08, 0.90 0.102 
Triglycerides 
15 g AX 1.32 0.64 1.47 0.82 0.42 -0.06, 0.89 0.083 
Placebo 5.38 0.49 5.39 0.66    
7.5 g AX 5.54 0.90 5.36 0.50 -0.08 -0.45, 0.28 0.659 
Glucose 
15 g AX 5.26 0.54 5.12 0.38 -0.24 -0.59, 0.12 0.186 
Placebo 75.8 29.8 62.4 26.3    
7.5 g AX 124.8 250.5 68.3 33.9 3.74 -25.4, 32.9 0.797 
Insulin 
15 g AX 70.7 35.9 68.4 48.7 6.26 -22.4, 34.9 0.661 
Placebo 0.26 0.01 0.27 0.02    
7.5 g AX 0.26 0.02 0.27 0.02 -0.0018 -0.01, 0.01 0.768 
QUICKI 
15 g AX 0.27 0.02 0.27 0.02 0.0003 -0.01, 0.01 0.963 
Differences between placebo, 7.5 g AX and 15 g AX tested with linear mixed model. The presented difference in 
means is corrected for baseline differences. AX, arabinoxylans. QUICKI, quantitative insulin sensitivity check index. 
 
Gastrointestinal tolerance 
No significant differences between intervention groups regarding reported GI symptoms 
were observed during the study (all P ≥ 0.118, data not shown). Mean scores remained 
under 2 during all treatments, which means that the participants during intervention 
experienced no troublesome symptoms. Neither 7.5 g nor 15 g AX significantly affected 
stool frequency or consistency throughout the entire study period (all P ≥ 0.271, data not 
shown). 
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Discussion 
In this study, we have shown that GI permeability is compromised in overweight and obese 
individuals when compared to lean controls. Six wks intake of 7.5 g or 15 g AX per day did 
not affect GI permeability, as assessed by the multi-sugar test. Although no differences were 
found in the relative abundance of the dominant phyla, intake of 15 g AX resulted in 
reduced microbial richness and diversity, when compared to placebo. AX supplementation 
increased fecal SCFA concentrations. Furthermore, 7.5 g AX intake significantly lowered 
fecal pH. This modulation of the intestinal luminal environment may positively affect the gut 
barrier, as reflected by upregulation in the transcription of different TJ proteins in sigmoid 
biopsies, although we did not detect significant changes in TJ protein expression. The 
decreased TNFα production by stimulated PBMCs in the high dose (15 g) AX group points 
to downstream positive anti-inflammatory effects.  
Evidence indicating that obesity is associated with an impaired gut barrier is mainly derived 
from animal models.3 Human studies on gut barrier and obesity are scarce, and results 
contradictory.22,23 Here, we showed that gut permeability is increased in obese compared 
to lean healthy volunteers. AX treatment did not affect gastroduodenal, small intestinal, 
colonic or whole gut permeability, as assessed with a multi-sugar test. However, 
interpretation of these results must be done with caution as permeability testing with sugars 
might be influenced by individual differences in gastric emptying and intestinal transit time, 
parameters we did not measure in these participants. Furthermore, although we aimed to 
examine a homogenous study population, possible confounders (i.e. lifestyle, sex) could have 
affected permeability results. Prebiotics, such as inulin, were shown to improve GI 
permeability in obese subjects after dietary intervention for 9 wks.24 The discrepancy in 
results between our and above study might be explained by various factors, such as 
differences in method of measuring GI permeability, sample size and duration of study 
product intake. Furthermore, we assessed the effects of AX intake during weight 
maintenance, while they investigated the effect during a weight loss intervention.24 Some 
animal studies have shown beneficial effects of AX on an impaired gut barrier.9,10 This is the 
first human study analysing the effects of a (putative) prebiotic on the expression of TJ 
proteins in sigmoid mucosa in overweight subjects. From a subset of our study population we 
obtained mucosal samples from sigmoid colon and despite the small sample size, 7.5 g AX 
showed to significantly upregulate gene transcription of the TJ protein occludin, while 15 g 
AX significantly upregulated claudin-3 and claudin-4. These proteins are structural 
transmembrane components, which organize complex TJ protein systems, determining 
paracellular permeability. These results are in line with the preclinical data in obese mice, 
where AX significantly increased mRNA concentrations of TJ proteins expression.9 No 
significant changes in sigmoid TJ protein concentrations were observed after AX treatment.  
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Modulating gut microbiota composition by prebiotic compounds, and thereby influencing its 
effect on intestinal homeostasis, appears to be a promising strategy to treat and prevent 
chronic diseases. This is the first human study investigating the effect of a high molecular 
weight AX on the microbial community composition in overweight and obese individuals. In 
vitro and mice studies have shown that long-chain AX can be efficiently fermented, leading 
to specific stimulation of bifidobacterial species and beneficial fermentation profiles.9,11 
While in previous studies the effect of this particular AX concentrate on the microbiota was 
assessed by selective qPCR protocols,10-12 in the current trial we made use of a 
metagenomic approach. Here, we observed a decrease in microbial richness and diversity 
after 15 g AX supplementation, but no change in overall microbiota composition was seen. 
Intestinal microbiota converts indigestible food components into metabolites, such as SCFA, 
that can be processed by the host. SCFA are able to exert antioxidant, anti-inflammatory 
and immunomodulating effects.25 Furthermore, the SCFA butyrate functions as the principal 
energy source for the proliferation and differentiation of colonic epithelial cells and is 
essential in establishing and maintaining the gut barrier by regulating the expression of TJ 
proteins.25 We demonstrated that the fecal concentration of the individual and total SCFA 
were increased upon intake of AX compared to a decrease in the placebo group. Our 
findings confirm previous data from in vitro and in vivo studies. Two different in vitro models, 
often used to assess modulation of the gut microbiome (SHIME, TIM-2), demonstrated that 
long-chain AX specifically increase propionate concentrations.11 In germ-free rats, 
inoculated with human feces, long-chain AX increased the concentrations of acetate, 
propionate, butyrate and total amount of SCFA.12 In a human study, medium-chain AX 
significantly increased fecal concentrations of both propionic and butyric acid after 4 wks 
intake.26 Other prebiotics, such as inulin and fructo-oligosaccharides, showed less 
pronounced effects on SCFA production in humans.27,28 Concomitantly, we found a 
significant decrease in fecal pH in the 7.5 g AX group. A more acidic luminal environment 
may contribute to the reduction of pathogenic bacteria and creates a more favourable 
environment for the growth of beneficial bacteria.  
To assess the effect of AX on immune response we applied an ex vivo model using PHA-
stimulated whole blood to evaluate the capacity to produce cytokines. We found a 
significant decrease in production of the pro-inflammatory cytokine TNFα after 
supplementation with 15 g AX, suggesting a capacity to reduce the intensity of an acute 
pro-inflammatory reaction. In obese mice AX showed to have an anti-inflammatory effect.9 
Human data regarding the effect of prebiotics on immune modulation, assessed via the 
current ex vivo model, are limited. One study in healthy subjects showed that a prebiotic 
mixture had the capacity to reduce the pro-inflammatory pathway and to stimulate anti-
inflammatory pathways.26 Pro-inflammatory cytokines are associated with the development 
of systemic IR, ß-cell dysfunction and CVD.29 One important function of SCFA is suppressing 
the production of such cytokines.25 In the present human trial we observed an increase in 
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fecal SCFA concentrations after AX treatment, providing a possible explanation for the 
decrease in TNFα production by PBMC.  
Obesity is typically associated with a wide cluster of metabolic alterations, including glucose 
homeostasis disorders and dyslipidemia. AX showed to improve glycemic control and blood 
triglycerides concentrations in subjects with an impaired glucose tolerance or DM2.29 In the 
present study, supplementation with AX in healthy overweight and obese subjects did not 
affect systemic glucose, insulin and lipid concentrations. This can be explained by the fact 
that the participants had normal values from beginning of the study.  
The daily ingestion of AX did not influence bowel habits, confirming previous observations in 
prebiotics intervention studies.28 The low prevalence of GI complaints during AX 
supplementation provides evidence that AX is well-tolerated by humans.  
This study followed a unique approach to assess the gut barrier, by combining functional 
analyses (multi-sugar test) with TJ analyses in mucosal tissue specimens. Some potential 
shortcomings should be considered. Firstly, we measured fecal SCFA concentrations to 
assess the microbiota fermentation capacity. SCFA are efficiently absorbed from the gut, 
with only 5% to 10% being excreted via the feces. Fecal SCFA concentrations hence do not 
accurately reflect the exact intestinal SCFA concentration. However, previous studies 
showed that the ratio between the respective SCFA, measured in feces and colon, is 
comparable to each other.31 Thus, changes in fecal SCFA concentration reflect relative 
changes in intestinal concentrations of the separate SCFA. Furthermore, as we choose to 
focus on the effects of AX on gut barrier function and gut microbiota, we did not obtain 
information regarding hepatic health of our study subjects. Prebiotics target multiple 
metabolic impairments associated with obesity-related non-alcohol fatty liver disease, and 
thus the effects of AX on hepatic health in this study population may be another interesting 
objective to assess. We did not control the diet and exercise pattern of our participants, as 
we aimed to evaluate the effects of AX when supplementing the habitual diet, which is in 
line with future applications. Furthermore, in this study we observed potentially 
advantageous findings regarding gut barrier and immune function, however these findings 
are still theoretical and were not translated into clinically positive outcomes. Future research 
is required to assess whether these findings can improve gut barrier function and immune 
health. 
In conclusion, we have shown that 6 wks AX supplementation resulted in a more beneficial 
fermentation (SCFA) profile in overweight and obese subjects. In addition, an increased 
gene transcription of several transmembrane proteins was observed, although no changes 
in TJ proteins expressions or GI permeability were detected. Furthermore, we showed that 
15 g AX might have an anti-inflammatory potential and that the intake of AX was well-
tolerated. 
Chapter 4 
88 
References 
1. Viggiano D, Ianiro G, Vanella G, et al. Gut barrier in health and disease: focus on childhood. Eur Rev Med 
Pharmacol Sci. 2015;19(6):1077-85. 
2. Guinane CM, Cotter PD. Role of the gut microbiota in health and chronic gastrointestinal disease: 
understanding a hidden metabolic organ. Therap Adv Gastroenterol. 2013;6(4):295-308. 
3. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut microbiota control inflammation in obese mice 
through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009;58(8):1091-103.  
4. Hotamisligil GS, Erbay E. Nutrient sensing and inflammation in metabolic diseases. Nat Rev Immunol. 
2008;8(12):923-34.  
5. Gibson GR, Roberfroid MB. Dietary modulation of the human colonic microbiota: introducing the concept of 
prebiotics. J Nutr. 1995;125(6):1401-12. 
6. Grootaert C, Van den Abbeele P, Marzorati M, et al. Comparison of prebiotic effects of arabinoxylan 
oligosaccharides and inulin in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol 
2009;69(2):231-42.  
7. Hughes SA, Shewry PR, Li L, et al. In vitro fermentation by human fecal microflora of wheat arabinoxylans. J 
Agric Food Chem. 2007;55(11):4589-95.  
8. Monobe M, Ema K, Kato F, Maeda-Yamamoto M. Immunostimulating activity of a crude polysaccharide 
derived from green tea (Camellia sinensis) extract. J Agric Food Chem. 2008;56(4):1423-7.  
9. Neyrinck AM, Possemiers S, Druart C, et al. Prebiotic effects of wheat arabinoxylan related to the increase 
in bifidobacteria, Roseburia and Bacteroides/Prevotella in diet-induced obese mice. PloS One 
2011;6(6):e20944.  
10. Chen H, Wang W, Degroote J, et al. Arabinoxylan in wheat is more responsible than cellulose for promoting 
intestinal barrier function in weaned male piglets. J Nutr. 2015;145(1):51-8.  
11. Van den Abbeele P, Venema K, Van de Wiele T, et al. Different human gut models reveal the distinct 
fermentation patterns of Arabinoxylan versus inulin. J Agric Food Chem. 2013;61(41):9819-27.  
12. Van den Abbeele P, Gerard P, Rabot S, et al. Arabinoxylans and inulin differentially modulate the mucosal 
and luminal gut microbiota and mucin-degradation in humanized rats. Environ Microbiol 2011;13(10): 2667-
80.  
13. Mujagic Z, Ludidi S, Keszthelyi D, et al. Small intestinal permeability is increased in diarrhoea predominant 
IBS, while alterations in gastroduodenal permeability in all IBS subtypes are largely attributable to 
confounders. Aliment Pharmacol Ther. 2014;40(3):288-97.  
14. van Wijck K, van Eijk HM, Buurman WA, et al. Novel analytical approach to a multi-sugar whole gut 
permeability assay. J Chromatogr B Analyt Technol Biomed Life Sci. 2011;879(26): 2794-801.  
15. Pijls KE, Koek GH, Elamin EE, et al. Large intestine permeability is increased in patients with compensated 
liver cirrhosis. Am J Physiol Gastrointest Liver Physiol. 2014; 306(2):G147-53.  
16. Keszthelyi D, Troost FJ, Jonkers DM, et al. Serotonergic reinforcement of intestinal barrier function is 
impaired in irritable bowel syndrome. Aliment Pharmacol Ther. 2014;40(4):392-402.  
17. Verstraelen H, Vilchez-Vargas R, Desimpel F, et al. Characterisation of the human uterine microbiome in non-
pregnant women through deep sequencing of the V1-2 region of the 16S rRNA gene. PeerJ 2016;4:e1602.  
18. Possemiers S, Verthe K, Uyttendaele S, Verstraete W. PCR-DGGE-based quantification of stability of the 
microbial community in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol. 
2004;49(3):495-507.  
19. Bremner JMaK, R.D. Steam distillation methods for determination of ammonium, nitrate and nitrite. Anal 
Chem Acta. 1965;32:485-95. 
20. Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with 
irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988;33(2):129-34. 
 Arabinoxylans in gut barrier 
89 
21. Kim H, Bartley GE, Young SA, et al. HPMC supplementation reduces abdominal fat content, intestinal 
permeability, inflammation, and insulin resistance in diet-induced obese mice. Mol Nutr Food Res. 
2012;56(9):1464-76.  
22. Teixeira TF, Souza NC, Chiarello PG, et al. Intestinal permeability parameters in obese patients are 
correlated with metabolic syndrome risk factors. Clin Nutr. 2012;31(5):735-40.  
23. Brignardello J, Morales P, Diaz E, et al. Pilot study: alterations of intestinal microbiota in obese humans are 
not associated with colonic inflammation or disturbances of barrier function. Aliment Pharmacol Ther. 
2010;32(11-12):1307-14.  
24. Xiao S, Fei N, Pang X, et al. A gut microbiota-targeted dietary intervention for amelioration of chronic 
inflammation underlying metabolic syndrome. FEMS Microbiol Ecol. 2014;87(2):357-67.  
25. Canani RB, Costanzo MD, Leone L, et al. Potential beneficial effects of butyrate in intestinal and 
extraintestinal diseases. World J Gastroenterol. 2011;17(12):1519-28.  
26. Lecerf JM, Depeint F, Clerc E, et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both 
the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic 
properties. Br J Nutr. 2012;108(10):1847-58.  
27. van Dokkum W, Wezendonk B, Srikumar TS, van den Heuvel EG. Effect of nondigestible oligosaccharides 
on large-bowel functions, blood lipid concentrations and glucose absorption in young healthy male subjects. 
Eur J Clin Nutr. 1999;53(1):1-7. 
28. Slavin J, Feirtag J. Chicory inulin does not increase stool weight or speed up intestinal transit time in healthy 
male subjects. Food Funct. 2011;2(1):72-7.  
29. Goldberg RB. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced 
coagulation in development of diabetes and its complications. J Clin Endocrinol Metab. 2009;94(9):3171-
82. 
30. Lu ZX, Walker KZ, Muir JG, O'Dea K. Arabinoxylan fibre improves metabolic control in people with Type II 
diabetes. Eur J Clin Nutr. 2004;58(4):621-8.  
31. Macfarlane G.T. GG. Microbiological aspects of production of short-chain fatty acids in the large bowel. 
Cambridge: Cambridge University Press, 1999. 
  
Chapter 4 
90 
Supplemental material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
. 
Fi
gu
re
S4
.1
C
O
N
SO
RT
 fl
ow
di
ag
ra
m
.
Fi
gu
re
S4
.1
C
O
N
SO
RT
 fl
ow
di
ag
ra
m
.
 Arabinoxylans in gut barrier 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.2 Clustering of samples due to intervention by PCoA, based on BC similarity distance, at baseline. 
Fecal samples collected from different treatment groups are represented by gray squares for 
placebo, black plusses for 7.5 g AX and lightgray dots for 15 g AX. No significant differences in 
microbial community composition between placebo, 7.5 g AX and 15 g AX during study period 
were observed, as assessed using two-way ANOSIM. ANOSIM, analysis of similarity. AX, 
arabinoxylans. BC, Bray-Curtis. PCoA, principle coordinate analysis. 
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Figure S4.3 Clustering of samples due to intervention by PCoA, based on BC similarity distance, after 3 wks 
intervention. Fecal samples collected from different treatment groups are represented by gray 
squares for placebo, black plusses for 7.5 g AX and lightgray dots for 15 g AX. No significant 
differences in microbial community composition between placebo, 7.5 g AX and 15 g AX during 
study period were observed, as assessed using two-way ANOSIM. ANOSIM, analysis of similarity. 
AX, arabinoxylans. BC, Bray-Curtis. PCoA, principle coordinate analysis. 
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Figure S4.4 Clustering of samples due to intervention by PCoA, based on BC similarity distance, after 6 wks 
intervention. Fecal samples collected from different treatment groups are represented by gray 
squares for placebo, black plusses for 7.5 g AX and light gray dots for 15 g AX. No significant 
differences in microbial community composition between placebo, 7.5 g AX and 15 g AX during 
study period were observed, as assessed using two-way ANOSIM. ANOSIM, analysis of similarity. 
AX, arabinoxylans. BC, Bray-Curtis. PCoA, principle coordinate analysis. 
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Abstract 
Background  
The bioavailability of hesperidin in humans is low, partly due to its poor water solubility. Micronization 
is known to decrease particle size of a compound, thereby improving its solubility and thus absorption. 
 
Objective 
To investigate the bioavailability of a single dosage micronized hesperidin 2S compared to an 
identical dosage standard non-micronized hesperidin in healthy individuals. 
 
Design 
In this double-blind, randomized, crossover exploratory study 11 healthy individuals attended to two 
test days. Subjects randomly consumed one dosage standard non-micronized hesperidin and one 
dosage micronized hesperidin 2S. Urine was collected for 24 h. Blood was sampled at 8 different 
time points over a 10 h period.  
 
Results 
LC-MS/MS analysis of urine and plasma samples revealed the metabolites hesperetin-3-O-
glucuronide, hesperetin-7-O-glucuronide and hesperetin-7-O-sulphate. The cumulative and relative 
excretion of total hesperetin (P = 0.032) and individual metabolites (all P ≤ 0.044) in 24 h was 
significantly higher after micronized hesperidin 2S intake, compared to standard hesperidin. Also the 
plasma hesperetin AUC0-4h was higher after intake of the micronized product, compared to non-
micronized product (P = 0.032). 
 
Conclusions 
The bioavailability of micronized hesperidin 2S was higher than standard non-micronized hesperidin. 
This finding may beneficially influence the biological activity and systemic health effects of this 
formulation. 
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Introduction 
Flavonoids comprise a large group of polyphenolic compounds present in fruits and 
vegetables. Several large studies have shown that the intake of flavonoid-rich foods has 
positive effects on cardiovascular diseases (CVD) and their related risk factors.1,2 Hesperidin 
(HE; hesperetin-7-O-rutinose 2S), a naturally extracted and purified flavanone glycoside 
from sweet orange peels, has drawn attention due to its positive effects on metabolic and 
cardiovascular health.3-6 In order to exert health effects in vivo, it is essential that flavonoids 
are bioavailable, absorbed from the gastrointestinal (GI) tract and reach the systemic 
circulation. Following oral administration, hesperidin is absorbed across the GI tract, but its 
bioavailability is low in humans.7,8 Several factors limit the bioavailability of hesperidin after 
oral intake, one of them is its poor water solubility.9 Furthermore, for many flavonoid 
glycosides, after conversion to its aglycone, the small intestine is the major site of 
absorption.10 However, hesperidin is a flavonoid consisting of a flavonoid backbone 
(hesperetin) bound to rutinose. To release and enable the absorption of the hesperidin 
aglycone, hydrolysis of rutinose by β-glucosidase derived from gut microbiota is required.11 
This process mainly occurs in the large intestine, where the aglycone hesperetin is released 
and further conjugated into glucuronidated and sulphated metabolites by enterocyte cells 
or by the liver, these metabolites may then be absorbed into the blood.8,12 As a result, 
circulating levels of hesperetin are very low: hesperetin sulfates (3’- and 7-O-sulfate) and 
glucuronides (3’- and 7-O-glucuronide) are the main circulating metabolites upon hesperidin 
consumption.7,8,13 An additional complex factor is related to the specific enantiomer 
configuration of hesperidin (i.e. S versus R). Hesperidin consists of a mixture of S- and 
R-enantiomers, it has a S:R ratio between 1:1 and 5:1, depending on its source.14,15 While in 
nature the 2S-enantiomer of hesperidin, and subsequently the S-hesperetin enantiomer, is 
dominant, commercially available hesperidin and hesperetin are a mixture of both stereo-
isomers. The two enantiomers may display distinct kinetic and dynamic properties, with 
stronger biological effects elicited by the S-enantiomer compared to the R-enantiomer.16,17 
Several attempts have been made to improve the bioavailability and subsequent bioactivity 
of hesperidin.18-20 Here, we developed a micronized hesperidin 2S formulation with a 
S:R ratio of 4:1 (Cordiart). Micronization has previously been used to increase the 
bioavailability of other polyphenols.21 The particle size of the micronized hesperidin 2S is 
approximately 10 times smaller than the standard hesperidin extract. 
Primary aim of this study was to investigate the bioavailability of a single dose of micronized 
hesperidin 2S, as measured by 24 h urinary excretion and plasma AUC of hesperidin 
metabolites, compared to a standard non-micronized hesperidin formulation (S:R ratio of 
1.5:1). We hypothesized that micronized hesperidin 2S has an improved bioavailability 
compared to a standard non-micronized hesperidin product, as shown by a higher 24 h 
urinary excretion and plasma AUC of hesperidin metabolites. 
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Subjects and methods 
The study was approved by the Medical Ethics Committee of the Maastricht University 
Medical Center + (MUMC+) and conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013 and with the Dutch Regulations on 
Medical Research involving Human Subjects (WMO, 1998). The study was performed at 
the MUMC+ in June and July 2013. All participants gave written informed consent before 
participation. 
Subjects 
Healthy volunteers aged 18-75 years with a BMI between 18-30 kg/m2 and normal 
laboratory values were recruited by advertising in the local media. Laboratory values 
included haemoglobin (Hb, defined as: M 8.2-11.0 mmol/l, F 7.3-9.7 mmol/l); haematocrit 
(Ht, defined as: M 0.41-0.52 l/l, F 0.36-0.48 l/l); serum alanine transaminase (ALT, defined 
as: M <45 U/l, F <34 U/l); serum aspartate transaminase (AST, defined as: M <35 U/l, 
F <31 U/l); gamma-glutamyl transferase (GGT, defined as: M <55 U/l, F <40 U/l); bilirubin 
total (defined as: <20 μmol/l); serum creatinine (defined as: M 60-115 μmol/l, 
F 50-100 μmol/l). Exclusion criteria were: any medical condition that might interfere with the 
study and might jeopardize the health status of the participant; smoking; use of medication / 
vitamin-, mineral-, or antioxidant supplements; pregnancy and lactation; history of any side 
effects towards the intake of flavonoids or citrus fruits; failure to comply with prohibited 
intake of hesperidin rich food products. 
Design and intervention 
In this double-blind, randomized, crossover exploratory study each subject attended to two 
test days with at least 1 week washout period in between. All participants and investigators 
remained blind to treatment until all analyses were completed. Participants were requested 
to abstain from strenuous physical exercise and consumption of alcohol the day prior to 
each test day. Furthermore, we instructed them to maintain their habitual diet during the 
study period, but to abstain from intake of hesperidin-rich foods starting 3 days prior to start 
of the study period. After an overnight fast, subjects arrived at the study site and an 
intravenous catheter was inserted into the antecubital vein of the arm. Blood sampling was 
performed at baseline and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h and 10 h after intake of the 
study product. Furthermore, after intake of the study product, subjects collected full urine 
output for 24 h. One hour after intake of the study product, the participants received a 
standard breakfast. During a test day they also received a standard snack, lunch and 
dinner. At the end of the test day the intravenous catheter was removed. 
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Micronized hesperidin 2S and standard hesperidin 
Micronized hesperidin 2S (450 mg, supplied as 500 mg Cordiart, BioActor BV, Maastricht, 
The Netherlands) was extracted from the Citrus sinesis immature fruits, containing both the S 
and R enantiomers in the natural 4:1 S:R ratio of hesperidin. Standard hesperidin (450 mg) 
was provided by Ferrer HealthTech (Spain) and had a S:R molar ratio of 1.5:1. A total of 
450 mg hesperidin corresponds to 222.8 mg hesperetin. The study products were 
formulated into capsules, each containing 250 mg study product. Subjects were asked to 
ingest two capsules within 1 min with 200 ml water. 
Urine collection 
Twenty-four hour urine was collected in 2L bottles with added dibutylhydroxytoluene (anti-
oxidant) to preserve the metabolites during the collection period. The total urine volume was 
weighed before samples were stored at -80°C until further analysis. 
Blood collection 
During a test day blood samples were taken for the determination of hesperidin, hesperidin 
2S and its metabolites. These samples were collected in sodium heparin tubes and 
immediately centrifuged at 1300 g for 10 min at 4°C. Thirty-six μl/ml 4 mM hydrochloric 
acid (HCl) was added to the plasma in support of the LC-MS measurements of the 
metabolites. All plasma samples were stored at -80°C until further analysis.  
LC-MS/MS analysis of metabolites 
LC-MS/MS analysis of the samples revealed the following metabolites: hesperetin-
3-O-glucuronide (Hp3G), hesperetin-7-O-glucuronide (Hp7G) and hesperetin-7-O-sulphate 
(Hp7S). The optimum mass spectrometer parameters for the detection of the hesperetin 
metabolites were optimized, connecting the column inlet directly to a special ionization 
source called ‘Jet Stream’. The source parameters were the following: capillary voltage 
-3500 V, charging potential -500 V, nebulizer pressure 40 (psi), auxiliary gas heated to 
275°C and introduced at a flow rate of pure nitrogen 9 L/min. The multiple reaction 
monitoring (MRM) was the method of choice due to the high selectivity and sensitivity in 
LC-MS/MS, monitoring 4 transitions for each analysis: hesperetin, m/z 301164; 
hesperetin glucuronide, m/z 477301; hesperetin diglucuronide, m/z 653(477)301; 
hesperetin sulfoglucuronide, m/z 557(477)301; hesperetin sulfate, m/z 381301; 
with a dwell time for each transition of 8 ms. Concentrations of hesperetin diglucuronide 
and hesperetin sulfoglucuronide metabolites were estimated by synthesized hesperetin 
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glucuronide calibration curves (10, 5, 1, 0.5, 0.1 μM). The cumulative excretion of total 
hesperetin in 24 h urine was calculated by adding the concentrations of the 3 different 
metabolites per test day. 
Statistical analyses 
Primary outcome of the study was the bioavailability of micronized hesperidin 2S, measured 
by the difference in cumulative excretion of hesperetin in 24 h urine and by the difference 
in the 240-min and 600-min area under the plasma concentration-time curves (AUC0-4h and 
AUC0-10h) of plasma total metabolite concentration between micronized hesperidin 2S and 
standard hesperidin. As this is an exploratory study, no formal sample size calculation was 
made. Based on other studies investigating the bioavailability of polyphenols by measuring 
the urinary excretion and the plasma concentrations of the metabolites, we estimated that at 
least 8 participants would be sufficient for evaluation of the primary aim.19,22 Baseline 
characteristics are presented as mean (SD) for numerical variables. The AUCs were 
calculated using the trapezoidal method. Differences in urinary excretion and plasma AUCs 
of Hp3G, Hp7G and Hp7S and total hesperetin between intervention groups (micronized 
hesperidin 2S or standard hesperidin) were assessed using linear mixed models with group 
(micronized hesperidin 2S or standard hesperidin) as fixed factor, where an unstructured 
covariance structure was used for repeated measures. The linear mixed model accounts for 
the correlation between repeated measures and missing data, where a likelihood approach 
was used assuming data missing at random. The estimated means and SEM obtained from 
this model were presented for each group. Two-sided P-values ≤ 0.05 were considered 
statistically significant. Statistical analysis was performed using IBM SPSS Statistics for 
Windows (version 21.0, Armonk, NY, USA). 
Results 
Study subjects 
Initially, 11 healthy volunteers were enrolled in the study [38% male; age 27 ± 8 yrs; BMI (in 
kg/m2) 22 ± 2], of which 10 completed the entire study protocol. From the drop-out only 
baseline characteristics were available. 
Urinary metabolites 
The cumulative and relative excretion of hesperetin in 24 h urine is shown in Table 5.1 and 
Figure 5.1. The urinary excretion of the individual metabolites Hp3G, Hp7G, Hp7S and of 
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total hesperetin was significantly higher after micronized hesperidin 2S intake compared to 
standard hesperidin intake (P = 0.044, P = 0.024, P = 0.018, P = 0.032 respectively). Relative 
urinary excretion of total hesperetin as a percentage of intake was 3.73% for the standard 
hesperidin formulation compared to 5.62% for the micronized hesperidin 2S formulation. 
 
Table 5.1 Ingested dose, plasma AUCs and 24 h urinary excretion of hesperetin after intake of standard 
hesperidin and micronized 2S HE1 
 Standard HE Micronized HE 2S P value 
Ingested dose (mg) 222.79 222.79 - 
AUC0-4h (μmol h/l) 0.4 ± 0.12 1.1 ± 0.3 0.032 
AUC0-10h (μmol h/l) 4.9 ± 1.1 7.1 ± 1.3 0.225 
Total urinary excretion (24 h) 
μmol 
mg 
 
27.52 ± 4.53 
8.31 ± 1.37 
 
41.48 ± 7.35 
12.53 ± 2.22 
 
0.032 
Relative urinary excretion 
percentage of intake 
 
3.73 ± 0.61 
 
5.62 ± 1.00 
 
0.032 
1Differences between standard hesperidin and micronized hesperidin 2S tested with linear mixed model. HE, 
hesperidin. 2Estimated mean ± SEM (all such values) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1 The cumulative excretion of Hp3G, Hp7G, Hp7S and total hesperetin in 24 h urine after intake of 
standard hesperidin and micronized hesperidin 2S. Data presented as: mean ± SEM. Data of 
standard hesperidin are represented by light gray, data of micronized hesperidin 2S by dark gray. 
Differences between standard hesperidin and micronized hesperidin 2S tested with linear mixed 
model. * significant (P ≤ 0.050) difference between standard hesperidin and micronized hesperidin 
2S. 
Plasma metabolites 
The AUC0-4h and AUC0-10h of plasma hesperetin are shown in Table 5.1 and Figure 5.2. The 
mean and individual time-vs.-plasma concentration curves for hesperetin are shown in Figure 
5.3, Figure 5.4A and 5.4B. The AUC0-4h of plasma hesperetin was significantly higher after 
micronized hesperidin 2S intake compared to standard hesperidin (P = 0.032). However, the 
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AUC0-10h was not significantly different between interventions (P = 0.225). Also, there were 
no significant between-group differences at each measured time point (all P ≥ 0.194). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2 The AUC0-4h and AUC0-10h of plasma total hesperetin after intake of standard HE and micronized 2S 
HE. Data presented as: mean ± SEM. Data of standard HE are represented by light gray, data of 
micronized 2S HE by dark gray. Differences between standard hesperidin and micronized 
hesperidin 2S tested with linear mixed model. * significant (P ≤ 0.050) difference between standard 
hesperidin and micronized hesperidin 2S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 Change in plasma concentration of total hesperetin (μM) from baseline to 10 h after intake of 
standard HE and micronized 2S HE. Data presented as: mean ± SEM. Data of standard HE are 
represented by light gray dots, data of micronized 2S HE by dark gray squares. Differences 
between standard hesperidin and micronized hesperidin 2S tested with linear mixed model. No 
significant differences in plasma total hesperetin per time point between interventions were 
observed (all P ≥ 0.194). 
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Figure 5.4A Individual plasma concentration curves for total hesperetin (μM) from baseline to 10 h after intake 
of standard hesperidin. Subject numbers are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4B Individual plasma concentration curves for total hesperetin (μM) from baseline to 10 h after intake 
of micronized hesperidin 2S. Subject numbers are shown. 
Discussion 
The present study demonstrates that micronized hesperidin 2S is more bioavailable than 
standard hesperidin, as shown by a significant increase in the cumulative excretion of the 
individual metabolites Hp3G, Hp7G and Hp7S and of total hesperetin in 24 h urine, after 
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ingestion of one dose micronized hesperidin 2S, compared to standard hesperidin. 
Additionally, plasma hesperetin AUC0-4h and AUC0-10h increased after intake of micronized 
hesperidin 2S, compared to standard hesperidin, being significant for the AUC0-4h. 
It has been shown that the oral bioavailability of hesperidin is low in humans, due to a 
combination of factors.7,8 Hesperidin is highly water insoluble and it requires colonic 
microbiota to release and enable the absorption of its aglycone hesperetin.8,9,11,12 A way to 
improve the dissolution process of a product is to reduce the size of the product particles by 
micronization.23 Here, we compared the bioavailability of a micronized hesperidin 2S 
formulation to that of a non-micronized hesperidin formulation. The micronized 2S product 
showed to be more bioavailable than the non-micronized standard product, by excreting 
significantly higher amounts of the 3 main hesperidin metabolites in 24 h urine. Human 
studies investigating the bioavailability of hesperidin have reported lower relative urinary 
excretion over 24 h.7,8,19,24,25 To assess plasma bioavailability we calculated the AUC0-10h of 
the individual metabolites and of total hesperetin. Higher AUCs were observed for the 
individual metabolites and for total hesperetin after micronized hesperidin 2S intake, 
compared to placebo, but it did not reach significance. Blood samples were taken at 
baseline and 15 min, 30 min, 1 h, 2 h, 3 h, 4 h and 10 h after study product intake. We 
particularly focused on the first 4 h after study product intake as we expected metabolites 
to be detected more rapidly in the plasma. We had two reasons to assume this: 1) we 
expected the micronized hesperidin 2S to be absorbed more rapidly, and 2) we 
administered the study product while the participant was fasted. Indeed, the individual 
plasma concentration curves for hesperetin show that in a number of cases detection of 
metabolites occurs earlier after intake of the micronized hesperidin 2S formulation, 
compared to the non-micronized hesperidin formulation. However, we have not determined 
plasma metabolite concentrations between 4 h and 10 h after study product intake. Based 
on literature data, a peak in plasma hesperetin is expected to occur between 5 to 7 h after 
study product intake.7,8,19,24 Therefore, the plasma AUC0-10h is probably not an accurate 
reflection of the real bioavailability. As hesperetin concentrations are higher at each 
measured time point after intake of micronized hesperidin 2S, it can be assumed that this is 
also the case between 4 h and 10 h. Very likely, the plasma AUC0-10h is an underestimation 
of the true bioavailability of the micronized product. As we measured plasma metabolites 
regularly during the first 4 h after study product intake, we are able to calculate an 
accurate plasma hesperetin AUC0-4h. Indeed, bioavailability of micronized hesperidin 2S, 
compared to standard hesperidin, showed to be significantly improved already during the 
first 4 h after study product intake. 
In the current study we observed interindividual variation regarding plasma metabolite 
excretions. In most subjects the plasma concentration peak lies between 4 and 10 h. The 
latter indicates that the compound is indeed absorbed from the distal parts of the small 
intestine or the colon where enzymes, capable of releasing the aglycone hesperetin, are 
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present.8,11,12 In some subjects, a peak in plasma metabolite concentration was observed 
within or at 1 h after study product intake. This might seem to be too short a time for a 
compound to reach the ileum or colon. However, subjects ingested the study product with 
water in a fasting state; this might have accelerated transit of the compound through the GI 
tract. Also, micronizing the compound could have affected the rate of absorption. 
Interindividual variation in polyphenol bioavailability has also been found in other human 
intervention studies.7,26-28 Most likely, the observed variations are caused by interindividual 
differences in intestinal microbiota composition and activity.28,29 Also, the colonic conversion 
rate of polyphenols to metabolites can vary greatly between individuals due to differences 
in transit time and substrate availability.30 
The present data show that the main circulating metabolites, formed after oral intake of 
hesperidin, were hesperetin glucuronides and sulphates. This is in line with other trials 
assessing the bioavailability of hesperidin in humans.3,18 Studies investigating the biological 
effects of these specific metabolites are limited. It has been reported that they beneficially 
contribute to cardiovascular health.31-33 An in vitro study demonstrated that hesperetin 
glucuronide increased nitric oxide (NO) release from endothelial cells, indicating that it is 
able to improve vascular dilatation.3 A study in hypertensive rats showed that hesperetin 
glucuronide has blood pressure lowering effects, endothelium-dependent vasodilatory 
activity and anti-inflammatory properties.31 Furthermore, glucuronated and sulphated 
metabolites of hesperidin showed to reduce the adhesion of monocytes to endothelial cells 
and to modulate the expression of genes related to inflammation, two important aspects 
involved in atherogenesis.32 Finally, Giménez-Bastida et al. found a reduction of PAI-1, a 
thrombogenic protein involved in a wide range of CVD as well as in cell migration, by 
hesperitin and its metabolites.33 It should be noted that the above mentioned results 
regarding the beneficial effects of hesperidin metabolites in cardiovascular health have 
been obtained from in vitro or animal studies. 
A limitation of the present study is the lack of available blood samples between 4 h and 
10 h after study product intake for measuring hesperidin metabolites. In line with this, we 
were not able to calculate an accurate AUC0-10h. However, as we regularly obtained blood 
samples between 0 h and 4 h after study product intake and collected full urine output over 
24 h, we could still reliably measure and interpret the bioavailability of hesperidin 2S in this 
study. 
In conclusion, the results of this study demonstrate that the bioavailability of micronized 
hesperidin 2S is higher compared to standard non-micronized hesperidin in healthy 
individuals. The enhanced bioavailability may positively affect its biological activity. Owing 
to a great interindividual diversity in intestinal environment, the bioavailability, biological 
activity and systemic health promoting effects of a polyphenolic compound can be highly 
variable within the human population. 
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Abstract 
Background 
Endothelial dysfunction (ED) is involved in the development of atherosclerosis. Hesperidin, a citrus 
flavonoid with antioxidant and other biological properties, potentially exerts beneficial effects on 
endothelial function (EF). 
 
Objective 
We investigated the effect of hesperidin 2S supplementation on EF in overweight individuals. 
 
Design 
This was a randomized, double-blind, placebo-controlled study in which 68 individuals were randomly 
assigned to receive hesperidin 2S (450 mg/d) or a placebo for 6 wk. At baseline and after 6 wk of 
intervention, flow-mediated dilation (FMD), soluble vascular adhesion molecule-1 (sVCAM-1), soluble 
intracellular adhesion molecule-1 (sICAM-1), soluble P-selectin (sP-selectin), systolic blood pressure 
(SBP), and diastolic blood pressure (DBP) were assessed. Acute, reversible ED was induced by intake 
of a high-fat meal (HFM). A second FMD scan was performed 2 h postprandially, and adhesion 
molecules were assessed 2 and 4 h postprandially. An additional exploratory analysis was performed 
in subjects with baseline FMD ≥ 3%. 
 
Results 
No significant change in fasting or postprandial FMD was observed after 6 wk of hesperidin intake 
compared with placebo intake. However, there was a trend for a reduction of sVCAM-1, sICAM-1, 
sP-selectin, SBP, and DBP after 6 wk of hesperidin treatment. In the FMD ≥ 3% group, hesperidin 
protected individuals from postprandial ED (P = 0.050) and significantly downregulated sVCAM-1 and 
sICAM-1 (all P ≤ 0.030). The results reported in the current article were not adjusted for multiplicity. 
 
Conclusions 
Six weeks of consumption of hesperidin 2S did not improve basal or postprandial FMD in our total 
study population. There was a tendency toward a reduction of adhesion molecules and a decrease in 
SBP and DBP. Further exploratory analyses revealed that, in subjects with baseline FMD ≥ 3%, 
hesperidin 2S improved ED after an HFM and reduced adhesion molecules. These results indicate the 
cardiovascular health benefits of hesperidin 2S in overweight and obese individuals with a relatively 
healthy endothelium. 
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Introduction 
The vascular endothelium is a monolayer of cells between the lumen and vascular smooth 
muscle cells. The vascular endothelium plays a crucial role in the maintenance of vascular 
homeostasis by keeping a refined balance between vasodilation and vasoconstriction.1 
Nitric oxide (NO) is of pivotal importance in the regulation of the arterial tone and, thus, 
endothelial function (EF).2 Chronic exposure to cardiovascular disease (CVD) risk factors [i.e., 
obesity,3 hypertension,4 diabetes mellitus 5,6] and to oxidative stress impairs the endothelium7 
and may lead to endothelial dysfunction (ED). ED is often manifested by an impaired 
capacity of the vascular endothelium to dilate as result of insufficient NO bioavailability.8 
ED has a key role in the development and progression of atherosclerosis, in which 
circulating leukocytes are recruited to the vascular endothelium and further migrate into 
subendothelial spaces, which are mediated by cellular adhesion molecules [i.e., soluble 
vascular adhesion molecule-1 (sVCAM-1), soluble intracellular adhesion molecule-1 
(sICAM-1), soluble E-selectin (sE-selectin), and soluble P-selectin (sP-selectin)].9,10 Hence, 
interventions aimed at improving ED may provide an attractive approach in the prevention 
of atherosclerosis and CVD. 
Hesperidin, which is a flavonoid that is abundantly present in the peels of citrus fruit, may 
have such potential. Hesperidin (hesperetin-7-O-rutinoside), to a large extent, reaches the 
colon intact where it is subsequently deglycosylated by intestinal microbiota to produce the 
active aglycone hesperitin.11,12 Hesperitin has previously been shown to upregulate 
endothelial NO-synthase activity and, therefore, has intrinsic potential to protectively affect 
EF.13 However, low solubility limits the bioavailability and resulting biological activity in 
humans. Furthermore, although natural products typically contain high concentrations of the 
most-active form of hesperidin (hesperitin-7-O-rutinoside 2S), typical hesperidin extracts 
mainly contain the less-active 2R enantiomer.14,15 To overcome both the limited 
bioavailability and the typically suboptimal enantiomer composition, we studied a hesperidin 
2S extract (Cordiart; BioActor BV) that has a specific enantiomer configuration that is similar 
to natural hesperidin and was specifically developed for having improved bioavailability 
profiles. 
The primary aim of our study was to investigate the efficacy of 6 wk of supplementation of 
the specific hesperidin 2S formulation on EF as measured with the use of flow-mediated 
dilation (FMD) in a population of healthy but overweight individuals. We selected 
overweight individuals because this condition is associated with chronic low-grade 
inflammation, and in these subjects, mild ED regularly occurs.16 Because we recruited from 
the general population rather than from a selection of a population with proven ED, we 
induced temporary, reversible ED by providing participants with a high-fat meal (HFM) 
during test days.17,18 This method allowed us to further assess the effect of a single dosage 
of hesperidin 2S on HFM-stressed EF. Our secondary aim was to investigate the 6-wk 
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effects of this formulation on circulating adhesion molecules, blood pressure (BP), and 
metabolic markers. We hypothesized that 6 wk of supplementation with this specific 
hesperidin 2S extract would improve EF, downregulate adhesion molecules, lower systolic 
blood pressure (SBP) and diastolic blood pressure (DBP), and enhance metabolic control. 
Methods 
The study was approved by the Medical Ethics Committee of the Maastricht University 
Medical Center+ and was conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013 and with the Dutch Regulations on 
Medical Research involving Human Subjects (1998). The study was performed at the 
Maastricht University Medical Center+ from March 2014 to October 2014. All 
participants gave written informed consent before participation. This trial was registered at 
clinicaltrials.gov as NCT02228291. 
Subjects 
Healthy volunteers who were aged 18–65 y and had BMI (in kg/m2) between 25 and 35 
were recruited through advertisements in the local media. Key exclusion criteria were as 
follows: type 2 diabetes mellitus (defined as fasting plasma glucose concentration 
≥ 7 mmol/L); any medical condition that might have interfered with the study and/or 
jeopardized the health status of the participant; smoking; abuse of alcohol (>20 alcoholic 
U/wk) and recreational drugs; no consistently stable body weight for ≥ 3 mo (±3 kg); plans 
to lose weight or follow an energy-restriction diet during the study period; any medication, 
vitamin supplements, mineral supplements, or antioxidant supplements during the study or in 
the 90 d before start of the study; use of antibiotics in the 90 d before the start of the study; 
pregnancy and lactation; history of any side effects toward intake of flavonoids or citrus 
fruit; and failure to comply with prohibited intake of hesperidin-rich food products and food 
products that influence EF. For the exploratory subgroup analysis, the following additional 
exclusion criterion was applied: baseline FMD <3%. The cutoff of 3% was based on data 
from a large meta-analysis on EF.19 In this study, it was illustrated that FMD values <3% were 
associated with a Framingham Risk Score of ∼40%, thereby making improvements of a short-
term intervention, as in our study, on a chronically impaired endothelium rather unlikely. In 
addition, the repeatability of low FMD values is decreased, thereby making results of 
statistical tests that evaluate FMD differences less robust.20,21 During the study period, 
subjects consumed their habitual diets. At the time of inclusion, all subjects were informed 
about the prohibited hesperidin-rich food products and food products that might potentially 
influence EF. 
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Design and intervention 
This study was designed as a randomized, placebo-controlled, double-blind, parallel-group 
study (Supplemental Figure S6.1). Each subject underwent 2 test days. Participants were 
randomly assigned in a double-blind fashion to one of the following 2 intervention arms: 
hesperidin 2S or placebo (cellulose). An independent and blinded person generated the list 
of random assignment with the use of a computerized procedure. All participants and 
investigators remained blind to the treatment until all analyses were completed. Participants 
were requested to abstain from strenuous physical exercise, consumption of alcohol and 
caffeine, and intake of vitamin C on the day before each test day.22 Assessments took place 
in a quiet, temperature-controlled (20–24°C) room. 
After an overnight fast, subjects arrived at the study site, and anthropometric measurements 
(height, body weight, and waist-to-hip circumference) were performed. After 30 min of rest 
in the supine position, subjects underwent BP measurements. Next, we assessed the first 
ultrasound FMD scan of the right brachial arterial lumen to test EF. After completion of the 
ultrasound scan, an intravenous catheter was inserted into the antecubital vein of the left 
arm, and blood samples were collected. Subjects consumed a standardized HFM to induce 
acute, mild, reversible ED. Synchronously with the HFM, one dosage of hesperidin 2S or 
placebo was ingested. Exactly 2 h after meal ingestion, a second FMD scan was performed. 
Blood sampling was performed at 2 and 4 h after the meal. At the end of the test day, the 
intravenous catheter was removed, and participants received the study products for the 
entire study period. After 6 wk of daily supplementation, test day 2 was organized. 
Measurements were identical to the measurements performed on test day 1. Figure 6.1 
shows the timeline of test days 1 and 2. To assess FMD variability and intrasonographer 
reproducibility in this specific study, a subset of 10% of participants underwent repeat FMD 
scans at study baseline and after 6 wk of supplementation. To assess compliance, 
participants were asked to save the empty and (partly) full blister packs and to return them 
at the last visit. Also, in the first week and last week of the study period, participants were 
asked to fill out a 3-d food record to assess whether they maintained their dietary habits 
throughout the study period. 
The primary aim of our study was to investigate the 6-wk effects of the specific hesperidin 
2S formulation on fasted and postprandial EF as measured with the use of FMD in healthy 
but overweight individuals. The secondary aim was to investigate the 6-wk effects of this 
formulation on circulating adhesion molecules, BP, and metabolic markers. In addition, an 
exploratory analysis was performed to assess the efficacy of this hesperidin 2S extract on 
FMD with the exclusion of subjects with strongly decreased baseline FMD values <3%. 
Because plasma concentrations of adhesion molecules are closely related to FMD values23, 
and factors that influence BP have been proposed to operate via mechanisms that are 
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linked to the release of substances from the endothelium24, the efficacy of hesperidin 2S 
regarding these variables was assessed in the FMD ≥3% group. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Timeline of test days 1 and 2. Blood samples, FMD, BP and HR values, and anthropometric 
measures were collected at different time points as indicated. BP, blood pressure; FMD, flow-
mediated dilation; HFM, high-fat meal; HR, heart rate. 
Hesperidin and placebo 
Hesperidin 2S (450 mg supplied as 500 mg Cordiart) was extracted from the Citrus sinesis 
peel, which contained both the S and R enantiomers in the natural 4:1 S:R ratio of 
hesperidin. Cellulose (500 mg microcrystalline cellulose; Aminolabs) was administered as the 
placebo. The study products were formulated into capsules, each of which contained 
250 mg of study product or placebo. Subjects were asked to ingest 2 capsules each 
morning with 200 mL H2O just before the consumption of breakfast for 6 wk. 
HFM 
The meal provided during test days was a standardized HFM (2.6 MJ; energy divided as 
61% fat, 33% carbohydrates, and 6% protein). The meal consisted of 125 g whole milk 
(Friesche Vlag; FrieslandCampina), 15 g sucrose (Van Gilse), 50 g whipped cream (Friesche 
Vlag; FrieslandCampina), and 150 g vanilla ice cream (Hertog; Unilever Nederland). 
FMD 
EF was assessed with the use of B-mode ultrasound brachial artery FMD as described 
previously.25 Two trained and certified sonographers performed the strictly standardized 
scan protocol. The effect of the intervention on FMD was assessed both without and with 
an HFM challenge. For quality-control (QC) purposes, on top of FMD measurements that 
were performed during both study visits, in ∼30% of participants, repeat-fasting QC scans 
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were performed at both visits (e.g., 6 scans in total). In a given participant, all FMD 
measurements were done by the same sonographer. Thus, the sonographer performed both 
FMD measurements on test days 1 and 2 and, if applicable, the QC FMD measurements of 
the participant. B-mode ultrasound scans of the diameter of the right brachial artery lumen 
were obtained with the sue of a Sonix Touch ultrasound machine (Ultrasonix) that was 
equipped with a 7.5-MHz linear array probe as well as a study-specific, ultrasound-
instrument scan protocol and settings as applied by the imaging core laboratory 
(Imagelabonline & Cardiovascular). A special probe-holder arm rest was used to optimize 
the stability and standardization of the position of the ultrasound probe. A BP cuff was 
placed around the forearm ∼1 cm below the antecubital fossa. At rest, measurements were 
obtained during 1 min after which the BP cuff was inflated to 250 mm Hg to occlude the 
brachial artery. After 5 min of forearm ischemia, the cuff was released, and brachial 
diameter measurements were continuously recorded for 3 min after cuff release. Image 
acquisition was electrocardiogram gated on the R wave, and the ultrasound images were 
saved in a Digital Imaging and Communications in Medicine clip. For QC purposes and to 
allow for repeat scans in the case of a methodologic failure, all study scans, together with 
their completed web-based scan forms, were transferred securely to the core laboratory 
after finishing a scan. For all scans, the imaging technicians of the core laboratory instantly 
provided an evaluation and feedback of the sonographer scan quality. To be accepted, a 
precuff occlusion difference diameter of the brachial artery between follow-up study scans 
had to be visualized in the ≤ 0.2-mm range. 
Image analysis 
Accepted scans were securely stored locally on the hard-disk drive of the ultrasound 
instrument and automatically backed-up on the Imagelabonline & Cardiovascular core 
laboratory server. Available scans were batched in a per-subject fashion. The image-
analysis technician was dedicated to analyze all scans of a subject and was blind to the 
clinical information, date of the scan, and intervention. Validated brachial FMD software 
(Brachial Analyzer version 6.2.3; Medical Imaging Applications) was used. In summary, the 
technician selected a region of interest in the longitudinal image of the brachial artery walls 
and lumen. The Brachial Analyzer software performed an automated tracing of the lumen-
wall interfaces,26 quantifying the brachial artery lumen diameter before cuff occlusion and 
after cuff release. Mean preocclusion diameters and the maximum after–cuff-release 
diameters were used to calculate22 the absolute (peak diameter minus baseline diameter) 
and FMD [(peak diameter - baseline diameter)/baseline diameter] * 100%. After the first 
batched series of 30 subjects, the remaining scans of subjects were analyzed. 
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Adhesion molecules 
During a test day, blood samples were collected in K2EDTA-coated evacuated tubes for 
the measurement of adhesion molecules when subjects were fasted and at 2 and 4 h after 
HFM intake, respectively. These samples were centrifuged at 1100 x g for 15 min at 4°C to 
obtain the plasma, which was divided into aliquots and kept frozen at −80°C until further 
analysis. Circulating sVCAM-1, sICAM-1, and sE-selectin in plasma were determined by 
commercially available ELISA kits and standards, according to the manufacturer's protocol 
(R&D System Europe Ltd.). Circulating plasma sP-selectin was measured by a quantitative 
sandwich immunoassay technique (R&D System Europe Ltd.). 
Blood pressure measurements 
BP was monitored with the use of a semicontinuous BP-monitoring device (Omron) on the 
upper left arm. At each occasion, in total, 4 BP measurements were performed. The first 
measurement was discarded, and the remaining 3 measurements were averaged. 
Measurements took place at baseline and at the end of the study period. During a test day, 
BP was measured before HFM consumption. 
Blood lipids, glucose and insulin analysis 
During a test day, blood samples were taken for the assessment of metabolic variables 
when subjects had fasted. Serum concentrations of glucose, total cholesterol, LDL 
cholesterol, HDL cholesterol, and triglycerides were measured with the use of 
spectrophotometry (Cobas 6000 analyzer series; Roche Diagnostics). Plasma insulin was 
determined with the use of a luminescence-enhanced immune-enzymatic assay (Immulite 
2000 immunoassay system; Siemens Healthcare). Insulin sensitivity was estimated with the 
use of a quantitative insulin-sensitivity check index27 as: 1 / (log insulin 0 h + log glucose 0 h).  
Statistical analyses 
The primary outcome of the study was the effect of 6 wk of hesperidin 2S supplementation 
on FMD compared with that of a placebo. As our secondary outcome, we investigated the 
effect of 6 wk of hesperidin 2S supplementation compared with that of placebo on 
adhesion molecules, BP, and metabolic variables. In addition, the postprandial effect of 
hesperidin 2S on EF was investigated. The sample size was determined for the primary 
outcome of the study with a significance-level α = 0.05 and a power of 80%. On the basis of 
previous work,28 we calculated that a sample size of 62 subjects would be required to 
detect a mean ± SD difference in FMD of 1.45% ± 2.0%. Baseline characteristics are 
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presented as means ± SDs for numerical variables and numbers (percentages) for 
categorical variables. Differences in FMD, BP, and blood variables between intervention 
groups (hesperidin 2S or placebo) were assessed with the use of linear mixed models with 
the group (placebo and hesperidin 2S), time (0 and 6 wk for the 6-wk hesperidin effect; 0, 
2, and 4 h for the postprandial hesperidin effect), and group x time as fixed factors, 
whereby a marginal model with an unstructured covariance structure was used for 
repeated measures (no random effects). The linear mixed model accounts for the correlation 
between repeated measures and missing data for which a likelihood approach was used 
with the assumption of data missing at random. The estimated means ± SEMs that were 
obtained from this model were presented for each group and each time point. A 2-sided 
P≤0.05 was considered statistically significant. The statistical analysis was performed with 
the use of IBM SPSS Statistics for Windows software (version 21.0; IBM). 
Results 
Study subjects 
Initially, 68 healthy volunteers were enrolled in the study of whom 63 subjects completed 
the entire study protocol. Three participants were included and randomly assigned to a 
treatment but never started participation because of personal reasons. From these 
participants, only baseline characteristics were available. Another participant terminated 
the study prematurely because of an occurrence of a skin rash, which disappeared after 
stopping the study product. We excluded 1 participant during the study period because of 
overt noncompliance. The FMD ≥ 3% group entailed 48 subjects with baseline FMD ≥ 3%. 
Baseline characteristics in the total study population and in the FMD ≥ 3% group are 
presented in Table 6.1. Dietary habits of the participants were maintained throughout the 
entire study period. 
 
Table 6.1 Baseline characteristics in the total study population and FMD ≥ 3% group.1 
 Total population 
(n = 68) 
Placebo 
(n = 34) 
Hesperidin 
(n = 34) 
FMD ≥ 3% group 
(n = 48) 
Placebo 
(n = 24) 
Hesperidin 
(n = 24) 
Age, y 53 ± 142 53 ± 14 54 ± 15 50 ± 15 50 ± 14 50 ± 16 
Sex, M/F, n 29/39 12/22 17/17 17/31 5/19 12/12 
WHR 0.94 ± 0.06 0.95 ± 0.06 0.94 ± 0.06 0.94 ± 0.06 0.94 ± 0.06 0.95 ± 0.05 
BMI, kg/m2 29.0 ± 2.6 29.7 ± 2.8 28.2 ± 2.2 29.1 ± 2.8 29.8 ± 3.0 28.5 ± 2.4 
1FMD, flow-mediated dilation; WHR, waist-to-hip-ratio. 2Mean ± SD (all such values) 
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FMD 
Effect of HFM 
As shown in Table 6.2, a nonsignificant decrease in FMD was observed after the ingestion 
of an HFM in both the placebo and the hesperidin group. The size of the decrease in 
postprandial FMD did not significantly differ between the 2 intervention groups (P = 0.670). 
Effects of HFM in subjects with FMD ≥ 3% 
In the FMD ≥ 3% group, the ingestion of an HFM reduced FMD in both the placebo and 
hesperidin groups. The size of the decrease in postprandial FMD did not significantly differ 
between the 2 intervention groups (P = 0.618) (Table 6.2). 
 
Table 6.2 Postprandial FMD after a single dosage in the total study population (placebo: n = 32; hesperidin: 
n = 33) and in the FMD ≥ 3% group (placebo: n = 24; hesperidin: n = 24) at baseline (test day 1).1 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values. There was no significant FMD decrease over time within 
intervention groups. FMD, flow-mediated dilation; HFM, high-fat meal. 
Six-week effect: fasted  
Fasted FMD did not change after 6 wk of hesperidin 2S supplementation compared with 
placebo intake (P = 0.881) (Table 6.3). 
Six-week effect: fasted, in subjects with FMD ≥ 3% 
No significant difference was observed in fasted brachial FMD between both interventions 
after 6 wk of supplementation (P = 0.872) (Table 6.3). 
 
Table 6.3 Fasted FMD at baseline and after 6 wk of supplementation in total study population (placebo: 
n = 32; hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; hesperidin: n = 24).1 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. FMD, flow-mediated dilation. 
Placebo Hesperidin  
Baseline fasting 2h after HFM Baseline fasting 2h after HFM 
P value 
FMD (%) 
   Total study population 5.57 ± 0.51 5.08 ± 0.53 4.50 ± 0.51 4.23 ± 0.51 0.670 
   ≥ 3% group 7.03 ± 0.48 6.37 ± 0.55 5.37 ± 0.48 5.04 ± 0.54 0.618 
Placebo Hesperidin  
Baseline End Baseline End 
P value 
FMD (%) 
   Total study population 5.57 ± 0.51 5.43 ± 0.47 4.50 ± 0.51 4.29 ± 0.47 0.881 
   FMD ≥ 3% group 7.03 ± 0.48 6.47 ± 0.49 5.37 ± 0.48 4.89 ± 0.50 0.872 
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Six-week effect: postprandial 
Postprandial FMD at 6 wk also did not significantly differ compared with the placebo (P = 
0.207) (Table 6.4). 
Six-week effect: postprandial, in subjects with FMD ≥ 3% 
After inducing ED by an HFM, hesperidin 2S significantly protected postprandial FMD from 
impairment compared with the effect of the placebo (P = 0.050) (Table 6.4). However, this 
effect was nonsignificant after any correction for multiple testing (e.g., Bonferroni correction 
for 8 tests performed as shown in Table 6.4). 
Variability assessment  
In total, 34 QC FMD scans were available of 19 study participants. The overall (mean) 
absolute difference between study FMD measurements and QC FMD measurements of 
complete FMD measurement sets was 0.87%. 
 
Table 6.4 Postprandial FMD after 6 wk of supplementation (test day 2) in the total study population (placebo: 
n = 32; hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; hesperidin: n = 24).1 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. FMD, flow-mediated dilation; HFM, high-fat meal. 
Adhesion molecules 
Six-week effect: fasted 
Changes in basal circulating adhesion molecules after 6 wk of intervention are shown in 
Table 6.5. A borderline significant downregulation of the adhesion molecules sVCAM-1 
(P = 0.052) and sICAM-1 (P = 0.056) was observed after 6 wk of supplementation with 
hesperidin 2S compared with the placebo. Furthermore, a downregulation of sP-selectin 
was seen in the hesperidin group, but this effect was NS (P = 0.086). No significant 
differences in sE-selectin concentrations were observed between the 2 treatments 
(P = 0.246). 
Placebo Hesperidin  
Baseline fasting 2h after HFM Baseline fasting 2h after HFM 
P value 
FMD % 
   Total study population 5.57 ± 0.51 5.08 ± 0.53 4.21 ± 0.48 4.38 ± 0.51 0.207 
   FMD ≥ 3% group 6.47 ± 0.49 5.81 ± 0.56 4.85 ± 0.51 5.28 ± 0.59 0.050 
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Six-week effect: fasted, in subjects with FMD ≥ 3% 
Although a significant downregulation of basal circulating sVCAM-1 (P = 0.030) and 
sICAM-1 (P = 0.017) was observed after 6 wk of hesperidin 2S supplementation compared 
with placebo intake, these effects were no longer significant after any multiple-testing 
correction (e.g., Bonferroni correction with 5 tests performed as shown in Table 6.5). 
Concentrations of sE-selectin and sP-selectin were not significantly different between the 2 
intervention groups (P = 0.211 and P = 0.936, respectively). 
 
Table 6.5 Basal circulating adhesion molecules at baseline and after 6 wk of supplementation in the total 
study population (placebo: n = 32; hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; 
hesperidin: n = 24).1 
Placebo Hesperidin  
Baseline End Baseline End 
P value 
Total study population, ng/mL 
   sVCAM-1 214 ± 10 215 ± 10 210 ± 10 190 ± 10 0.052 
   sICAM-1 107 ± 5 107 ± 5 110 ± 5 100 ± 5 0.056 
   sE-selectin 12 ± 1 11 ± 2 11 ± 1 12 ± 2 0.246 
   sP-selectin 78 ± 5 83 ± 5 94 ± 5 83 ± 5 0.086 
FMD ≥ 3% group, ng/mL 
   sVCAM-1 210 ± 11 215 ± 12 208 ± 11 184 ± 12 0.030 
   sICAM-1 104 ± 5 107 ± 5 114 ± 5 103 ± 5 0.017 
   sE-selectin 12 ± 2 12 ± 2 11 ± 2 11 ± 2 0.936 
   sP-selectin 76 ± 5 84 ± 6 94 ± 5 87 ± 6 0.211 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. FMD, flow-mediated dilation; sE-selectin, soluble E-
selectin; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin, soluble P-selectin; sVCAM-1, soluble 
vascular cell adhesion molecule-1. 
 
Six-week effect: postprandial 
The effect on postprandial adhesion molecule concentrations at 6 wk was not significantly 
different between both interventions (all P ≥ 0.154) (Table 6.6). 
Six-week effect: postprandial, in subjects with FMD ≥ 3% 
In the subgroup analysis, no significant differences in postprandial adhesion molecule 
concentrations were observed between both interventions (all P ≥ 0.123) (Table 6.6). 
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Table 6.6 Postprandial circulating adhesion molecules after 6 wk of supplementation (test day 2) in the total 
study population (placebo: n = 32; hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; 
hesperidin: n = 24).1 
Placebo Hesperidin  
Baseline 
fasting 
2h after 
HFM 
4h after 
HFM 
Baseline 
fasting 
2h after 
HFM 
4h after 
HFM 
P1 P2 
Total study population, ng/mL 
   sVCAM-12 215 ± 10 208 ± 9 200 ± 10 190 ± 10 185 ± 9 180 ± 10 0.686 0.462 
   sICAM-12 107 ± 5 105 ± 5 102 ± 5 100 ± 5 98 ± 5 96 ± 5 0.857 0.976 
   sE-selectin2 11 ± 2 9 ± 2 10 ± 2 12 ± 2 11 ± 2 11 ± 2 0.154 0.358 
   sP-selectin 83 ± 5 - 94 ± 5 83 ± 5 - 89 ± 5 - 0.479 
FMD ≥ 3% group, ng/mL 
   sVCAM-12 216 ± 12 211 ± 10 203 ± 11 184 ± 12 179 ± 10 171 ± 11 0.999 0.988 
   sICAM-12 107 ± 5 106 ± 6 103 ± 5 103 ± 5 101 ± 6 97 ± 5 0.841 0.756 
   sE-selectin2 12 ± 2 10 ± 2 10 ± 2 11 ± 2 11 ± 2 11 ± 2 0.182 0.123 
   sP-selectin 84 ± 6 - 96 ± 6 87 ± 6 - 95 ± 6 - 0.555 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. P1 represents P values for the analysis of baseline 
compared with 2h after the HFM between placebo and hesperidin. P2 represents P values for the analysis of 
baseline compared 4h after the HFM between placebo and hesperidin. FMD, flow-mediated dilation; HFM, high-
fat meal; sE-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin, soluble P-
selectin; sVCAM-1, soluble vascular cell adhesion molecule-1. 2Time by treatment interaction, P > 0.050. 
Acute effect 
After intake of the HFM with one dosage of hesperidin 2S, there was a trend (P between 
0.05 and 0.10) that was observed for a downregulation of the adhesion molecule sICAM-1 
at both 2 h (P = 0.088) (Table 6.7) and 4 h (P = 0.092) (Table 6.7). No significant postprandial 
differences were observed regarding sVCAM-1, sE-selectin, and sP-selectin between both 
study groups (all P ≥ 0.193) (Table 6.7). 
Acute effect in subjects with FMD ≥ 3% 
At baseline, after intake of an HFM with one dosage of hesperidin 2S (Table 6.7), we 
observed a significant downregulation of sICAM-1 after both 2 h (P = 0.035) and 4 h (P = 
0.050) and a trend for a downregulation of sE-selectin after 4 h (P = 0.062). Again, after 
any multiple testing correction (e.g., Bonferroni correction with 8 tests performed as shown in 
Table 6.7), these effects were no longer significant. No significant postprandial differences 
were observed regarding sVCAM-1 and sP-selectin between both study groups (all P ≥ 
0.111). 
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Table 6.7 Postprandial adhesion molecules after a single dosage in the total study population (placebo: n = 32; 
hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; hesperidin: n = 24) at baseline (test 
day 1).1 
Placebo Hesperidin  
Baseline 
fasting 
2h after 
HFM 
4h after 
HFM 
Baseline 
fasting 
2h after 
HFM 
4h after 
HFM 
P1 P2 
Total study population, ng/mL 
   sVCAM-12 214 ± 10 213 ± 9 206 ± 10 210 ± 10 207 ± 9 209 ± 10 0.818 0.489 
   sICAM-12 107 ± 5 105 ± 4 109 ± 5 110 ± 5 100 ± 4 104 ± 5 0.088 0.092 
   sE-selectin2 12 ± 1 12 ± 2 12 ± 2 11 ± 1 10 ± 2 11 ± 2 0.356 0.998 
   sP-selectin 78 ± 5 - 83 ± 4 94 ± 5 - 90 ± 4 - 0.193 
FMD ≥ 3% group, ng/mL 
   sVCAM-12 210 ± 11 215 ± 10 206 ± 11 208 ± 11 199 ± 10 202 ± 11 0.139 0.863 
   sICAM-12 104 ± 5 103 ± 5 108 ± 6 114 ± 5 102 ± 5 107 ± 6 0.035 0.050 
   sE-selectin2 12 ± 2 12 ± 2 12 ± 2 11 ± 2 10 ± 2 10 ± 2 0.111 0.062 
   sP-selectin 76 ± 5 - 83 ± 5 94 ± 5 - 91 ± 5 - 0.263 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. P1 represents P values for the analysis of baseline 
compared with 2h after the HFM between placebo and hesperidin. P2 represents P values for the analysis of 
baseline compared 4h after the HFM between placebo and hesperidin. FMD, flow-mediated dilation; HFM, high-
fat meal; sE-selectin, soluble E-selectin; sICAM-1, soluble intercellular adhesion molecule-1; sP-selectin, soluble 
P-selectin; sVCAM-1, soluble vascular cell adhesion molecule-1. 2Time by treatment interaction, P > 0.050. 
 
Blood pressure 
Six-week effect: fasted 
Results regarding the effect of hesperidin 2S administration on BP are given in Table 6.8. In 
the hesperidin 2S group, we observed a mean reduction of 5 mm Hg in SBP after 6 wk of 
intake, whereas in the placebo group, we observed a mean reduction of 2 mm Hg in SBP. 
DBP was reduced by 2 mm Hg after hesperidin 2S supplementation, whereas DBP 
increased by 1 mm Hg after placebo supplementation. A trend (P between 0.05 and 0.10) 
toward a lower SBP (P = 0.095) and DBP (P = 0.095) was observed after 6 wk of hesperidin 
2S supplementation compared with placebo intake. 
Six-week effect: fasted, in subjects with FMD ≥ 3% 
After 6 wk of hesperidin 2S intake, a trend (P between 0.05 and 0.10) toward a reduction 
in both SBP (P = 0.051) and DBP (P = 0.069) in the FMD ≥ 3% group was observed 
compared with in the placebo group. 
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Table 6.8 BP and HR at baseline and after 6 wk of supplementation in the total study population (placebo: 
n = 32; hesperidin: n = 33) and in the FMD ≥ 3% group (placebo: n = 24; hesperidin: n = 24).1 
Placebo Hesperidin  
Baseline End Baseline End 
P value 
Total study population 
   Systolic BP, mmHg 131 ± 3 129 ± 2 135 ± 2 130 ± 2 0.095 
   Diastolic BP, mmHg 80 ± 2 81 ± 2 83 ± 1 81 ± 2 0.095 
   HR, beats/min 62 ± 1 61 ± 1 61 ± 1 62 ± 1 0.220 
FMD ≥ 3% group 
   Systolic BP, mmHg 128 ± 2 127 ± 2 135 ± 2 129 ± 2 0.051 
   Diastolic BP, mmHg 79 ± 2 79 ± 2 84 ± 2 81 ± 2 0.069 
   HR, beats/min 62 ± 2 61 ± 2 62 ± 2 63 ± 2 0.256 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. BP, blood pressure; FMD, flow-mediated dilation; HR, 
heart rate. 
 
Blood lipids, glucose and insulin (six-week effect: fasted) 
Baseline total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, glucose, and insulin 
were all within normal blood value ranges. These variables were not significantly altered by 
6 wk of supplementation with hesperidin 2S compared with the placebo (all P ≥ 
0.097) (Table 6.9). Also, no significant change in insulin sensitivity was observed between 
intervention groups (P = 0.225) (Table 6.9). 
 
Table 6.9 Blood lipids, glucose, insulin, and QUICKI at baseline and after 6 wk of supplementation in the total 
study population (placebo: n = 32; hesperidin: n = 33)1 
Placebo Hesperidin  
Baseline End Baseline End 
P value 
Total cholesterol, mmol/L 5.7 ± 0.2 5.6 ± 0.2 5.5 ± 0.2 5.4 ± 0.2 0.752 
LDL cholesterol, mmol/L 3.6 ± 0.2 3.6 ± 0.2 3.5 ± 0.2 3.4 ± 0.2 0.585 
HDL cholesterol, mmol/L 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 1.5 ± 0.1 0.884 
Triglyceride, mmol/L 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 1.3 ± 0.1 0.620 
Glucose, mmol/L 5.0 ± 0.1 5.0 ± 0.1 4.9 ± 0.1 5.0 ± 0.1 0.348 
Insulin, pmol/L 58 ± 21 53 ± 20 74 ± 21 81 ± 20 0.097 
QUICKI 0.42 ± 0.01 0.23 ± 0.01 0.34 ± 0.01 0.42 ± 0.01 0.225 
1All values are estimated means ± SEMs. Differences between placebo and hesperidin were tested with the use of 
a linear mixed model with correction for baseline values.. QUICKI, quantitative insulin sensitivity check index. 
 
Discussion 
In this trial, the 6-wk effect of hesperidin 2S on EF and CVD risk markers were studied in 
overweight and obese but healthy individuals. To investigate the effect of treatment on EF in 
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this healthy population, we performed a stress test and induced reversible ED through the 
consumption of an HFM. After 6 wk of daily intake of hesperidin 2S, no significant changes 
in fasted or postprandial FMD were observed. However, a nonsignificant (but nearly 
significant) downregulation of adhesion molecules sVCAM-1, sICAM-1, and sP-selectin was 
observed after 6 wk of hesperidin 2S supplementation compared with after placebo intake. 
Furthermore, hesperidin 2S tended to reduce both SBP and DBP. The deterioration in FMD 
after consumption of an HFM was attenuated by hesperidin 2S in a group of subjects with 
baseline FMD ≥ 3%. In addition, in this subgroup, the downregulation in sVCAM-1 and 
sICAM-1 was significant. However, all significant results were no longer significant after 
correction for multiple testing. 
Atherosclerosis is a complex process involving a number of factors and inflammatory cells 
interacting throughout different stages of development. This process is initiated by circulating 
plasma LDL entering the subendothelial space in the blood vessel. LDL is oxidized by 
reactive oxygen species and upregulates adhesion molecules (e.g., sVCAM-1, sICAM-1, sE-
selectin and sP-selectin) on the endothelium and induces the expression of chemotactic 
agents in endothelial cells.29 In addition, optimal functioning of the endothelium itself is 
essential for undisturbed functioning of the cardiovascular system. To study this endpoint, 
FMD is the gold-standard method for noninvasive EF assessment.30 FMD is considered a 
direct and reliable measure of the vascular reactivity of the macrocirculatory system.31,32 In 
the current study, we aimed to assess the effect of a specific hesperidin 2S formulation in a 
generally healthy population. Because this population was not screened for impaired FMD 
variables, it would have been unlikely that major effects on FMD could have been 
observed in an unchallenged condition. This unlikelihood was confirmed by the fact that no 
significant effect was observed on basal FMD after 6 wk of daily hesperidin 2S intake. 
However, after inducing temporary ED through the consumption of an HFM, hesperidin 2S 
attenuated the postprandial impairment of FMD in a subgroup of subjects with baseline 
FMD ≥ 3%. The current data support a promising preventive role for hesperidin in mitigating 
fed-state oxidative stressors that are known to contribute to early, preclinical atherogenesis 
in subjects with a relatively healthy endothelium. In the literature, one other human 
intervention trial, to our knowledge, investigated the effect of hesperidin on FMD and 
showed a significant increase in basal FMD after 3 wk of hesperidin supplementation. The 
study was conducted in individuals with metabolic syndrome who were specifically included 
for moderately impaired FMD.13 Results from human trials that have examined the effect of 
other polyphenols on basal FMD have been contradicting, with some trials showing an 
improvement,28,33,34 whereas other trials did not observe any effect35,36 after several weeks 
of supplementation. Only a few studies investigated the effect on postprandial FMD in 
humans. Results of some studies37-41 were in line with ours with some investigators indicating 
that a change in FMD over time may even be more closely related to a benefit of the 
intervention and prognosis than of a single FMD measurement.42  
 
Plasma adhesion molecule concentrations reflect the degree of EF.25 In the current study, a 
borderline significant downregulation of sVCAM-1 and sICAM-1 and a nonsignificant (but 
nearly significant) downregulation of sP-selectin was observed in the total study population 
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after 6 wk of hesperidin 2S intake. In the FMD ≥ 3% group, the reduction in plasma 
sVCAM-1 and sICAM-1 was significant. However, after correction for multiple testing, 
these results were no longer significant. A reduction of sVCAM-1 and sICAM-1 may reduce 
plaque formation, whereas the downregulation of sP-selectin may result in a more-balanced 
control of platelet aggregation. The combination of both effects may result in a synergistic 
protection of the endothelium against atherosclerosis. Other human trials that have 
investigated the effect of hesperidin on adhesion molecules have been scarce. Rizza et al.13 
showed a downregulation of the adhesion molecule sE-selectin after 3 wk of hesperidin 
supplementation in metabolic syndrome individuals. However, another study in overweight 
men did not observe significant differences in circulating adhesion molecules after 4 wk of 
supplementation with hesperidin.43 Human trials that have investigated the effect of other 
polyphenols on adhesion molecules have shown conflicting results.34,44-48 We anticipated 
seeing the effects of repeated intake of hesperidin for a certain period. The study design 
allowed us to also assess the effect of a single dosage of hesperidin 2S. In the FMD ≥ 3% 
group, the postprandial downregulation of sICAM-1 was observed after 1 dose of 
hesperidin 2S in response to a fat load. This observation is in line with other literature.47,49-51 
The BP-lowering effect of hesperidin, and of polyphenols more generally, has been shown 
in several human-intervention studies28,34,43,52-54 although the effect has not been confirmed 
in all studies.13,33,45 Possible mechanisms by which polyphenol-rich food products lower BP 
involve an increase in the NO-synthase concentration55,56 or the inhibition of the 
angiotensin-converting enzyme.57,58 As previously discussed, the mitigation of fed-state 
oxidative stressors and the downregulation of molecules by 6 wk of hesperidin 2S use might 
reflect an improved functionality of the endothelium, which is capable of producing NO, 
with a consequent vasodilatation and decrease in BP. In this study, a nonsignificant (but 
nearly significant) reduction in both SBP and DBP was observed in the total study 
population and in the subgroup. There is a linear relation between BP and mortality from 
stroke and ischemic heart disease that underscores the importance of BP control.59 The 
hesperidin-induced lowering of SBP (5 mm Hg) may be of clinical relevance because 
reductions of this magnitude are associated with a decrease in mortality of 14% from stroke 
and 9% from coronary heart disease.60 In addition, we observed a hesperidin-induced 
reduction of 2 mm Hg in DBP, which has been calculated to result in a 17% decrease in the 
prevalence of hypertension, a 15% reduction in risks of stroke and transient ischemic 
attacks, and a 6% reduction in risk of coronary heart disease in a general population.61 
Obesity is typically associated with a wide cluster of metabolic alterations including 
dyslipidemia and glucose homeostasis disorders. Both in vitro and in vivo studies have shown 
beneficial effects of hesperidin treatment on cholesterol62-65 and glucose metabolism.63,66,67 
In the current study, supplementation with hesperidin 2S in overweight but otherwise healthy 
volunteers did not affect systemic glucose, insulin, and lipid concentrations. This finding was 
not unexpected, because the participants had completely normal values at the start of the 
trial. 
Because we aimed to work with a broad, representative population rather than screening 
for a specific suboptimal population, we applied a unique test design to evaluate both the 
acute and 6-wk effects of hesperidin 2S. Some potential shortcomings should be considered. 
First, brachial FMD was used for measuring EF; an extrapolation of our findings to the 
coronary circulation should be made with caution. However, there has been extensive 
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evidence on the correlation of EF in the 2 vascular beds.68,69 Second, to assess the 
postprandial effect of hesperidin 2S, we chose to perform the postprandial FMD 2 h after 
intake of the HFM. It is possible that we missed an effect between the time of intake and 2 
h after intake. Furthermore, we did not fully control the diets of our participants. We 
instructed the subjects to maintain their habitual diets during the study period but to abstain 
from intakes of hesperidin-rich foods. We aimed to assess the effect of hesperidin 2S when 
supplementing the habitual diet, which is in line with future applications. 
In conclusion, 6 wk of hesperidin 2S supplementation in healthy, overweight individuals did 
not improve basal or postprandial FMD. However, the supplementation appeared to 
reduce circulating adhesion molecules and tended to lower both SBP and DBP. In a subset 
of subjects with baseline FMD ≥ 3%, 6 wk of hesperidin 2S intake protected them from a 
deterioration in FMD after intake of an HFM. In addition, in this subgroup, the reduction in 
adhesion molecules was significant. Further research to confirm these exploratory findings is 
warranted. However, these results reflect the potential preventive therapeutic properties of 
hesperidin 2S. These properties were not observed when looking at the population as a 
whole, probably because a number of participants had such a deteriorated endothelium 
that could not be affected by an intervention. Our exploratory findings suggest that 
hesperidin 2S might be beneficial in individuals with a relatively healthy and, therefore, 
favorably modifiable endothelium. This possibility underlines the need for early diagnosis 
and reveals the opportunities for the cardiovascular health benefits of hesperidin 2S in 
preventive medicine. 
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Abstract 
Background 
The intestinal ecosystem plays an important role in host homeostasis. Obesity-related changes in gut 
microbiota composition and microbial activity may promote the development of metabolic 
disturbances, such as insulin resistance. Hesperidin, a citrus polyphenol with antioxidant and other 
biological properties, is poorly absorbed in the small intestine and therefore reaches the colon, where 
it interacts with the colonic microbiota. In line with this, it may therefore exert beneficial effects on 
gastrointestinal (GI) and systemic metabolic disturbances. 
 
Objective 
Primary aim of the study was to investigate the effect of 12 wks hesperidin 2S supplementation on 
glucose regulation. Secondly, we aimed to investigate the effect of hesperidin 2S on modulation of the 
intestinal environment and on systemic metabolic parameters in subjects with features of metabolic 
syndrome (MetS). 
 
Design 
In this randomized, double-blind, placebo-controlled study, 50 individuals were randomly assigned to 
groups receiving hesperidin 2S (Citrus sinensis extract; 450 mg/d) or placebo for 12 wks. 
Measurements at baseline and after 12 wks intervention included oral glucose tolerance test (OGTT), 
blood lipids, blood pressure (BP), fecal short-chain fatty acids (SCFA) and fecal calprotectin. 
Additionally, after 6 wks intervention fasting glucose, insulin, blood lipids and BP were measured. 
 
Results 
No significant changes in fasting glucose and insulin and in AUC0-120min glucose and AUC0-120min insulin 
were observed after 12 wks hesperidin intake, compared to placebo. While hesperidin 2S did not 
quantitatively affect total fecal SCFA concentrations, it beneficially altered the SCFA profile by 
inducing a shift from acetate to butyrate (P = 0.020). Fecal calprotectin showed a near-significant 
reduction after 12 wks hesperidin supplementation, compared to placebo (P = 0.058). No significant 
changes in blood lipids and BP were observed after hesperidin intake, compared to placebo. 
 
Conclusions 
Twelve weeks consumption of hesperidin 2S beneficially altered the fecal SCFA profile and 
calprotectin concentrations, without affecting glucose regulation, blood lipids or BP in subjects with 
features of MetS. 
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Introduction 
The rapidly growing prevalence of obesity, and its metabolic and gastrointestinal (GI) 
consequences, is a major public health concern.1 Hence, developing new preventive and 
therapeutic strategies is important. In this respect, the use of polyphenols appears to be an 
attractive approach as these compounds are potent antioxidants exerting anti-inflammatory, 
anti-diabetic, anti-hypertensive and antihyperlipidemic effects.2 Hesperidin (hesperetin-7-O-
rutinoside), a polyphenol abundantly present in the peels of citrus fruits, is such a promising 
compound. It showed to decrease the gene expression of cyclooxygenase-2, demonstrating 
its anti-inflammatory potential.3 Furthermore, it significantly improved hyperglycemia by 
increasing glucose utilization in a diabetic mice model.4 In humans, three weeks daily 
supplementation of hesperidin caused a trend towards improving insulin resistance in MetS 
patients.5 Additionally, it showed to exert lipid lowering activity in hyperlipidemic rats6 and 
hyperlipidemic humans.7 Also blood pressure (BP) was reduced after hesperidin treatment, 
both in spontaneously hypertensive rats8 and in humans.9 Obesity and metabolic syndrome 
(MetS) have also been associated with changes in gut health, mainly caused by alterations 
in the composition of gut microbiota, microbial and metabolic activity.10,11 Interestingly, 
recent data suggest that different polyphenolic compounds, including hesperidin, are able 
to modulate the gut microbiome structure and function, thereby beneficially affecting gut 
health.12,13 As hesperidin is poorly absorbed in the small intestine, a major fraction reaches 
the colon where it indeed can interact with the intestinal microbiota.14 However, low 
solubility of hesperidin limits its bioavailability and biological activity in vivo, including local 
effects in the intestine.15 Furthermore, while natural products contain high concentrations of 
the most active form of hesperidin (hesperitin-7-O-rutinoside 2S), typical hesperidin extracts 
on the market mainly contain the less active 2R enantiomer.16 
This study was conducted to investigate the effect of 12 wks supplementation of a 
hesperidin 2S extract (Cordiart), a hesperidin enantiomer which has an improved 
bioavailability and biological activity, on GI and on systemic metabolic parameters in 
individuals with features of MetS. We hypothesized that 12 wks hesperidin 2S 
supplementation will exert a) gastrointestinal effects with changes in metabolic activity of gut 
microbiota and intestinal inflammation, and b) systemic effects consisting of improvement in 
glucose regulation, lowering of systolic and diastolic BP, and improvement of blood lipid 
profile in individuals with features of MetS. Primary aim of our study was to investigate the 
effect of 12 wks supplementation of hesperidin 2S on glucose regulation, assessed via an 
oral glucose tolerance test (OGTT). Secondary, we aimed to investigate: 1) gastrointestinal 
effects, by measuring fecal short-chain fatty acids (SCFA) concentrations and fecal 
calprotectin and 2) systemic effects, by measuring BP and blood lipids. 
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Materials and methods 
The study was approved by the Medical Ethics Committee of the Maastricht University 
Medical Center (MUMC+) and conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013 and with the Dutch Regulations on 
Medical Research involving Human Subjects (WMO, 1998). The study was performed at 
the MUMC+ from February 2015 to November 2015. All participants gave written 
informed consent before participation. The trial has been registered in the Clinical Trials 
register (NCT02610491). 
Subjects 
Volunteers were recruited by advertising in the local media. Inclusion criteria were age 
between 18 and 66 yrs, and two of the following: waist circumference >102 cm (males) or 
>88 cm (females), abnormal fasting serum triglycerides ≥1.7 mmol/l, abnormal fasting serum 
HDL-cholesterol ≤1.0 mmol/l (males) or ≤1.3 mmol/l (females), systolic BP (SBP) ≥130 mmHg 
and/or diastolic BP (DBP) ≥85 mmHg, elevated fasting plasma glucose ≥6.1 mmol/l.17 
Exclusion criteria were: diabetes mellitus (defined as fasting plasma glucose of ≥7 mmol/l); 
any medical condition that might interfere with the study and might jeopardise the health 
status of the participant; smoking; abuse of alcohol (>20 alcoholic units / week) and drugs; 
no consistently stable body weight for at least 3 months (±3 kg); plans to lose weight or 
following energy restriction diet during study period; use of medication / vitamin-, mineral- 
or antioxidant supplements; use of antibiotics in the 90 days prior to start of the study; 
pregnancy and lactation; history of any side effects towards the intake of flavonoids or 
citrus fruits; failure to comply with prohibited intake of hesperidin rich food products. During 
the study period, subjects consumed their habitual diet. During the trial intake of hesperidin-
rich food products was prohibited. 
Design and intervention 
This study was designed as a randomized, placebo-controlled, double-blind, parallel group 
study (Online Supplemental Material Figure S7.1). Each subject underwent 3 test days. 
Participants were randomly assigned in a double-blind fashion to one of the two 
intervention arms: hesperidin 2S or placebo (cellulose). An independent person generated 
the randomization list, using a computerized procedure. All participants and investigators 
remained blind to treatment until all analyses had been completed. From 4 days prior to 
start of the study until the last test day, participants were instructed to refrain from 
consuming any hesperidin rich food products. Furthermore, participants were requested to 
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abstain from strenuous physical exercise and consumption of alcohol on the day before 
each test day. Assessments took place in a quiet, temperature-controlled (20-24°C) room.  
After an overnight fast, subjects collected a fecal sample on the first test day. Subsequently, 
anthropometric measurements (height, body weight, waist-to-hip circumference) were 
performed and BP was measured. Subsequently, an intravenous catheter was inserted into 
the antecubital vein of the arm and blood samples were collected. Next, the participant was 
instructed to ingest 75 g glucose (OranGluc75, Novolab, Geraardsbergen, Belgium) within 
5 minutes. Blood samples for glucose and insulin concentrations were collected before and 
at 30, 60, 90 and 120 minutes after ingestion of the glucose load, respectively. At the end 
of the test day the intravenous catheter was removed and participants received the study 
products for the first 6 wks. After 6 wks of daily supplementation, test day 2 was organized. 
After an overnight fast, BP was measured and blood samples were taken. Again, study 
products for another 6 wks were provided. Test day 3 was conducted at the end of the 
supplementation period of 12 wks. Measurements were identical to the measurements 
performed on test day 1. To assess compliance, participants were asked to save the empty 
and (partly) full blister packs and to return these at the last visit. Also, in the first and last 
week of the study period participants were asked to fill out a 3-day food record to assess 
whether they maintained their dietary habits throughout the study period. 
Hesperidin 2S and placebo 
Hesperidin 2S (450 mg, supplied as 500 mg Cordiart, BioActor BV, Maastricht, The 
Netherlands) was extracted from the Citrus sinesis immature fruit, containing both the S and 
R enantiomers in the natural 4:1 S:R ratio of hesperidin. Cellulose (500 mg microcrystalline 
cellulose; Aminolabs; Hasselt; Belgium) served as placebo. The study products were 
formulated into capsules, each containing 250 mg study product or placebo. Subjects were 
asked to ingest two capsules each morning with 200 ml water, just before consuming 
breakfast, for 12 wks. 
Fecal SCFA determination 
Fecal samples were collected by the participants and stored at -20°C until handed in at the 
study site. For SCFA analysis, aliquots of approximately 1 g of fecal samples were diluted 
and homogenized with 6 ml demineralized water. After removal of the particulate material 
by centrifugation (10 min, 500 x g), the supernatants were stored at -20°C prior to 
analysis.18 SCFA concentrations in the supernatants were determined using gas 
chromatography with flame ionization detector. Total SCFA was defined as the sum of 
acetate, propionate, butyrate, isobutyrate, valerate, isovalerate, caproate and isocaproate. 
The analysis was identical to the SCFA analysis described by Possemiers et al.19 
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Fecal calprotectin 
Fecal calprotectin concentration levels were determined using an ELISA for human 
calprotectin (Hycult Biotechnology, Uden, Netherlands), according to the manufacturer's 
protocol. Briefly, 5 ml of extraction buffer (0.1 M Tris, 0.15 M NaCl, 1.0 M Urea, 10 mM 
CaCl2H2O, 0.1 M Citric Acid and 0.5% BSA, pH 8) was added to 100 mg of feces. The 
suspension was vortexed and shaken for 30 minutes with a rotating shaker at 4°C. After 
shaking, the suspension was centrifuged at 10,000 rpm for 20 minutes at 4°C. The 
supernatant was stored at -20°C until analysis. 
Glucose / insulin metabolism 
Oral glucose tolerance test (OGTT) 
Blood samples for measuring glucose and insulin concentrations were collected before and 
at 30, 60, 90 and 120 minutes after ingestion of the glucose load, respectively. Serum 
concentrations of glucose were measured by spectrophotometry (cobas 6000 analyzer 
series, Roche Diagnostics, Indianapolis, USA). Plasma insulin was determined using a 
luminescence-enhanced immune-enzymatic assay (Immulite 2000 immunoassay system, 
Siemens Healthcare, Erlangen, Germany). Results are presented as glucose and insulin 
120-min AUC (AUC0-120 min). The AUC0-120min was calculated by the trapezoidal method. 
Homeostasis model assessment of insulin resistance (HOMA-IR) 
OGTT values were used for calculating HOMA-IR index, an index of insulin resistance.20 It 
was calculated as the product of fasting plasma glucose (mmol/l) and insulin (mU/l) 
concentrations divided by 22.5.  
Quantitative insulin sensitivity check index (QUICKI) 
OGTT values were also used for calculating the QUICKI, an index of insulin sensitivity.21 It 
was calculated as: 1 / (log insulin 0 h + log glucose 0 h). 
Insulin sensitivity index (ISI) – Matsuda22 
OGTT values were used for calculation the composite ISI, an index of insulin sensitivity. It 
was calculated as: 10,000 / (√(glucose 0 h * insulin 0 h) * √(glucose mean * insulin mean)). 
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Blood lipids 
Blood samples were collected at baseline, after 6 wks supplementation and at completion 
of the study at 12 wks. Serum concentrations of total cholesterol, LDL- and HDL-cholesterol 
and triglycerides were measured by spectrophotometry (cobas 6000 analyzer series, 
Roche Diagnostics, Indianapolis, USA). 
Blood pressure measurements 
BP was monitored using a semi-continuous BP monitoring device (Omron, Hoofddorp, The 
Netherlands) at the upper left arm. On each occasion, after 30 minutes of rest in the supine 
position, 4 consecutive BP measurements were performed. The first measurement was 
discarded and the remaining 3 measurements were averaged. Measurements took place at 
baseline, after 6 wks supplementation and at the end of the study period. 
Statistics 
The primary outcome of the study was the effect of 12 wks hesperidin 2S supplementation 
on glucose regulation, assessed via an OGTT, compared to placebo. Secondly, we 
investigated the effects of 12 wks hesperidin 2S supplementation on local GI parameters: 
fecal SCFA concentrations and fecal calprotectin, and on systemic metabolic parameters: 
blood lipids and BP. Sample size was determined for the primary outcome of the study, 
using a significance level alpha = 0.05 and a power of 80%. Based on a study investigating 
the effect of polyphenols on insulin sensitivity in overweight individuals,23 we calculated that 
a sample size of 50 subjects would be required to detect a difference in ISI index of 0.98 ± 
1.2% (mean ± SD). Baseline characteristics are presented as mean (SD) for numerical 
variables and number (%) for categorical variables. Differences in fecal SCFA, fecal 
calprotectin, glucose regulation, blood lipids and BP between intervention groups 
(hesperidin 2S and placebo) were assessed using mixed models with group (placebo and 
hesperidin 2S), time (0, 6 wks and 12 wks) and group*time as fixed factors, where an 
unstructured covariance structure was used for repeated measures. The linear mixed model 
accounts for the correlation between repeated measures and missing data, where a 
likelihood approach was used assuming data missing at random. The estimated means and 
SEM obtained from this model were presented for each group and each time point. Two-
sided P-values ≤ 0.05 were considered statistically significant. Statistical analysis was 
performed using IBM SPSS Statistics for Windows (version 21.0, Armonk, NY, USA). 
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Results 
Participants 
Initially, 53 healthy volunteers were enrolled in the study, of which 50 completed the entire 
study protocol. Three participants were included and randomized to a treatment but never 
started participation due to private reasons. Baseline characteristics of the study 
participants are presented in Table 7.1.  
 
Table 7.1 Baseline characteristics of study participants.1 
 Total population 
(n = 50) 
Placebo  
(n = 27) 
Hesperidin 2S 
(n = 23) 
Age, yr 51 ± 132 50 ± 13 52 ± 11 
Sex, M/F 18/32 9/18 9/14 
WHR 0.93 ± 0.07 0.91 ± 0.07 0.94 ± 0.07 
BMI, kg/m2 30.8 ± 3.80 31.4 ± 4.20 30.0 ± 3.20 
1WHR, waist-to-hip-ratio. BMI, body mass index. 2Mean ± SD (all such values). 
 
Fecal SCFA 
Data on fecal SCFA concentrations are shown in Table 7.2. Twelve wks daily intake of 
hesperidin 2S did not significantly change fecal concentrations of total SCFA, branched 
SCFA, and of acetate, propionate and butyrate, compared to placebo. However, the 
butyrate proportion of the total SCFA significantly increased after 12 wks hesperidin 2S 
intake (P = 0.031). Furthermore, the butyrate over acetate ratio significantly increased in the 
hesperidin 2S group, compared to placebo (P = 0.020). 
Fecal calprotectin 
Fecal calprotectin showed a trend towards a reduction after 12 wks hesperidin 2S 
supplementation, compared to placebo (P = 0.058, Table 7.2). 
Glucose / insulin metabolism 
Baseline glucose and insulin concentrations were all within normal blood value ranges. No 
significant differences were observed in AUC0-120min for both glucose and insulin between 
intervention groups (Table 7.3). Neither were significant effects of the intervention found in 
glucose and insulin concentrations at baseline and at 30 min, 60 min, 90 min and 120 min 
after glucose load, respectively (data not shown). Consistent with these findings, hesperidin 
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2S supplementation did not improve insulin sensitivity or reduce insulin resistance after 6 or 
12 wks supplementation, compared to placebo. 
 
Table 7.2 Gastrointestinal parameters at baseline and after 12 wks supplementation with placebo or 
hesperidin 2S.1 
Placebo Hesperidin 2S  
Baseline 12 wks Baseline 12 wks 
P value 
Proteins 
   Calprotectin (ng/ml) 32.9 ± 7.82 42.5 ± 7.6 47.5 ± 8.7 37.1 ± 8.4 0.058 
Short-chain fatty acids 
   Total (μmol/g feces) 59.8 ± 5.1 68.2 ± 5.9 72.9 ± 5.5 79.4 ± 6.4 0.806 
   Branched (μmol/g feces)   3.1 ± 0.3   3.2 ± 0.4   3.6 ± 0.4   3.9 ± 0.4 0.807 
   Acetate (μmol/g feces) 32.9 ± 3.0 38.4 ± 3.4 39.8 ± 3.3 42.9 ± 3.6 0.625 
   Propionate (μmol/g feces) 11.1 ± 1.3 12.9 ± 1.6 13.9 ± 1.4 14.1 ± 1.7 0.465 
   Butyrate (μmol/g feces) 10.4 ± 1.1 10.9 ± 1.3 12.4 ± 1.2 15.0 ± 1.4 0.249 
   Acetate / total SCFA ratio   0.61 ± 0.01   0.62 ± 0.01   0.61 ± 0.01   0.60 ± 0.02 0.079 
   Propionate / total SCFA ratio   0.20 ± 0.01   0.20 ± 0.01   0.21 ± 0.01   0.20 ± 0.01 0.812 
   Butyrate / total SCFA ratio   0.19 ± 0.01   0.18 ± 0.01   0.18 ± 0.01   0.20 ± 0.01 0.031 
   Butyrate / acetate ratio   0.32 ± 0.02   0.29 ± 0.02   0.31 ± 0.03   0.35 ± 0.02 0.020 
1 Differences between placebo and hesperidin tested with linear mixed model with correction for baseline values. 
P value represents the p-value for the analysis of baseline versus 12 wks intervention between placebo and 
hesperidin 2S. 2Estimated mean ± SEM (all such values). 
 
Blood lipids 
Baseline total cholesterol, LDL- and HDL-cholesterol and triglycerides were all within normal 
blood value ranges. These parameters were not significantly altered by 6 or 12 wks 
supplementation with hesperidin 2S, compared to placebo (Table 7.3). 
Blood pressure 
Results regarding the effect of hesperidin 2S administration on BP are given in Table 7.3. 
No significant changes in SBP, DBP and HR were observed after 6 or after 12 wks 
supplementation between intervention groups. 
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Discussion 
The effects of hesperidin 2S on glucose regulation, local GI parameters and systemic 
metabolic parameters were assessed in subjects with features of MetS. After 12 wks daily 
intake of hesperidin 2S, no significant changes were observed in glucose regulation, 
compared to placebo. Interestingly, although the total SCFA production did not change, 
hesperidin 2S significantly altered the SCFA profile by inducing a shift from acetate to 
butyrate. Furthermore, hesperidin 2S supplementation resulted in a reduction in fecal 
calprotectin that just failed to reach statistical significance. No differences in blood lipids or 
in BP were observed between the intervention groups.  
It has been suggested that dietary polyphenols lower the risk of developing DM2. Several 
mechanisms of action have been described explaining through which the blood glucose 
lowering effects of hesperidin are mediated. First, polyphenols were shown to inhibit the 
digestion of dietary carbohydrates by inhibition of key enzymes involved in carbohydrate 
digestion.24 Second, absorption of glucose in the intestine can be impeded by polyphenols.25 
Third, enhanced insulin-mediated tissue uptake of glucose has been observed with different 
polyphenols.26 Fourth, another mechanism includes the potential of polyphenols to protect 
against cytokines induced pancreatic β-cell damage, thereby maintaining insulin secretion.27 
Additionally, by increasing hepatic glucokinase activity, which augments glucose utilization, 
and by suppressing hepatic glucose production (i.e. gluconeogenesis) antidiabetic effects 
can be exerted by several polyphenols.28 Finally, polyphenol-mediated modulation of 
inflammation was shown to improve insulin sensitivity in obese mice and rats.29 
Another mechanism through which polyphenols were shown to induce hypoglycemic effects 
is by modulating gut microbiota composition and their metabolic activity.13,30 It has become 
evident that the gut microbiota fulfill an important role in host homeostasis, being involved in 
many processes such as metabolism of nutrients and drugs, regulation of several metabolic 
pathways, maintaining epithelial integrity, modulating GI motility, stimulation and maturation 
of both systemic and mucosal immunity, and production of vitamins and micronutrients.31 
SCFA are produced by bacterial fermentation of mainly undigested dietary carbohydrates. 
Many of the beneficial physiological properties of the gut microbiota can be attributed to 
the production of SCFA as these metabolites showed to exert antioxidant, anti-inflammatory 
and immune modulating effects.32 SCFA are able to bind and activate G-protein-coupled 
receptors in gut epithelial cells. Activation of these receptors induces gut hormone secretion, 
such as glucagon-like peptide (GLP)-1, GLP-2 and peptide YY (PYY), which increase insulin 
sensitivity and decrease inflammation.33 It has also been suggested that SCFA are able to 
modulate insulin sensitivity by altering fatty acid flux. Lowering postprandial free fatty acids 
(FFA) appeared to improve insulin sensitivity and insulin secretion.34 The SCFA butyrate 
beneficially affects oxidative stress in the colonic mucosa, by increasing expression levels of 
the antioxidant glutathione and decreasing expression levels of uric acid, a predictor in the 
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development of insulin resistance.35 In humans, increasing intestinal butyrate-producing 
microbes concomitantly improved insulin sensitivity.36 
In this intervention study, we measured fecal SCFA concentrations to assess microbial 
activity. We did not observe differences in the quantity of acetate, propionate or butyrate 
production between the intervention groups. However, we did observe a hesperidin-
induced alteration in SCFA profile. A significant shift from acetate towards the health-
promoting SCFA butyrate was identified, possibly via an intestinal stimulation of butyrate-
producing bacteria. This finding is in line with recent evidence, suggesting that a number of 
polyphenols and their metabolites are able to influence microbiota composition and 
microbial activity.12,13 Butyrate not only improves insulin sensitivity, but also serves as an 
energy source for epithelial cells, exerts anticarcinogenic, anti-inflammatory and antioxidant 
effects, and is essential in maintaining the colonic defence barrier.37 We did not observe 
any change in glucose regulation (both circulating concentrations of glucose and insulin) in 
the present study. It should be noted that virtually all participants had normal fasting blood 
glucose values and OGTT values at start of the trial. Results might have been different when 
glucose-intolerant subjects had been studied. However, even in glucose-intolerant subjects 
controversial results have been reported. Dark chocolate polyphenols showed to improve 
insulin sensitivity,38 while epigallocatechin-3-gallate supplementation did not.39 
Calprotectin, a protein secreted by neutrophils infiltrating the intestinal mucosa, is 
considered a marker of whole gut inflammation. Elevated concentrations of fecal 
calprotectin are found in patients with chronic intestinal inflammation such as inflammatory 
bowel disease, but also in obese individuals.40 We found fecal calprotectin levels within the 
normal range, but higher than those reported in healthy controls. After the intervention, 
fecal calprotectin was reduced in the hesperidin 2S treated group vs. placebo, although this 
difference just failed to reach statistical significance. It is tempting to speculate on the 
mechanism of this reduction: whether it is related to changes in gut microbiota and gut 
metabolism.41 It has previously been shown that pre- and probiotics can reduce fecal 
calprotectin levels, probably through alterations in the gut microbiome.42,43 
The presence of dyslipidemia is common in obesity.44 Hesperidin is known to lower blood 
lipids in vitro and in vivo, possibly by affecting enzymes involved in lipogenesis, fatty acid 
biosynthesis, triglyceride synthesis, cholesterol synthesis and cholesterol absorption, and by 
facilitating fecal triglyceride and cholesterol excretion.28,45-47 Here, we did not observe 
alterations in systemic lipid concentrations after 6 or 12 wks hesperidin 2S intake. This 
finding was not unexpected as participants had completely normal values at start of the trial. 
In the present study, hesperidin 2S did not improve systolic or diastolic BP. Most of the 
studies reporting a polyphenol-induced BP reduction have included hypertensive subjects, 
while in our study BP values at baseline were within normal ranges. Putative methods by 
which polyphenols lower BP include increasing nitric oxide synthase concentrations48 or 
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inhibiting angiotensin-converting enzyme.49 Hesperidin and other polyphenols showed to 
have the potential to reduce BP in vivo,9,38 although other studies have not observed this.5,50 
A few limitations of our study should be considered. First, we used the OGTT, a surrogate 
marker for insulin sensitivity instead of the euglycemic hyperinsulinemic clamp, which is 
considered the gold standard method. However, that method is an expensive, time 
consuming, labor intensive method requiring an experienced operator. Second, to assess the 
microbiota fermentation capacity we measured fecal SCFA concentrations. As these 
metabolites are efficiently absorbed from the gut - with only 5% to 10% being excreted via 
the feces - they may not accurately reflect the exact intraluminal SCFA concentrations. 
However, previous studies have shown that the ratio between the respective SCFA 
concentrations, measured in feces and colon, is comparable.51 Thus, changes in fecal SCFA 
concentration reflect relative changes in intestinal concentrations of the separate SCFA. 
Furthermore, although we included subjects at risk for MetS, most baseline parameters were 
already within normal ranges at start of the study. Inducing a systemic beneficial effect in a 
generally healthy population through a dietary intervention is challenging. Finally, we did 
not fully control the diet of our participants. We instructed them to maintain their habitual 
diet during the study period, but to abstain from intake of hesperidin-rich foods. We aimed 
to assess the effect of hesperidin 2S when supplementing the habitual diet, which is in line 
with future applications. 
In conclusion, 12 weeks oral supplementation with hesperidin 2S did not significantly 
influence glucose regulation in subjects with features of MetS. Interestingly, it modulated the 
GI environment as reflected by a shift in fermentation (SCFA) profile from acetate to 
butyrate, and a near-significant reduction in fecal calprotectin levels. These changes were 
not accompanied with changes in blood lipids or BP. These results reinforce the hypothesis 
that polyphenolic compounds are able to modulate gut microbiota composition and function, 
thereby promoting gut and host health. 
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Chapter 8 
Randomized controlled trial on the intestinal fate and 
effects of the carotenoid-producing Bacillus strain PD01 on 
gastrointestinal and systemic parameters in overweight 
individuals 
 Salden BN, Stevens YR, Troost FJ, Possemiers S, Masclee AA 
Chapter 8 
158 
 Intestinal fate and effects of carotenoid-producing bacillus strain PD01 
159 
Abstract 
Background 
Bacillus indicus PD01 is a spore-forming bacterium, which naturally produces high levels of gastric-
stable carotenoids with superior bioavailability and antioxidant properties as compared to plant 
carotenoids. In combination with potential direct probiotic properties of PD01 itself, the intestinal 
release of carotenoids may both have local effects in the intestine and systemic effects on 
cardiovascular or metabolic parameters. Until now no reports have been described confirming these 
properties in humans. 
 
Objective 
In this explorative study we aimed to confirm the intestinal fate of PD01 and the bioavailability of its 
carotenoids and to investigate the effect of 6 wks PD01 supplementation on both gastrointestinal (GI) 
and systemic parameters related to oxidative stress in overweight individuals. 
 
Design 
In this randomized, double-blind, placebo-controlled study, 68 overweight yet healthy individuals 
were randomly assigned to groups receiving PD01 or placebo for 6 wks. On each test day, blood 
was sampled to measure bacterial carotenoids, antioxidant activity, oxidative stress biomarkers, 
adhesion molecules and metabolic markers. Fecal samples were obtained to assess the intestinal fate 
of PD01 and its effect on gut microbiota composition, microbial activity and calprotectin levels. Urine 
was collected to assess oxidative stress and GI permeability markers. Also blood pressure (BP) was 
measured, and questionnaires were filled out. 
 
Results 
PD01 was able to germinate efficiently (73% vegetative cells in feces) and to release its carotenoids 
as shown by the detection of PD01 carotenoids in blood. In this explorative study no significant effects 
on intestinal barrier function nor microbiota composition nor intestinal or systemic effects could be 
confirmed. No adverse events were reported in relation to PD01 intake, confirming that repeated 
intake of PD01 was well tolerated. Additionally, PD01 intake was associated with a significant 
reduction in symptoms of indigestion. 
 
Conclusions 
This study provides the first evidence in humans that PD01 is able to germinate and release bacterial 
carotenoids, which are absorbed and detected in human blood. No intestinal or systemic effects were 
observed but GI symptoms improved significantly. These encouraging results warrant further large-
scale research in specific target populations to investigate the specific bioactivities of PD01 at 
intestinal and systemic level. 
Chapter 8 
160 
Introduction 
The incidence of cardiovascular diseases (CVD) varies worldwide, but is notably lower in 
countries where a ‘Mediterranean diet’ predominates. This diet contains relatively large 
amounts of fruit, vegetables and olive oil.1 Carotenoids, the pigments responsible for the 
yellow to red color of some fruits and vegetables, have been indicated as one of the 
beneficial components of the Mediterranean Diet.2 Associations between high carotenoid 
intake and protection against oxidative stress, inflammation, endothelial dysfunction, 
hypertension and atherosclerotic progression have been demonstrated.3,4 The protective 
effects of carotenoids are related, at least in part, to their potent antioxidant capacity, 
which has been well demonstrated in in vitro assays.5 However, the relevance of their 
antioxidant properties in vivo is still debated. It is likely that other biological effects of 
carotenoids also contribute to their health protective effects.6 
Carotenoids are lipophilic antioxidants, synthesized mainly in plants. Humans are not able to 
synthesize carotenoids and therefore are dependent on dietary sources. The majority of 
commercially available natural carotenoids are derived from plant-based materials. 
However, the quality and consistency of these carotenoids varies considerably. Interestingly, 
carotenoid-like molecules are also synthesized in nature by a number of bacterial species. In 
this respect, carotenoids produced by a variety of spore-forming bacillus strains are of 
specific interest.7,8 In vitro studies have shown that these bacterial carotenoids are stable in 
the stomach, are equally or even more bioaccessible and bioavailable than dietary 
carotenoids currently on the market, and exert a tenfold higher antioxidant activity 
compared to lycopene, one of the most potent antioxidants known. Furthermore, the 
carotenoid-producing bacillus strain itself may also possess probiotic properties.9 
Previous in vitro and animal studies have provided evidence that a specific Bacillus indicus 
strain, named PD01, has excellent intestinal survival and can germinate and replicate under 
intestinal conditions (unpublished data). Furthermore, its carotenoids are released in the 
intestine and they were shown to have a high bioavailability and a promising biological 
activity profile with strong antioxidant properties and effects both on CVD risk markers and 
on the intestinal environment (unpublished data). As such effects have not yet been 
confirmed in humans, the present human intervention study was undertaken to investigate 
whether PD01 is able to survive transit through the gastrointestinal (GI) tract and thereby is 
able to release systemically absorbable carotenoids in an in vivo setting. Additionally, the 
GI and systemic effects of the bacillus strain and its bacterial carotenoids were examined. 
We specifically chose to study a healthy, yet overweight-obese population, as this condition 
has previously been associated with higher risk of a wide range of GI and systemic 
metabolic alterations including gut microbiota,10 intestinal barrier,11 GI and systemic low-
grade inflammation,12,13 endothelial function,14 hypertension15 and glucose and lipid 
homeostasis.16,17 We hypothesized that PD01 is able to survive transit through the human GI 
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tract and that it is able to release bacterial carotenoids that can be absorbed and detected 
in human plasma. Furthermore, we hypothesized that 6 weeks daily PD01 supplementation 
beneficially affects 1) GI microbiota, barrier and metabolic function and 2) systemic 
antioxidant activity and metabolic function and 3) is well-tolerated in overweight individuals. 
Primary aim of our study was to investigate the efficacy of 6 wks daily supplementation of 
PD01 on oxidative stress, as measured by 24 h urinary excretion of F2-isoprostanes, in 
healthy overweight individuals. Secondary, we aimed to assess the plasma bioavailability of 
the bacterial carotenoids during 6 wks daily PD01 supplementation, and to investigate: 1) 
GI effects, by assessing gut microbiota composition, fecal short-chain fatty acids (SCFA) 
concentrations, GI permeability, fecal calprotectin, digestive tolerance and 2) systemic 
effects, by measuring total antioxidant capacity, plasma malondialdehyde (MDA), plasma 
adhesion molecules, fasting blood glucose, insulin and lipids markers and blood pressure. 
Subjects and methods 
This study was approved by the Medical Ethics Committee of the Maastricht University 
Medical Center + (MUMC+) and conducted in full accordance with the principles of the 
Declaration of Helsinki of 1975 as amended in 2013 and with the Dutch Regulations on 
Medical Research involving Human Subjects (WMO, 1998). The study was performed at 
the MUMC+ from August 2015 to December 2015. All participants gave written informed 
consent before participation. The trial has been registered in the Clinical Trials register 
(NCT02622425). 
Subjects 
Healthy, overweight or obese volunteers aged 18-70 years with a BMI between 
25-35 kg/m2 were recruited by advertisement. Exclusion criteria were: any medical 
condition that might interfere with the study and might jeopardize the health status of the 
participant; smoking; high intake of fruits and vegetables (> 75th percentile of dietary intake 
of fruits and vegetables in general Dutch population); abuse of alcohol (> 20 alcoholic units / 
wk) and drugs; no consistently stable body weight for at least 3 months (± 3 kg); plans to 
lose weight or following hypocaloric diet during study period; use of medication / vitamin-, 
mineral- or antioxidant supplements; consumption of pro-, pre- or synbiotics during study 
period and in 30 days prior to start of the study; use of antibiotics in the 90 days prior to 
start of the study; pregnancy and lactation; history of any side effects towards the intake of 
pro-, pre-, synbiotic supplements or carotenoids; failure to comply with prohibited intake of 
carotenoid-rich food products. During the study, the subjects consumed their habitual diet. At 
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the time of inclusion, all subjects were informed about the prohibited carotenoid-rich food 
products, pro-, pre- and synbiotics. 
Design and intervention 
This study was designed as a randomized, placebo-controlled, double-blind, parallel-group 
study. Each subject underwent three test days. Participants were randomly assigned in a 
double-blind fashion to one of the two intervention arms: PD01 or placebo (maltodextrin). 
An independent and blinded person generated the randomization list, using a computerized 
procedure. All participants and investigators remained blind to treatment until all analyses 
were completed. Participants were instructed to abstain from strenuous physical exercise, 
consumption of alcohol and carotenoid-rich food products on the day prior to each test 
day. Assessments were performed in a quiet, temperature-controlled (20-24°C) room. 
Subjects handed in a fecal sample on the first test day. Then, anthropometric measurements 
(height, body weight, waist-to-hip circumference) and BP measurements were performed. 
Subsequently, venous blood samples were collected from an antecubital vein in the fore-
arm. Then, subjects ingested a multi-sugar drink and collected full urine output for 24 h for 
measurement. Finally, the subject completed a questionnaire to assess the presence of GI 
symptoms, stool frequency and stool consistency. After completion of the baseline 
measurements, participants received the study product for the following 6 wks. After 3 wks 
of daily supplementation, the second test day was organized. Measurements were identical 
to the baseline measurements performed during the first test day, with the exception of the 
multi-sugar drink with 24 h urine collection, which was not performed after 3 wks of 
intervention. After 6 wks of daily administration of the study product, the third test day was 
organized, which was identical to the first test day. Furthermore, a 3-day food record was 
completed prior to start of the study (during screening) and in the last week of the 
intervention period, to assess whether the participants maintained their dietary habits 
throughout the study period. To assess compliance, participants were asked to collect the 
empty sachets and to return these at the last visit. 
PD01 and placebo 
PD01 (ProDigest, Ghent, Belgium) is a food-grade bacterial formulation containing 
carotenoid-producing Bacillus indicus spores, which were grown and lyophilized on a 
maltodextrin (Pineflow; Matsutani Chemical Industry, Hyogo, Japan) carrier by Biopolis 
(Paterna, Valencia, Spain). The study products were provided as a powder in sachets. The 
PD01 group received per day one sachet containing each 5*109 CFU PD01 with 
maltodextrin (3 g) as carrier material. The PD01 carotenoid content of the clinical batch was 
quantified as 2.81 μg per 109 CFU, thus participants received in total 14.05 μg PD01 
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carotenoids per day. The placebo group received one sachet containing 3 g maltodextrin 
per day. Subjects were asked to stir the content of one sachet in 150 ml whole fat milk and 
ingest the solution each morning, just before consuming breakfast, for 6 wks. 
Fecal PD01 quantification 
Plate counting  
Prior to analysis, fecal samples were thawed for 20 minutes and homogenized in sterile 
distilled water. Homogenized fecal samples were serially diluted in PBS buffer. Part of the 
dilutions was pasteurized (30 min at 65°C) to discriminate spores and viable cells. Both 
pasteurized and non-pasteurized samples were plated on agar plates, and incubated 
overnight at 37°C. Yellow to orange colonies were counted as these represent PD01. 
Blood sample pretreatment 
Plasma and serum isolation 
After blood collection, plasma was directly isolated by centrifugation (10 min, 1400 g, 4°C) 
and stored at -80°C. For serum isolation, blood samples were first kept at room temperature 
for 30 minutes. Then, serum was isolated by centrifugation (10 min, 1400 g, 21°C) and 
stored at -80°C. 
Bioavailability bacterial carotenoids  
After blood collection, blood samples were kept in an ice-water bath and light exposure 
was avoided. Plasma was isolated by centrifugation (10 min, 1400 g, 4°C) within 2 h 
following collection and stored at -80°C. 
Bioavailability of bacterial carotenoids in plasma 
Carotenoid extraction 
In a glass tube, 1 ml of methanol containing internal standard (echinenone at 0.5 mg/l) was 
added to 1 ml of plasma sample. The mixture was vortexed for 10 minutes and 1 ml of 
dichloromethane was added. After 10 additional minutes of vortexing, the mixture was 
centrifuged for 10 minutes at 10°C at 800 g. The organic phase was collected and 
evaporated under argon gas. 
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Lipolysis of carotenoid esters 
The dry extract was dissolved in 500 μl of 0.1 M phosphate buffer at pH 7.5 containing 
30 mg/ml of bile salts. 250 μl of lipase from Candida sp. and 250 μl of lipase from 
Thermomyces lanuginosis were added, and the solution was incubated for 1 hour at 37°C 
while stirring. After incubation, 500 μl of methanol was added, the mixture was vortexed for 
10 minutes, and 2 ml of methyl tert-butyl ether (MTBE) was added. After 10 additional 
minutes of vortexing, the mixture was centrifuged for 10 minutes at 10°C at 800 g. The 
organic phase was collected and evaporated under argon gas. 
HPLC analysis 
After evaporation to dryness, all extracts were dissolved in 200 μl of methanol:MTBE (1:1, 
v:v) and carotenoids were quantified by reverse-phase HPLC using an HP1100 Agilent 
system equipped with a YMC C30 column as described by Gleize et al.18 The non-
esterified carotenoids were identified based on retention time and UV-Visible spectra 
(Figure 8.1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 HPLC-UV VIS chromatogram of a lipophilic human plasma extract spiked with PD01 carotenoids to 
validate the method (1: Lutein, 2: Methyl-glycosyl-apo-8’-lycopenoate (non-esterified form of orange 
carotenoid produced by PD01 strain), 3: Glycosyl-apo-8’-lycopene (non-esterified form of yellow 
carotenoid produced by PD01 strain), 4: β-Carotene, 5: Lycopene). 
 
Fecal microbiota composition and microbial activity 
DNA extraction 
Total genomic DNA suitable for PCR analysis was extracted from frozen human fecal 
samples using the QIAamp® DNA Stool Mini Kit (QIAGEN) following manufacturer’s 
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instructions. The PCR products were purified, a metagenomics library prepared, sequenced 
and analyzed, as previously described by Hevia et al.19 
Gut microbiota composition 
Partial 16S rRNA gene sequences (V3 and V4 region) were amplified and sequenced as 
previously reported by Milani et al.20 The obtained individual sequence reads were filtered 
to remove low quality and polyclonal sequences, trimmed, and exported as .fastq files. These 
.fastq files were processed using a QIIME-based custom script.21 Quality control retained 
reads with a length between 140 and 400 bp, mean sequence quality scores > 20, and 
allowed truncation at the first base if a low- quality moving 10 bp window was found. 
Presence of homopolymers > 7 bp, and sequences with mismatched primers were omitted. In 
order to calculate downstream diversity measures (alpha and beta diversity indices, Unifrac 
analysis), 16S rRNA Operational Taxonomic Units (OTUs) were defined at ≥ 97% sequence 
homology using uclust.22 All reads were classified to the lowest possible taxonomic rank 
using QIIME and a reference dataset from the SILVA database.23 Similarities between 
samples were calculated by unweighted uniFrac.24 The range of similarities was calculated 
between 0 and 1. 
Fecal pH, SCFA, lactate and ß-glucuronidase activity  
Prior to analysis, fecal samples were thawed for 20 min and homogenized in sterile distilled 
water. Stool pH was determined for each sample upon tenfold dilution in sterile distilled 
water. pH was measured with a standard pH meter (Senseline F40; ProSense, Oosterhout, 
The Netherlands) with a conventional pH electrode (QP2111T; ProSense). 
SCFA concentrations were determined as described previously by Van de Wiele et al.25 
Homogenized stool samples were centrifuged at 7600 g for 5 minutes. Cell free 
supernatant (50 μl) was used for lactate measurement using a commercially available 
enzymatic assay kit (R-Biopharm, Darmstadt, Germany). Furthermore, cell free supernatant 
was diluted 1:1 (v:v) in sterile distilled water and transferred (50 μl) into a 96-well plate 
containing 50 μl/well of a 5 mM solution of 4-nitrophenyl β-D-glucuronide (Sigma-Aldrich, 
St-Louis, Missouri, USA). After 30 minutes of incubation at 37°C, the release of p-nitrophenol 
was quantified based on the absorbance at 405 nm using a Synergy HT multiplate reader 
(BioTek Instruments, Winooski, Vermont, USA). The results were expressed in μmol 
p-nitrophenol released per minute and per gram feces. 
Metabolomic analysis on fecal samples 
Metabolomic analysis was applied as previously described in detail by Vanden Bussche et 
al.26 
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Gastrointestinal permeability 
Gastrointestinal permeability was assessed by using a validated multi-sugar test, measuring 
the 24 h urinary excretion of ingested sugar probes reflecting permeability of 4 segments of 
the GI tract. The method of measurement has been described previously by Mujagic et al.27 
Urinary sugar probes were determined by HPLC-MS as previously described.28 
Fecal calprotectin 
Fecal calprotectin concentration levels were determined using an ELISA for human 
calprotectin (Hycult Biotechnology, Uden, Netherlands), according to the manufacturer's 
protocol. 
Antioxidant activity and biomarkers of oxidative stress 
Total antioxidant capacity (TAC) 
Plasma TAC was measured by a commercially available quantitative colorimetric assay kit, 
according to the manufacturer´s instructions (BioAssay Systems, Hayward, USA). Briefly, 
Cu2+ was reduced by the available antioxidants in the sample to Cu+. The resulting Cu+ 
formed a colored complex with a dye reagent, which was quantified colorimetrically 
(Bio-Tek, Synergy HT, Winooski, USA). This is proportional to the TAC in the sample. The total 
antioxidant capacity was expressed in mM Trolox equivalents. 
Urinary F2-isoprostanes 
Urinary F2-isoprostane concentration was measured by a commercially available enzyme 
immune assay (EIA) kit, according to the manufacturer’s instructions (Cayman Chemical Co., 
Ann Arbor, MI). Briefly, 500 μl urine was acidified to pH 4 and samples were applied to 
prewashed C-18 SPE cartridges (Cayman Chemical Co, Ann Arbor, MI), after which the 
eluate was added. The ethyl acetate/methanol eluate from the SPE cartridges was 
subsequently dried using vacuum centrifugation and reconstituted in EIA buffer. The samples 
were assayed in duplicate with standards (0–3000 pg/ml of 8-iso-PGF2a), and blanks. After 
an incubation period of 1 h the plate was washed and pNPP reagent was added. The 
resultant color reaction was read after approximately 1 h using a Bio-Rad plate reader at 
420 nm, the color development being inversely proportional to the concentration of 8-iso-
PGF2a measured. To optimize the assay, it was necessary to use ultrapure water for all 
aqueous reagents and to manually wash the plates. 
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Malondialdehyde (MDA) 
Plasma MDA was quantified by a commercially available microplate assay kit, according to 
the manufacturer’s protocol (Cohesion Biosciences Limited, London, United Kingdom). Briefly, 
the MDA in the sample reacted with Thiobarbituric Acid (TBA) to generate the MDA-TBA 
adduct. The MDA-TBA adduct was quantified colorimetrically (Bio-Tek, Synergy HT, 
Winooski, USA). 
Adhesion molecules 
Circulating soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble intercellular 
adhesion molecule-1 (sICAM-1), soluble E-selectin (sE-selectin) and soluble P-selectin 
(sP-selectin) were determined by commercially available ELISA and standards, according to 
the manufacturer´s protocol (Bender MedSystems GmbH, Vienna, Austria). 
Blood glucose, insulin and lipids 
Serum concentrations of glucose, total cholesterol, low-density lipoprotein (LDL)- and high-
density lipoprotein (HDL)-cholesterol and triglycerides were measured by 
spectrophotometry (cobas 6000 analyzer series, Roche Diagnostics, Indianapolis, USA). 
Plasma insulin was determined using a luminescence-enhanced immune-enzymatic assay 
(Immulite 2000 immunoassay system, Siemens Healthcare, Erlangen, Germany). Insulin 
resistance (IR) was estimated by the homeostasis model assessment of insulin resistance 
(HOMA-IR) index. It was calculated as the product of fasting plasma glucose (mmol/L) and 
insulin (mU/l) concentrations divided by 22.5. Insulin sensitivity (IS) was assessed using the 
quantitative insulin sensitivity index (QUICKI), calculated as: 1 / (log insulin 0 h + log glucose 
0 h). 
Blood pressure and heart rate measurements 
BP was monitored using a semi-continuous BP monitoring device (Omron, Hoofddorp, The 
Netherlands) at the upper right arm. At each occasion, after 30 minutes of rest in the supine 
position, 4 consecutive BP measurements were performed. The first measurement was 
discarded and the remaining 3 measurements were averaged.  
Digestive tolerance 
The occurrence of GI symptoms was assessed using the validated gastrointestinal symptom 
rating scale (GSRS), consisting of 15 items combined into five symptom clusters describing 
reflux, abdominal pain, indigestion, diarrhea, and constipation.29 In the seven-point graded 
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Likert-type GSRS, a score of 1 represents absence of troublesome symptoms and a score of 
7 represents very troublesome symptoms. Defecation frequency and stool consistency were 
assessed using the Bristol Stool Form Scale Chart.30 
Statistical analysis 
The primary outcome of the study was the effect of 6 wks PD01 supplementation on 24 h 
urinary excretion of F2-isoprostanes, compared to placebo. Sample size was determined for 
the primary outcome of the study, using a significance level alpha = 0.05 and a power of 
90%. Based on previous research,31 we calculated that a sample size of 60 subjects would 
be required to detect a difference in 24 h urinary F2-isoprostanes of 104 ± 85 pg/ml 
(mean ± SD). Baseline characteristics are presented as mean (SD) for numerical variables 
and number (%) for categorical variables. Differences in gut microbiota composition, 
microbial activity, GI permeability, GI inflammation, antioxidant activity, oxidative stress, 
adhesion molecules, metabolic markers, BP, and questionnaires between intervention groups 
(PD01 or placebo) were assessed using linear mixed models with group (placebo and 
PD01), time (1, 3 and 6 wks for 3 and 6 wks PD01 effect) and group*time as fixed factors, 
where an unstructured covariance structure was used for repeated measures. The linear 
mixed model accounts for the correlation between repeated measures and missing data, 
where a likelihood approach was used assuming data missing at random. The estimated 
means and SEM obtained from this model were presented for each group and each time 
point. In case of asymmetrical distribution of data, medians with interquartile ranges were 
displayed. The Friedman test with post-hoc Wilcoxon Signed Rank test was applied to 
compare the presence of PD01 in feces and bacterial carotenoids in plasma between 
baseline samples and samples obtained after 3 and 6 wks PD01 supplementation. The 
Wilcoxon Singed Rank test was used to compare the fecal microbiota composition at genus 
level between baseline samples and samples obtained after 6 wks supplementation in a 
treatment group. These statistical analyses were performed using IBM SPSS Statistics for 
Windows (version 21.0, Armonk, NY, USA).  
For the metabolomics analysis, chemometric data analysis was applied. First, extensive data 
pre-processing was conducted on the obtained full scan HRMS data files with SieveTM 2.2 
software (Thermo Fischer Scientific). Next, normalization of the dataset was performed to 
correct for instrumental drift. Next, a logarithmic transformation and a Pareto scaling 
(1/√SD, where SD is the standard deviation) were performed for inducing normality and 
standardizing the range of independent X-variables, respectively. Finally, multivariate 
regression techniques (Simca 13.5.0, Umetrics, Sweden) were used to differentiate between 
the obtained fingerprints. Principal component analysis (PCA) was used to reveal outliers, 
groups and trends, whereas (orthogonal) partial least square-discriminant analysis ((O)PLS-
DA) was used to construct a prediction model that could predict the treatment from the 
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fecal metabolic fingerprint to explore possible suppressed metabolic effects. For all 
analyses, two-sided P values ≤ 0.05 were considered statistically significant. 
Results 
Subjects 
In total 67 healthy volunteers were enrolled in the study, of which 62 completed the entire 
study protocol. One participant never started participation for a personal reason. Four 
participants dropped out during the intervention period; one due to the need for antibiotic 
treatment, another for unspecified, private reasons, while two participants experienced mild 
GI complaints. These complaints were present already at the start of the study and not 
associated to PD01 intake. From these participants only baseline characteristics were 
available. Baseline characteristics are presented in Table 8.1. 
 
Table 8.1 Baseline characteristics of study participants.1 
 Total population 
(n = 67) 
Placebo  
(n = 34) 
PD01  
(n = 33) 
Age, yr 53 ± 132 50 ± 15 56 ± 10 
Sex, M/F 29/38 12/22 17/16 
WHR 0.91 ± 0.08 0.90 ± 0.08 0.93 ± 0.08 
BMI, kg/m2 29.9 ± 3.4 30.3 ± 3.6 29.5 ± 3.2 
1BMI, body mass index. WHR, waist-to-hip-ratio. 2Mean ± SD (all such values). 
 
Fecal PD01 quantification 
PD01 was not detected in any of the fecal samples of subjects receiving placebo. In the 
PD01 group, PD01 was not detected in any of the fecal samples of any of the subjects at 
baseline, but was present in fecal samples of all subjects after 3 wks of supplementation 
and in 27 of the 29 subjects after 6 wks of supplementation. There was a statistically 
significant difference in PD01 total cells (χ2 (2) = 39.38, P = 0.000) and spores (χ2 (2) = 42.74, 
P = 0.000) in feces after PD01 supplementation. Post hoc analysis with Wilcoxon signed-rank 
tests was conducted with a Bonferroni correction applied, resulting in a significance level 
set at P < 0.017. As shown in Table 8.2, significantly higher amounts of PD01 total cells 
were found in feces both after 3 wks and 6 wks supplementation, compared to baseline (all 
P < 0.001). No significant differences could be observed between 3 and 6 wks 
supplementation both for total cells and spores (both P ≥ 0.039), pointing to a steady state 
after 3 wks of PD01 supplementation. The total amount of viable PD01 cells in human feces 
after 6 wks of PD01 supplementation was quantified as 2.26*107 CFU/g, of which 3.43*106 
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CFU/g are PD01 spores. While administered as spores, PD01 was therefore mainly present 
in feces as vegetative cells (1.99*107 CFU/g; 73% of total counts), indicating effective 
germination under intestinal conditions.  
 
Table 8.2 PD01 total cells and spores (CFU/g) in fecal samples at baseline, after 3 wks and after 6 wks 
supplementation with PD01 (n = 29).1 
 Baseline 3 wks 6 wks 
Total cells3,4 0 [0; 0]2 2.50E7 [1.11E7; 3.98E7] 2.26E7 [1.06E7; 4.19E7] 
Spores3,4 
Percentage of total 
0 [0; 0] 
0 
5.77E6 [1.28E6; 1.56E7] 
30.2 [11.1; 52.9] 
3.43E6 [1.85E6; 1.06E7] 
26.6 [6.7; 39.5] 
Vegetative cells3,4 
Percentage of total 
0 [0; 0] 
0 
1.70E7 [4.20E6; 3.95E7] 
69.8 [47.1; 88.9] 
1.99E7 [5.65E6; 2.93E7] 
73.4 [60.5; 93.3] 
1Differences between baseline and 3 wks and 6 wks supplementation tested with Friedman test with post hoc 
Wilcoxon signed rank test. 2Medians [Q1; Q3] (all such values). 3Significant difference between baseline vs. 3 wks 
intervention. 4 Significant difference between baseline vs. 6 wks intervention. 
 
Bioavailability of bacterial carotenoids in plasma 
PD01 carotenoids were detected in fasted plasma samples of all subjects after 3 wks and 
after 6 wks of PD01 supplementation. The plasma concentration of PD01 carotenoids 
significantly increased during the 6 wks of daily supplementation (0.000 μM at baseline, 
0.044 μM at 3 wks, 0.076 μM at 6 wks, respectively; all P ≤ 0.009, Table 8.3). The 
presence of (bacterial) carotenoids in plasma samples of subjects of the placebo group was 
not assessed.  PD01 supplementation did not induce significant changes in the plasma 
content of lutein, β-carotene or lycopene during the study period (all P ≥ 0.121, Table 8.3). 
 
Table 8.3 Carotenoid concentrations (μM) in fasted plasma at baseline and after 3 wks and 6 wks 
supplementation with PD01 (n = 29).1 
 Baseline 3 wks 6 wks 
PD01 carotenoids3,4,5 0 [0; 0]2 0.044 [0.002-0.167]1 0.076 [0.019-0.233] 
Lutein 0.126 [0.038-0.267] 0.124 [0.034-0.283] 0.121 [0.035-0.237] 
β-Carotene 0.279 [0.029-0.887] 0.316 [0.036-0.786] 0.317 [0.031-0.786] 
Lycopene 0.181 [0.018-0.461] 0.182 [0.026-0.445] 0.177 [0.018-0.392] 
1Differences between baseline and 3 wks and 6 wks supplementation tested with Friedman test with post hoc 
Wilcoxon signed rank test. 2Medians [Q1; Q3] (all such values). 3Significant difference between baseline vs. 3 wks 
intervention. 4Significant difference between baseline vs. 6 wks intervention. 5Significant difference between 3 wks 
and 6 wks intervention. 
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Fecal microbiota and metabolic activity 
Relative abundance at phylum and genus level 
The dominant phyla across all baseline fecal samples were firmicutes (mean 80.3%, SD 
10.9%) and bacteroidetes (mean 10.3%, SD 10.0%), followed by actinobacteria (mean 6.3%, 
SD 5.4%) and proteobacteria (mean 0.9%, SD 3.6%). The relative abundance of these 4 
dominant phyla did not change significantly during 6 wks intake of PD01, compared to 
placebo (Figure 8.2). The obtained sequence reads were analyzed to obtain information on 
the bacterial composition of each sample at genus level. No significant changes in bacterial 
composition at genus level between the two treatments were observed during intervention. 
When analyzing the bacterial composition at genus level within the PD01 group, we 
observed significant increases in the fecal abundance of Alloprevotella (P = 0.044), Blautio 
(P = 0.020), Butyrivibrio (P = 0.017), Dorea (P = 0.033), Flavonifractor (P = 0.037), and a 
species belonging to the ruminococcaceae family (P = 0.010) after 6 wks intervention, while 
in the placebo group the fecal abundance of none of these bacteria significantly altered (all 
P ≥ 0.163). These effects are, however, no longer significant after any multiple testing 
correction (e.g. Bonferroni). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.2 Relative abundance of the main phyla according the 16S-targeted Illumina data for placebo and 
PD01 at baseline (0) and after 6 wks supplementation (6). No significant differences in relative 
abundance between placebo and PD01 were observed during study period, as tested with linear 
mixed model with correction for baseline values. 
 
Fecal samples alpha diversity 
Alpha diversity was calculated through the alpha_diversity.py script using different metrics 
(Chao, Shannon diversity index) to take into account the species evenness and richness in 
each sample (Figure 8.3A and Figure 8.3B). These alpha diversity plots show that the 
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microbial diversity was very similar between the two interventions at baseline and after 6 
wks of supplementation and, therefore, that intervention did not have major effects on the 
overall microbial diversity of the subjects.  
 
           A 
 
 
 
 
 
 
 
 
 
 
 
 
           B 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.3 Alpha-diversity plots obtained using the Chao1 index at baseline (A) and after 6 wks of treatment 
(B). (red: PD01; blue: placebo). 
 
Fecal samples beta diversity 
The beta diversity index was evaluated in order to analyze the microbial diversity between 
samples. As shown in Figure 8.4, the sequences from the various samples were not 
organized into clusters but were evenly distributed, indicating that the treatment did not 
have major effects on the overall microbial diversity of the human gut.  
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Figure 8.4 Example of beta-diversity plots comparing samples from participants receiving placebo (blue 
symbols) and PD01 (red symbols), collected at baseline (A) and after 6 wks supplementation (B). 
 
Fecal pH, SCFA, lactate and β-glucuronidase activity 
Results on gut metabolic activity are shown in Table 8.4. Stool pH and lactate did not 
significantly alter during PD01 supplementation, compared to placebo. Intake of PD01 did 
not significantly change the total level of SCFA, branched SCFA and the levels of the 
individual SCFA, compared to placebo. Neither were differences in β-glucuronidase activity 
after 3 wks and after 6 wks of treatment between the two intervention groups observed. 
Metabolomics analysis of fecal samples 
Figure 8.5 represents the PCA score plot for samples obtained at baseline and after 6 wks 
PD01 supplementation. No effect of intervention was observed. To investigate more in 
depth the metabolic effects induced by PD01, supervised OPLS-DA models were 
constructed per ionization mode. For the datasets, the OPLS-DA score plot (Figure 8.6) also 
showed no significant effect of PD01 intervention. Individuals tend to cluster as other 
variables (e.g. genetic variation, lifestyle) induced more pronounced metabolic changes than 
the type of intervention. To reduce the inter-individual effect, the datasets were categorized 
according to the combination of treatment and time of sampling, resulting in 6 categories. In 
this way, it was possible to compare the different time points within the PD01 treated 
individuals. No significant changes in metabolomics between interventions were observed 
throughout the study. The PCA score plots displayed a good clustering of all quality control 
samples, but no clear trend could be observed. 
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Figure 8.5 PCA score plot for the dataset categorized according to a combination of PD01 and time of 
sampling, where comparison is made between the human fecal metabolome at baseline (green) and 
after 6 wks of PD01 supplementation (purple). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.6 OPLS-DA score plot for the positively charged ions detected in the human feces by means of 
UHPLC-HRMS. (green: PD01 treatment including test day 1, 2 and 3; blue: Placebo including test 
day 1, 2 and 3). 
 
Gastrointestinal permeability 
Table 8.5 presents the GI permeability data. No statistically significant changes in 
gastroduodenal, small intestinal or colonic and whole gut permeability were observed after 
6 wks PD01 supplementation compared to placebo. When analyzing the results in more 
detail it is apparent that a 37% decrease in gastroduodenal permeability was observed in 
response to PD01 compared to a 5% decrease in response to placebo (P = 0.131). In 
addition, a 33% decrease in colonic permeability was observed in the PD01 group 
compared to no decrease in the placebo group (P = 0.104).  
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Table 8.5 Permeability test: sugar excretion (μmol) and ratios of excreted sugars as measured in urine (in 0-2, 
0-5, 5-24 and 0-24 h fraction).1 
Placebo PD01  
Baseline 6 wks Baseline 6 wks 
P value 
0-5 h sucrose 5.290 
[2.930; 11.625]2 
5.030 
[3.460; 12.520] 
6.975 
[2.140; 19.248] 
4.370 
[2.540; 9.575] 
0.131 
0-5 h L/R ratio 0.030 
[0.020; 0.040] 
0.030 
[0.020; 0.040] 
0.035 
[0.020; 0.050] 
0.030 
[0.020; 0.040] 
0.842 
5-24 h S/E ratio 0.010 
[0.010; 0.020] 
0.010 
[0.010; 0.015] 
0.015 
[0.010; 0.020] 
0.010 
[0.010; 0.020] 
0.104 
0-24 h S/E ratio 0.010 
[0.010; 0.020] 
0.010 
[0.010; 0.010] 
0.010 
[0.010; 0.020] 
0.010 
[0.010; 0.020] 
0.266 
1Differences between placebo and PD01 tested with linear mixed model. L/R, lactulose/l-rhamnose. S/E, 
sucralose/erythritol. 2Median [IQR, i.e. Q1; Q3] (all such values).  
Fecal calprotectin 
Fecal calprotectin did not significantly change after 6 wks PD01 supplementation, 
compared to placebo (placebo: 32.6 ng/ml to 36.2 ng/ml; PD01: 46.6 ng/ml to 42.9 ng/ml; 
P = 0.341).  
Antioxidant activity and biomarkers of oxidative stress 
Plasma TAC and MDA, and 24 h urinary excretion of F2-isoprostanes were not significantly 
changed during 6 wks PD01 supplementation, compared to placebo (Table 8.6). 
 
Table 8.6 Antioxidant activity and biomarkers of oxidative stress at baseline and after 6 wks supplementation 
with placebo or PD01.1 
Placebo PD01  
Baseline 6 wks Baseline 6 wks 
P value 
Total antioxidant capacity (μM) 366 ± 102 351 ± 9 375 ± 10 363 ± 9 0.777 
F2-isoprostanes (pg/mL) 169  
[100; 242]3 
142  
[82; 290] 
171  
[108; 312] 
157  
[99; 289] 
0.323 
Malondialdehyde (nmol/mL) 0.21  
[0.15; 0.28] 
0.21  
[0.15; 0.26] 
0.21  
[0.15; 0.26] 
0.21  
[0.15; 0.26] 
0.435 
1Differences between placebo and PD01 tested with linear mixed model with correction for baseline values. 
2Estimated mean ± SEM (all such values). 3Median [IQR, i.e. Q1; Q3] (all such values). 
 
Adhesion molecules  
Basal circulating adhesion molecules at baseline and after 6 wks intervention for both the 
placebo and the PD01 groups are presented in Table 8.7. No significant differences in 
sVCAM, sICAM, sE-selectin and sP-selectin concentrations were observed between the 
two interventions. 
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Blood glucose, insulin and lipids 
Baseline total cholesterol, LDL- and HDL-cholesterol, triglycerides, glucose and insulin were 
all within normal blood value ranges. These parameters were not significantly altered by 3 
wks or 6 wks supplementation with PD01 compared to placebo (Table 8.7). Also, no 
significant changes in insulin resistance and insulin sensitivity, expressed by the HOMA-IR 
and QUICKI indices, were observed between intervention groups (Table 8.7). 
Blood pressure and heart rate 
Baseline systolic BP, diastolic BP and HR were all within normal value ranges at baseline. 
No significantly changes regarding these parameters were observed between intervention 
groups both after 3 wks and 6 wks supplementation (data not shown). 
Digestive tolerance 
Participants receiving daily PD01 scored lower on the GSRS subdimension for indigestion 
syndrome after 3 wks supplementation (P = 0.061, Figure 8.7), becoming significant at the 
end of the study period (P = 0.045, Figure 8.7). Neither PD01 nor placebo did affect stool 
frequency or consistency throughout the study period (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.7 Change in GSRS score for indigestion syndrome from baseline to end of the study period. Values 
are means with their standard errors represented by vertical bars. * P ≤ 0.050. 
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Discussion 
This is the first human study evaluating the intestinal fate of a carotenoid-producing bacillus 
strain as well as its potential GI and systemic effects. We have shown that PD01 survived 
transit through the GI tract and was able to germinate into vegetative cells under intestinal 
conditions and release carotenoids in situ. The latter were shown to have excellent 
bioavailability, with levels in blood at the end of the study in similar ranges as plant 
carotenoids. Repeated intake of PD01 was well tolerated and was even associated with a 
significant improvement of indigestion symptoms. In this first explorative study with obese, yet 
healthy volunteers, no significant effects on gut microbiota and barrier function, nor systemic 
effects on antioxidant activity, oxidative stress, adhesion molecules, glucose and insulin 
homeostasis, blood lipids and BP could be observed. 
PD01 survived passage through the human GI tract and daily PD01 supplementation over 
a period of 6 wks led to a significant accumulation of PD01 carotenoids in plasma. PD01 
carotenoids were detected in all subjects supplemented with PD01, demonstrating 
absorption and transport to the systemic circulation. Plasma concentrations of PD01 
carotenoids were lower in comparison with those of some of the dietary carotenoids, but it 
should be taken into account that intake of these dietary carotenoids is of a much higher 
magnitude. On the other hand, intestinal absorption of bacterial carotenoids appears to be 
more efficient than that of dietary carotenoids. More specifically, the average lutein intake 
is estimated at 1-3 mg/day,32 with plasma lutein concentrations of 0.12-0.13 μM. The 
calculated intake of PD01 carotenoids was only 0.014 mg/day with plasma concentrations 
of 0.04-0.08 μM. Despite the almost 100-fold lower intake of PD01 carotenoids, plasma 
levels were therefore only 2-fold lower as compared to lutein. No changes in plasma 
concentrations of dietary carotenoids were observed, indicating that these novel PD01 
carotenoids do not compete with other carotenoids for absorption and transport. 
In vitro, PD01 was shown to modulate the microbial intestinal environment by increasing the 
presence of two bacterial groups, namely the firmicutes and Clostridium 
coccoides/Eubacterium rectale groups. In this human intervention study we did not observe 
a significant effect of PD01, compared to placebo, on gut microbiota composition. No 
significant changes in the relative abundance of the dominant phyla or on the microbial 
composition at genus level were observed between groups. However, when analyzing the 
microbial composition over time separately in the PD01 group, significant increases in the 
fecal presence of several bacteria belonging to the lachnospiraceae and ruminococcaceae 
(part of the firmicutes) were observed, while in the placebo group no alterations in these 
species were detected. The lachnospiraceae and ruminococcaceae groups include many 
butyrate-producers, and an increase might be beneficial as butyrate plays a key role in 
maintaining gut homeostasis and epithelial integrity.33 
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In vitro, PD01 also altered SCFA profiles by inducing a shift from acetate to butyrate and 
by increasing lactate production. Here, no significant alterations were observed after PD01 
vs. placebo supplementation. In both treatment groups, baseline stool pH was within normal 
ranges and did not significantly change after treatment. Additionally, SCFA production, 
monitored as a marker of saccharolytic fermentation, was stable throughout the study 
period and between groups. We also determined β-glucuronidase activity in the fecal 
samples, but found no between-group differences after 6 wks supplementation. High 
microbial β-glucuronidase activity has been associated with development of colon cancer 
as it may transform pro-carcinogenic substances carcinogenic.34 On the other hand, high 
microbial β-glucuronidase activity is considered beneficial as it is associated with an 
increase in butyrate-producing microorganisms from the firmicutes phylum, particularly within 
clostridial clusters XIVa and IV.34 
With respect to PD01-induced effects on the gut metabolome: PCA score plots revealed 
that interindividual variation caused by genomic variation and exposome influence (e.g. 
lifestyle factors35) were more dominant than potential bacillus-induced metabolomic effects, 
as analyzed by hierarchical clustering analysis. The best option to visualize the bacillus-
induced changes would be to correct for the confounding factors (genetics, dietary factors, 
etc.) and to create a plot per individual. One could question the coverage of the detected 
metabolome but this proved more than adequate, as over 30% of the detected metabolites 
proved significantly altered when implementing the metabolomics fingerprinting approach 
on digestive fluid samples derived from in vitro gut simulations (unpublished data). 
The above-discussed results of PD01 supplementation suggest that the current human study 
lacked sufficient resolution to confirm previously obtained in vitro and in vivo data. On the 
other hand, the obtained data should be interpreted as positive because a metabolic effect 
has been established (carotenoid production) without significantly disturbing microbiota 
composition or intestinal homeostasis of gut metabolomics. Indeed, the low incidence of GI 
complaints underpins the excellent tolerability of PD01 in our healthy obese individuals. 
Furthermore, in addition to being well tolerated, the daily intake of PD01 for 6 wks even 
resulted in a significant decrease in GI symptoms of indigestion, such as borborygmi, 
abdominal distension, eructation and increased flatulation. This is in line with literature 
reports on (potential) pre-, pro- or sybiotics in healthy individuals or individuals with irritable 
bowel syndrome (IBS).36-38 A possible explanation for a decrease in such symptoms is a GI 
decrease in bacterial groups with gas-producing abilities.39,40 
Probiotics are suggested to improve GI permeability by stimulation of the intestinal mucosal 
defence.41 The only available human intervention trial that evaluated the effect of a 
probiotic on GI permeability in similar subjects did not provide evidence for an 
improvement.42 Interestingly, our findings suggest that GI effects of PD01 extend to 
improvement of GI permeability. While between group effects in GI permeability did not 
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reach significance, an indication towards improvement in gastroduodenal and colonic gut 
permeability was noted, as assessed with a validated multi-sugar test. 
As PD01 produces carotenoids that have high structural similarity to lycopene, our study 
findings related to CVD risk markers should be compared with studies on lycopene. 
Human intervention studies have shown that daily consumption of lycopene (20-30 mg/day; 
a dose 1000-fold higher than PD01 in this study) exerts beneficial effects on biomarkers of 
oxidative stress in healthy volunteers.43 In our study, the bacterial carotenoids did not induce 
significant changes in TAC, urinary F2-isoprostanes excretion or MDA. Baseline TAC values 
of our study population were however found to be higher than expected for overweight 
and obese subjects,44 potentially masking beneficial effects of PD01. 
The presence of PD01 carotenoids did not influence circulating adhesion molecules 
concentrations. These proteins, expressed on the vascular endothelium and on circulating 
leukocytes, mediate inflammatory processes and play an important role in the development 
and stability of atherosclerotic plaques.45 Plasma concentrations reflect the degree of 
endothelial function. In our study, baseline plasma adhesion molecules values were 
comparable to those reported for similar study populations using the same analysis.46 Human 
data among the effects of lycopene on plasma adhesion molecules are scarce and 
contradictory.47,48 
Obesity may be associated with a wide cluster of metabolic alterations, including glucose 
homeostasis disorders and dyslipidemia. In animal studies, lycopene proved to decrease 
serum glucose, reduce total and LDL-cholesterol and to increase HDL-cholesterol.49,50 In 
humans, results regarding the beneficial effects of lycopene on these parameters are not 
uniform.51,52 Supplementing the carotenoid-producing bacillus strain PD01 to overweight 
and obese, but otherwise healthy volunteers, did not affect systemic glucose, insulin and 
lipid levels. In retrospect, since the participants had completely normal values at baseline, no 
significant improvement through dietary intervention was to be anticipated. 
The BP lowering effect of lycopene, and of carotenoids in general, is supported by 
several,53,54 yet not all,55 human intervention trials. Carotenoids have been demonstrated to 
scavenge free radicals and to lower levels of reactive oxidative species, thus lowering 
oxidative stress. This may prevent oxidation of LDL-cholesterol, which in turn can trigger a 
cascade of events associated with atherogenesis.56 Furthermore, oxidized LDL particles 
impair normal endothelial function by inhibiting nitric oxide release, an important vasodilator, 
and thus affect BP.57 In our intervention study, no effects of PD01 treatment on systolic and 
diastolic BP were observed compared to placebo. 
Some potential shortcomings of our study design should be mentioned. Firstly, with most 
baseline parameters within normal ranges, the induction of systemic beneficial changes in 
generally healthy subjects through dietary supplementation is challenging and when present 
often only marginal. Another possible limitation is the lack of a well-controlled diet. We 
instructed participants to maintain their habitual dietary intake throughout the study period, 
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as we aimed to assess the effects of PD01 as supplement to their habitual diet, which is in 
line with future applications. Based on the unchanged plasma concentrations of lutein, 
lycopene, and β-carotene it can be assumed that the habitual diet was indeed maintained. 
We cannot exclude that the presence of dietary carotenoids may have masked the additive 
effect of the bacterial carotenoids. 
In conclusion, this study provides the first evidence in humans that PD01 survives transit 
through the GI tract and is able to germinate and release bacterial carotenoids, which are 
absorbed and detected in human blood plasma. Furthermore, even though systemic effects 
of the carotenoids could not be confirmed in this explorative study, repeated intake 
improved local GI parameters. These promising results warrant further research in specific 
target populations to investigate the specific bioactivities of PD01 in the intestine and on 
systemic parameters. 
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Background  
The relationship between food and health is complex, being multifactorial and 
multidimensional. Food contributes to human health and enhances the health potential, but 
can also be a key actor negatively influencing health and initiating or contributing to illness. 
The primary role of food is to provide sufficient nutrients to meet the nutritional requirements 
of an individual. Furthermore, food supplies the body with materials that can be used for the 
construction and repair of body tissues. This allows an individual to grow and thrive. 
Recently, there has been a growing interest in the health-enhancing role of specific foods in 
addition to their nutritional value. Efforts to identify functional and bioactive components 
from many natural sources have been intensified and have eventually led to a new group of 
products, the so-called functional foods. A food can be classified as “functional” when it 
contains a component (whether a nutrient or not) that affects one or more functions in the 
body in a targeted way so that positive effects on health1 are to be expected, or when the 
component has a physiological or psychological effect beyond the traditional nutritional 
effect.2 Functional foods may originate from plant and animal sources, from microorganisms 
or marine organisms. 
In many low- and middle income countries access to food, availability and quality of 
food/nutrition are major concerns. To date, worldwide, approximately 800 million individuals 
are plagued by undernourishment and food insecurity.3 These individuals, often children, 
consume insufficient protein and energy, and the adverse health effects of this are often 
compounded by deficiencies of vitamins and minerals. In these countries, easy-to-remedy 
nutritional deficiencies prevent 1 of 38 newborns from reaching an age of 5 years.4 In 
contrast, the prevalence of overweight and obesity, linked to excess food intake and 
overnutrition, has more than doubled since 1980. In 2014, worldwide, more than 1.9 billion 
adults aged 18 years and older were overweight, and of these, over 600 million were 
obese.5 Overweight and obesity are associated with alterations in gut microbiota 
composition and activity,6,7 impaired gut barrier function,8-10 gastrointestinal and systemic 
low-grade inflammation,11-14 impaired vascular functions,15,16 and glucose and lipid 
homeostasis disorders.17,18 These gastrointestinal and systemic metabolic abnormalities are 
major risk factors for the development of diabetes mellitus type 2 (DM2) and 
cardiovascular diseases (CVD).19-21 Worldwide, overweight and obesity now cause more 
deaths than underweight. Consequently, obesity and related illnesses have an enormous 
health and economic impact on society.22 
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Nutritional interventions in healthy, overweight and obese 
individuals 
The aim of this thesis was to investigate the effects of several nutritional interventions on 
gastrointestinal and metabolic health in healthy, overweight and obese individuals. This 
thesis presents the results of six randomized-controlled trials. The nutritional interventions we 
studied included a prolyl endoprotease, a putative prebiotic supplement, a putative 
probiotic species, and two different phytonutrients. 
Gastrointestinal gluten degradation by a prolyl endoprotease 
Ingestion of gluten - a storage protein present in wheat, barley and rye - can induce a wide 
range of gluten related disorders with different pathogenic pathways, globally affecting a 
large proportion of the population.23,24 In subjects suffering from celiac disease and wheat 
allergy, the presence of gluten peptides in the small intestine triggers an abnormal immune 
response resulting in intestinal inflammation and ultimately villous atrophy and crypt 
hyperplasia.25 The mechanisms by which gluten induce symptoms in subjects with non-celiac 
gluten sensitivity remain largely unknown, but involvement of the innate immune system has 
been well established.26,27 For all conditions, strict adherence to a gluten-free diet is the only 
effective treatment. However, the high cost, poor availability and poor palatability of 
gluten-free products makes it difficult to strictly adhere to such diet on the longer term.28 In 
addition, gluten-free food products available on the market often contain trace amounts of 
gluten.29 When maintained appropriately, a gluten-free diet is not nutritionally optimal; it 
may predispose to an undesirable high intake of fat and carbohydrates and lead to poor 
vitamin status and detrimental weight gain or weight loss.30 Due to the consequences of 
gluten-free dieting, an unmet need for alternative therapies exists. Several options have 
been investigated. One approach is to use compounds that do not have the immunogenic 
proteins found in wheat derived gluten. Several wheat substitutes are available, including 
sorghum, almonds, rice, corn and legumes.25,31 Another option is selecting and breeding 
wheat products that only contain low amounts of T-cell stimulatory sequences, thereby 
reducing the immunotoxic effects.32 Furthermore, developing genetically modified gluten with 
reduced immunogenicity might be a potential future option for celiac disease patients. By 
blocking glutamine residues, the affinity of gluten peptides to bind to DQ2 and DQ8 
molecules is reduced, resulting in a reduced T-cell-mediated inflammatory response.33 
Wheat fermentation with sourdough lactobacilli and fungal proteases has also been shown 
to reduce wheat toxicity.34-36 However, as gluten protein is important in baking due to its 
strengthening and binding properties, it will be difficult to alter or select a variety of wheat 
completely devoid of gluten without compromising its mechanical properties. Binding glutens 
to polymers in the gastrointestinal tract may also prevent degradation, absorption and 
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triggering of an immunologic response.37 Another interesting alternative treatment is oral 
enzyme supplementation to degrade gluten peptides. Food-derived gluten contains 
considerable amounts of proline and glutamine amino acids, which are highly resistant to 
enzymatic proteolysis within the human digestive tract.38 Prolyl endoproteases are enzymes 
that are able to target and destroy proline and glutamine residues into small nontoxic gluten 
peptides before they enter the intestinal epithelium.39 In Chapter 2 we studied the in vivo 
gluten-degrading potential of Aspergillus Niger-derived prolyl endoprotease (AN-PEP). AN-
PEP showed to efficiently degrade gluten from a meal in the stomach of healthy volunteers, 
within the time period a meal normally resides in the stomach. These in vivo results 
confirmed previously obtained in vitro observations.40,41 In addition, we hypothesized that 
increasing the caloric density of a meal enhances gluten degradation by delaying gastric 
emptying rate, thereby prolonging exposure time of gluten proteins to AN-PEP, endogenous 
proteases and gastric acid. Indeed, increasing meal caloric density delayed gastric 
emptying and prolonged the gastric residence time of AN-PEP, but it did not affect its 
efficiency in degrading gluten. To standardize each meal intake we intragastrically 
administered the test meal via a triple lumen nasogastroduodenal tube, this obviously does 
not represent a fully physiological meal setting. Thus, data on the gluten-degrading potential 
of AN-PEP in an actual meal setting in gluten-intolerant subjects are needed. Also microbial 
prolyl endopeptidases from other species, as well as germinating cereal enzymes, have 
shown to possess the capacity to hydrolyze gluten peptides in vitro42-44 and in vivo.45-47 A 
combination of both, known as ALV003, already proved that it is able to attenuate gluten-
induced mucosal injury in celiac disease patients.46 
In summary, enzyme supplementation therapy targeted at degradation of immunogenic 
gluten peptides appears to be a promising approach. Development of such a supplement as 
alternative for a gluten-free diet is still in its early phase of validations and subsequent 
implementation. It is anticipated that enzymes first will be marketed as a supplement 1) 
when ingested in combination with a gluten-free diet, 2) when ingested with a normal gluten 
containing meal, for social reasons or 3) in conditions where persons report gluten 
hypersensitivity in absence of celiac disease. 
Food-drug interaction 
To exert a systemic effect, a compound has to be absorbed from the gastrointestinal tract. 
The onset of a systemic effect heavily depends on the rate of absorption, which is in part 
determined by the gastric emptying rate. In Chapter 3 we critically evaluated a well-
established method of measuring gastric emptying, namely by measuring plasma 
concentrations of paracetamol. It is assumed that paracetamol is absorbed almost 
immediately after reaching the small intestine and that the transit time of paracetamol 
through the stomach is identical to that of the water phase of a meal. Thus, gastric emptying 
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rate might be derived from the time course of plasma paracetamol appearance.48,49 
However, in Chapter 3, we demonstrated that paracetamol when added to a meal and 
mixed, was divided in two fractions. One fraction was dissolved in the liquid content of the 
meal which quickly left the stomach and was absorbed in the duodenum, reflected by an 
early, high plasma peak. A second paracetamol fraction was encapsulated by the meal, 
leaving the stomach more slowly and was even not taken up instantaneously after reaching 
the intestine. Both fractions did not accurately reflect gastric emptying rate. Additionally, this 
showed us that the rate-limiting factor for absorption was actually the bioaccessibility, i.e. 
release of paracetamol from the food matrix. The food matrix and structure can have both 
positive and negative effects on bioaccessibility.50 Thus, it is important to realize that food-
drug interactions are not limited to the effect of food on gastric emptying alone. 
The human gut microbiome 
The human gut microbiome harbors several trillion microbes residing in the gut.51 It serves a 
wide array of functions, including regulating normal functioning of the gastrointestinal tract, 
harvesting energy from indigestible parts of the diet, maintaining intestinal epithelial 
integrity, metabolizing indigestible polysaccharides, absorbing short-chain fatty acids 
(SCFA) produced by bacterial fermentation and regulating intestinal transit.10,52-55 The 
colonization of the human gut by micro-organisms starts at gestation, during birth and 
immediately afterwards. Bacteria from the mother and surrounding environment colonize 
the infants gut. It is affected by several factors such as genetic background, gestational age, 
mode of delivery, type of feeding, exposure to antimicrobials and, very important, the diet 
throughout life.56 Long-term perturbations to the intestinal ecosystem can induce changes in 
the microbiota, contributing to the development and progression of a number of 
gastrointestinal disorders57 such as irritable bowel syndrome, celiac disease, inflammatory 
bowel disease and colorectal cancer, as well as systemic diseases such as allergic 
diseases,58 non-alcoholic steatohepatitis,59 obesity54,60,61 and diabetes.62 Thus, targeting the 
microbiome seems to offer a promising approach to potentially ameliorate above 
mentioned gastrointestinal and metabolic diseases. A number of dietary strategies are 
available for modulating the composition and function of the intestinal microbiota; pre- and 
probiotics are among the most well established. 
Gut microbiota, gut barrier and immune modulation by prebiotics  
Prebiotics are non-digestible compounds that selectively stimulate growth and/or activity of 
one or a limited number of microbial species in the gut with potential health benefits to the 
host.63 Many animal studies showed positive results of prebiotics in the prevention or 
treatment of gastrointestinal and chronic metabolic diseases, but human data remain 
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ambiguous.64 SCFA are produced by bacterial fermentation of non-digestible compounds. 
These metabolites display several important functions; they maintain energy homeostasis, 
are able to affect cell proliferation and differentiation, have anti-inflammatory and 
immunomodulating effects, serve as an energy source for colonocytes and are essential in 
establishing and maintaining the gut barrier by regulating expression of tight junction 
proteins.65-67 Furthermore, high amounts of intestinal SCFA lower intestinal pH, affect 
microbiota composition by inhibiting the growth of pathogenic bacteria, and creating a 
more favourable environment for the growth of beneficial bacteria.68,69 Most studied 
prebiotics are fructooligosaccharides, galactooligosaccharides, inulin and resistant starch. 
These prebiotics are predominantly fermented in the more proximal colon and are limited in 
reaching the distal colon.70,71 However, several chronic colonic diseases originate from the 
distal colon; consequently, there is a great interest in finding prebiotics that are able to 
reach, are fermented, and act in the more distal regions of the colon. Arabinoxylans (AX) 
form an interesting novel class of such type prebiotics, as they rely on a whole spectrum of 
microbial enzymes for their degradation, resulting in a more distal fermentation and 
action.72-74 In Chapter 4 we have described the results of a human study supplementing an 
AX extract to overweight and obese individuals for several weeks. Previous in vitro and 
animal studies already had shown that this specific extract was able to modulate gut 
microbiota composition and microbial activity and, as a consequence, gut barrier 
function.70,75-77 In our in vivo study the overall microbiota composition of participants did not 
significantly change following AX treatment, but increases in fecal SCFA concentrations and 
a decrease in fecal pH were observed.  
Modulation of gut microbiota by prebiotics has been associated with improvements in gut 
barrier function. The exact underlying mechanisms are poorly understood. An increased 
villus height and crypt depth, a thickened mucosal layer, increased transcription and 
consequently increased synthesis of tight junction proteins, and a change in the distribution 
and localization of tight junction proteins may contribute.9,78-81 The integrity of the 
gastrointestinal epithelium depends on formation of adhesive contacts between 
neighbouring epithelial cells. This is mediated by the apical junctional complex, which is 
composed of the tight junction and subjacent adherence junction. These multi-protein 
complexes are considered critical regulators of the gastrointestinal barrier function. 
Adherence junctions are required for assembly of the tight junction, which seals the 
paracellular space. Tight junction proteins consist of transmembrane proteins, peripheral 
membrane (scaffolding) proteins and regulatory molecules. The two major tight junction 
transmembrane proteins are the claudins and occludins. Peripheral membrane proteins, such 
as members of the zonula occludens family, function as scaffolding proteins between 
transmembrane and cytoplasmic proteins. In addition, it has been proposed that these 
proteins link adherence junctions to tight junctions through protein linkages.82,83 In Chapter 4, 
AX showed to affect gut barrier function; as upregulation in the transcription of the tight 
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junction proteins claudin-3, claudin-4 and occludin in sigmoid biopsies was observed. The 
changes in tight junction gene expression were not accompanied with changes in mucosal 
tight junction protein expression or in gastrointestinal permeability as assessed with a 
functional test.  
Another important function of the colonic microbiota is its role in the development and 
maturation of the immune system. The gut contains an important component of the body’s 
immune system, called gut-associated lymphoid tissue. The immune system must establish an 
appropriate balance between tolerance to the gut commensal microbiota and vigilance to 
guard against infectious agents and opportunistic pathogens. The cross-talk between the 
intestinal microbiota and host involves both the innate and adaptive immune system. 
Imbalances in gut microbiota and consequently in immune homeostasis may lead to a 
number of pathologies, such as obesity, DM2, inflammatory bowel disease and colorectal 
cancer.84 Previous studies indicate that prebiotics can exert direct immunomodulatory 
effects85,86 and indirect immunomodulatory effects through changing the gut microbiome.87 
Microbiota-dependent changes affecting the immune system include stimulation of the 
growth and metabolism of protective commensal intestinal bacteria. An increase in the 
presence of beneficial bacteria, such as bifidobacteria and lactobacilli, will provide 
antimicrobial effects by direct competition with pathogenic bacteria for available binding 
sites on the intestinal epithelium and for nutrients.88,89 Furthermore, some bacterial species 
are able to produce antibacterial substances that can inhibit the growth and survival of 
pathogens.90 In addition, SCFA might have direct immunomodulatory properties.91-93 To 
assess the effects of AX on immune response, we applied an ex vivo model using PHA-
stimulated whole blood to evaluate the capacity to produce cytokines (Chapter 4). With AX 
treatment we observed a significantly decreased production of the pro-inflammatory 
cytokine TNFα, suggesting a capacity to reduce the intensity of an acute pro-inflammatory 
reaction. As SCFA are able to suppress the production of such cytokines, the decrease in 
TNFα production might be linked to the observed increase in fecal SCFA. 
Altogether, the data presented in Chapter 4 suggest that AX modulate gut microbial activity 
and thereby may positively affect gut barrier and immune function. 
Gut microbiota and gut barrier modulation by probiotics 
Probiotics are live microorganisms that, when administered in adequate amounts, confer a 
health benefit on the host.94 Most commercial probiotic products contain lactic acid 
bacteria, such as lactobacilli, streptococci and bifidobacteria.95 For a probiotic it is 
important that it survives the acidic intestinal environment, not being degraded before 
reaching the site where it is presumed to be active. As with prebiotics, despite convincing 
and reproducible results from animal studies showing beneficial effects of different probiotic 
strains on gastrointestinal and metabolic health, the data in humans remain equivocal.64,96 In 
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Chapter 8 we studied the effects of a Bacillus indicus strain on the gut microbiota 
composition and activity in overweight and obese individuals. Bacillus species are gram-
positive bacteria able to form endospores, i.e. uniquely robust entities that are able to 
survive extremes of temperature, irradiation and long-term storage.97 While some spore-
forming species play a role in food poisoning, several species of bacillus are consumed as 
food ingredients and regarded safe for human consumption.98 Bacillus spores are able to 
pass the gastric barrier without loss of function, are stable to many food processing steps 
and can be stored at room temperature, making them attractive as a probiotic. Previous 
(unpublished) in vitro research showed that this carotenoid-producing Bacillus indicus strain 
was able to survive and germinate in the gastrointestinal tract and to modulate the intestinal 
environment by increasing the presence of two bacterial groups, namely the firmicutes and 
Clostridium coccoides/Eubacterium rectale group. Furthermore, it was shown to alter SCFA 
profiles by inducing a shift from acetate to butyrate, and it increased the lactate production.  
This shift may provide health benefits for the host. Indeed, in Chapter 8 we demonstrated 
that in vivo the Bacillus indicus strain was able to survive passage throughout the digestive 
tract as viable PD01 cells and spores were found in the feces of all individuals 
supplemented with the strain. However, no significant treatment effects regarding intestinal 
microbiota composition and microbial activity were observed. We also did not observe 
modulation of gut barrier function by the Bacillus indicus treatment. The only significant 
improvement with this Bacillus indicus strain we observed was a decrease in reported 
gastrointestinal symptoms such as borborygmi, abdominal distension, eructation and 
increased flatulation. The occurrence of gastrointestinal symptoms was already low at 
baseline of the study, but significantly reduced after 6 weeks PD01 supplementation 
compared to placebo. In IBS patients, it has been shown that a difference in gut microbiota 
composition and activity causes more intestinal gas production, impairs the transit and 
tolerance of gas, resulting in gastrointestinal symptoms such as bloating. It was also shown 
that modulation of the gut microbiome by probiotics caused a relief in these symptoms, 
suggesting that these products are able to induce a quantitative and qualitative 
gastrointestinal decrease of bacterial groups with gas-producing abilities, such as clostridium 
species, in the colonic mucosa.99-101 Our findings are in line with previous literature reports 
on effects of (potential) pre-, pro- or synbiotics on symptoms or gastrointestinal function in 
healthy individuals or individuals with irritable bowel syndrome.102-104 
Metabolic consequences of gut microbiota modulation 
Alterations in gut microbiota composition have been shown to underlie or influence the 
development of metabolic disorders.7,105,106 Both in Chapter 4 and Chapter 8 we explored 
the effect of putative pre- and probiotic products on metabolic markers. Data with respect 
to beneficial effects on glucose homeostasis and lipid metabolism in animals are widely 
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available,75,107-110 while human studies investigating these parameters report conflicting 
results.111-119 Both the AX extract and the Bacillus indicus strain did not affect fasting 
glucose, insulin and lipid concentrations in our study population. However, baseline values 
were already within the normal ranges, making it difficult to improve these values. Long-term 
intervention studies in people with pre-diabetes, metabolic syndrome or hyper-
cholesterolemia are required to determine whether pre- or probiotics exert beneficial 
effects in high-risk individuals. 
In vivo bioavailability of hesperidin 
Large epidemiological studies have shown that the intake of fruits and vegetables exerts 
positive effects on metabolic and cardiovascular health.120-123 These effects are partly due 
to the large amount of polyphenols that these products contain. Hesperidin is such a type 
polyphenol. It is abundantly present in the peels of citrus fruits.124-129 In order to exert 
systemic health effects, it is essential that a compound is bioavailable and absorbed from 
the gastrointestinal tract into the systemic circulation. It has been demonstrated that the 
bioavailability of hesperidin is low in humans,130,131 due to a combination of factors. 
Hesperidin is poorly water soluble132 and it requires to be fermented by colonic microbiota 
to release and enable the absorption of its aglycone.131,133,134 It has been hypothesized that 
glycosyl hydrolases from the genus bifidobacterium are involved in the hydrolysis of glycol-
conjugate forms of phytochemicals.135 Commercially available hesperidin supplements often 
elicit less biological effects than natural hesperidin due to a different enantiomer 
configuration. As a result, several attempts have been made to improve the bioavailability 
of hesperidin.136-138 One way to improve bioavailability is by micronization of this poorly 
soluble compound. Micronization decreases the particle size resulting in an improved rate 
of dissolution and thus absorption from the gastrointestinal tract into the systemic 
circulation.139 In Chapter 5 we demonstrated that the bioavailability of a micronized 
hesperidin 2S extract, which has a specific enantiomer configuration similar to natural 
hesperidin, was improved over that of a non-micronized hesperidin extract with an 
enantiomer configuration similar to commercially available hesperidin extracts. Improving the 
bioavailability of hesperidin is important to fully exploit its beneficial properties concerning 
vascular and metabolic health, as studied in the paragraphs below. Furthermore, we 
observed considerable inter-individual differences regarding plasma metabolite 
concentrations. This finding is supported by other human trials investigating the 
bioavailability of polyphenols.130,140,141 As differences in gut microbiota composition 
between subjects are common, significant inter-individual differences in the microbial 
transformation of polyphenols will exist.142-144 This may serve as an explanation for inter-
individual differences with respect to biological activity and systemic health effects of a 
polyphenolic compound. 
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The role of hesperidin in vascular health 
Based on the results of Chapter 5, we have chosen the micronized hesperidin 2S 
formulation to study hesperidin-induced effects on cardiovascular and metabolic 
parameters in overweight and obese individuals (Chapter 6 and Chapter 7). Hesperidin is 
considered a strong antioxidant.145,146 It has been demonstrated that it increases the 
production of nitric oxide (NO) in the vascular endothelium by phosphorylation and 
activation of endothelial NO synthase (eNOS).126 NO participates in highly active 
metabolic and regulatory functions including the regulation of endothelial function and 
blood pressure, and plays a protective role in the development of atherosclerosis.147-150 
Both in vitro and animal studies have reported consistent, beneficial effects of hesperidin on 
endothelial function and blood pressure,126,151,152 while human data is limited and 
contradicting.125,126 As demonstrated in Chapter 6, six weeks daily hesperidin 
supplementation significantly reduced the levels of circulating adhesion molecules, reflecting 
an improvement in endothelial function.153 Basal flow-mediated dilation (FMD), the gold 
standard method for measuring endothelial function,154 was not improved by hesperidin. 
However, after inducing temporary endothelial dysfunction, hesperidin protected from 
postprandial deterioration in FMD in a subgroup of subjects. We excluded subjects with a 
very low FMD value as it is unlikely that short-term dietary interventions are able to improve 
such chronically impaired endothelial function155 and additionally, the FMD measurement 
becomes inaccurate.156,157 In addition, hesperidin treatment appeared to reduce both 
systolic and diastolic blood pressure, but this was only significant in the subgroup. As shown 
in Chapter 7, we did not find any effect of the same hesperidin product on blood pressure 
after six or twelve weeks daily intake. These contradictory findings reflect the current 
situation of discrepant results of hesperidin, but also of other polyphenols, on vascular 
function in humans.142,158 
Impact of hesperidin on metabolic parameters 
Hesperidin is able to induce glucose lowering effects through altering the transcription of 
genes encoding regulatory enzymes of glycolysis, gluconeogenesis and glucose utilization in 
the liver. In addition, it is able to change the expressions of hepatic glucose transporter 2 
and adipocyte glucose transporter 4, both playing a critical role in glucose and insulin 
homeostasis. Furthermore, hesperidin has blood lipid lowering properties, possibly by 
affecting enzymes involved in lipogenesis, fatty acid biosynthesis, triglyceride synthesis, 
cholesterol synthesis and cholesterol absorption, and by facilitating fecal triglyceride and 
cholesterol excretion.159 Both in vitro and animal studies have indeed shown beneficial 
effects of hesperidin on lipids159-162 and glucose metabolism.159,162-164 Positive human results 
also exist, but only in (pre)diabetic and hyperlipidemic subjects.126,128,165 Both in Chapter 6 
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and Chapter 7 no blood glucose- or lipid lowering effects of hesperidin treatment were 
observed. This can be explained by the fact that the participants had normal values from 
start of the trial. Long-term intervention studies in subjects with (pre)diabetes, metabolic 
syndrome or hypercholesterolemia are needed to establish and confirm beneficial 
hesperidin-induced effects on systemic metabolic health markers. 
Gut-microbiota dependent effects of polyphenols 
As noted above, the gut microbiome plays a critical role in transforming dietary polyphenols 
into absorbable biologically active species. Recent data suggests that different types of 
polyphenolic compounds, including hesperidin, are also able to modulate the gut microbiota 
composition and function towards a more ‘health promoting profile’.166-171 In Chapter 7 we 
demonstrated that hesperidin did not affect the quantity of SCFA production, but was able 
to alter the SCFA profile. Hesperidin induced a significant shift from acetate to the health-
promoting SCFA butyrate, possibly via intestinal stimulation of butyrate-producing bacteria. 
Butyrate functions as an important energy source for colonocytes, exerts anticarcinogenic, 
anti-inflammatory and antioxidant effects, reinforces the colonic defence barrier, and is able 
to modulate gut motility and satiety.172 These results strengthen the hypothesis that 
polyphenols are able to modulate gut microbiota composition and function, in turn 
promoting gut and host health. However, more human intervention studies with a large 
number of subjects are needed to establish the potential prebiotic-like effects of hesperidin 
and other polyphenols. 
Antioxidant activity of carotenoids 
The incidence of CVD is notably lower in countries with a ‘Mediterranean diet’, containing 
a large amount of fruit, vegetables and olive oil.173,174 These foods are rich in carotenoids, 
and a link between carotenoid intake and protection against oxidative stress, 
atherosclerotic progression, hypertension, inflammation and endothelial dysfunction has 
been shown.175-177 The protection by carotenoids is mainly through their antioxidant activity. 
They act as antioxidants via several mechanisms. Firstly, they are able to quench highly 
reactive oxygen species, that have the capacity to oxidize nucleic acids, unsaturated fatty 
acids or amino acids.178 Furthermore, they are able to inhibit free radical reactions, 
impeding the process of lipid peroxidation, with repair of vitamin E and C radicals.179,180 
Besides intervening in radical reactions, carotenoids have also been shown to upregulate 
the antioxidant response element, resulting in another way of protecting cells against highly 
reactive oxygen species.181 The antioxidant capacity of carotenoids is well demonstrated in 
vitro,178,182 but in humans evidence is still lacking that carotenoids act as antioxidants.183 
Other mechanisms explaining the beneficial effects of carotenoids include their influence on 
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gap-junction communication, gene function regulation, hormone and immune modulation, 
and modulation of drugs metabolism.184-186 
In vivo bioavailability of bacterial carotenoids 
Humans lack the capacity to synthesize carotenoids by themselves, and therefore depend 
on dietary intake and subsequent absorption. The majority of commercially available natural 
carotenoids are derived from plant-based materials, but also some bacterial species are 
able to synthesize these compounds. The quality and consistency of plant-based carotenoids 
are dependent on plant growth conditions, which vary tremendously.187,188 Furthermore, 
these carotenoids are degraded in the acidic environment of the stomach.187,188 Bacterial 
carotenoids, produced by spore-forming bacillus strains, deliver gastric-stable carotenoids 
which are equally or more bioaccessible and bioavailable than plant-based carotenoids. In 
Chapter 8 we studied the in vivo bioavailability of bacterial carotenoids in overweight and 
obese subjects. After supplementing the participants with a carotenoid-producing bacillus 
strain for six weeks, we were able to confirm that bacterial carotenoids were present in the 
plasma and levels increased throughout the study period. This indicates that the bacillus 
strain produces in vivo bacterial carotenoids, which are absorbed and transported to the 
systemic circulation. Absorption of plant-based carotenoids occurs once carotenoids are 
released from the food matrix. Dissolution of released carotenoids in bulk lipid droplets is 
followed by the formation of micelles and uptake of these micelles by duodenal mucosal 
cells occurs through passive diffusion. The micellular carotenoids are then incorporated into 
chylomicrons and via the lymphatics released into the circulation.189 The mechanism of 
absorption of these bacterial carotenoids has not been elucidated up to now. Possibly, the 
mechanism is the same as for lycopene due to the high structural similarity of the bacterial 
carotenoids with lycopene.190 Furthermore, uptake of the bacterial carotenoids did not 
impede the presence of lutein, β-carotene and lycopene in plasma. It has been suggested 
that carotenoids may compete with each other or with other lipid-soluble nutrients for their 
absorption and metabolism, but there is discrepancy in results from the various studies in 
humans.191-195 
Carotenoids in vascular and metabolic health 
Compared to plant-based carotenoids, the bacterial carotenoids were shown to have a 
ten-fold higher in vitro antioxidant activity. As noted before, the relevance of the antioxidant 
properties of plant-based carotenoids in vivo remains a matter of debate. The effects of 
carotenoids on oxidative stress,196-199 endothelial function,196,197,200 glucose homeostasis,201 
lipid metabolism197-199,201,202 and blood pressure199,201,203 in humans also remain 
contradictory. Most of the beneficial effects were obtained in individuals at risk for 
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developing CVD or DM2. In Chapter 8 we also explored the antioxidant effects, and 
effects on cardiovascular and metabolic parameters of the bacterial carotenoids. No 
cardiovascular or metabolic effects were observed, probably due to the fact that 
participants had normal values at start of the supplementation period for most parameters. 
Furthermore, other dietary carotenoids may have masked the effects of the bacterial 
carotenoids, or the production and/or absorption of the bacterial carotenoids was not high 
enough to induce systemic health effects. 
In summary, the use of bacterial carotenoids over plant-based carotenoids may be 
preferred for several reasons. In vitro studies have shown that these bacterial carotenoids 
deliver gastric-stable carotenoids, which have equal or larger bioaccessibility and 
bioavailability levels than other, well-established sources of dietary carotenoids, and exert a 
higher antioxidant capacity. Furthermore, the carotenoid-producing bacillus strain also 
possesses the ability to act as a probiotic product.204 In addition, a microbial fermentation 
using standard optimized conditions allows for producing a high-quality product with a 
consistent purity. However, more human in vivo studies are required to confirm the improved 
bioavailability, antioxidant capacity and systemic health effects of bacterial carotenoids 
over plant-based carotenoids.  
Implications, suggestions for future research 
Food provides taste, aroma, nutritive value and the elements for an individual to grow and 
live. Recently, functional and bioactive components from foods, inducing positive health 
effects, have been identified, the so-called functional foods. In this thesis, we have described 
the results of six randomized controlled trials investigating different nutritional interventions 
in healthy, overweight and obese individuals. All of the studied nutritional interventions may 
affect one or more functions in the body in a positive way and thus may be considered a 
functional food.  
In summary, we examined food-drug interactions on the intestinal absorption of a compound, 
using paracetamol. In addition, the in vivo bioavailability of a polyphenol and of bacterial 
carotenoids was explored. The efficacy of a prolyl endoprotease in gastrointestinal gluten 
degradation was investigated in healthy humans. In overweight and obese individuals, the 
gut microbiota and gut barrier modulating capacities of a potential pre- and probiotic 
product were assessed. Furthermore, the effects of a polyphenol (hesperidin) and of 
bacterial carotenoids on cardiovascular and metabolic health parameters have been 
studied. 
The potential of the gluten-degrading enzyme AN-PEP is obvious; it efficiently degrades 
gluten from a meal, within the time period a meal usually resides in the stomach. From a 
clinical perspective, additional data are needed from randomized controlled trials, 
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exploring the efficacy of AN-PEP in an actual meal setting in subjects intolerant to gluten. 
Targeting the gut microbiota by pre- and probiotics seems to be a promising approach to 
prevent the development or to ameliorate many gastrointestinal and metabolic diseases. In 
vitro and animal studies are widely available, showing convincing and reproducible data of 
pre- and probiotic products on gastrointestinal and metabolic health. However, human data 
are scarce. In this thesis we found clear AX-related effects on gut microbial activity, limited 
AX-related effects on the gut barrier and immune system, and no effects regarding gut 
microbiota composition. The putative probiotic, which produces carotenoids, did not induce 
any effects on the gut microbiota composition and function or on gut barrier, which might be 
considered positive: stimulating a metabolic effect (carotenoid production) without further 
affecting microbiota composition or intestinal homeostasis. In this thesis we also studied the 
effects of two different phytochemicals in overweight and obese individuals. Both hesperidin 
and carotenoids act as antioxidants, and many in vitro and animal studies have reported 
consistent, beneficial effects of these compounds on cardiovascular and metabolic 
parameters. Again, data in humans are contradictory. In our human studies, hesperidin 
showed to have beneficial influences endothelial function and blood pressure, while the 
carotenoids did not induce significant improvements. In order to exert systemic health effects 
it is essential that a compound is bioavailable and absorbed from the gastrointestinal tract 
into the systemic circulation. We have observed that several factors affect bioavailability 
and absorption of a compound including structure, solubility and particle size of the 
compound, gut microbiota composition and activity, and bioaccessibility. The different 
compounds, studied in this thesis, all showed to have beneficial effects in in vitro and in 
animal studies, but their efficacy in humans remains equivocal. Several explanations can be 
given for this. 
In most studies we investigated the effects of the nutritional intervention in overweight and 
obese individuals. We consider overweight and obesity as “mild disease”, associated with a 
broad spectrum of well-recognized risk factors for the development of chronic metabolic 
diseases such as cardiovascular diseases and diabetes mellitus type 2. However, usually 
these individuals were healthy at baseline. Therefore, an improvement of an already ‘stable 
and excellent’ onset condition is not to be anticipated after giving an intervention. 
Furthermore, a great variation exists between individuals with regard to general health, 
genetic make-up and expression, gut microbiome, environmental factors, lifestyle and diet. 
Also, large inter-individual variability exists regarding metabolite excretion of the 
compounds that have been described.140,205 In addition, components of the habitual diet can 
impact on the bioavailability of a compound. We could not control these factors in our 
studies. This leads to large inter-individual differences regarding the bioavailability, 
absorption and biological activity of a compound.  
The development of nutritional therapies that target on either prevention or on improvement 
of an already existing derangement of chronic gastrointestinal, cardiovascular and 
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metabolic diseases is important and is considered an attractive alternative for medication 
use. First, we need large, well-designed, placebo-controlled randomized trials investigating 
the safety and efficacy in well-defined or phenotyped high-risk populations. Another 
approach is to apply a stressor in order to induce a disturbance in homeostasis and 
evaluate the nutritional intervention either before or during application of the stressor. It is 
important that the international scientific community reaches consensus on standardized 
study designs for nutritional interventions in human beings. In addition, it is mandatory to 
study nutritional interventions in well-defined study populations to clarify in which people the 
intervention is actually effective. 
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Summary  
The primary role of food is to provide sufficient quantitative and qualitative supply of 
nutrients to meet the nutritional requirements of an individual. In addition food may also have 
health promoting effects. Initially, scientific focus was given on the identification of essential 
elements and their role in the treatment and prevention of various deficiencies and of 
diseases associated with specific deficiencies. In recent years, the role of diet in diseases 
linked to excess food intake and to ‘overnutrition’ has become topic of clinical interest and 
of research. The discovery and further development of functional foods is a fast growing 
segment of the food industry. Functional foods are defined as foods or food ingredients that 
affect one or more functions in the body in a targeted way so that positive effects on health 
are to be expected, or when the component has a physiological or psychological effect 
beyond the traditional nutritional effect. The role of functional foods in disease prevention 
and health promotion is nowadays a research topic. 
In this thesis, we aimed to investigate the effects of several nutritional interventions on 
gastrointestinal and metabolic health in healthy, overweight and obese individuals. The 
nutritional interventions we studied include a prolyl endoprotease, a putative prebiotic 
product, a putative probiotic species and two different phytonutriets. 
 
Gluten, a protein rich in proline, is poorly degraded in the gastrointestinal tract due to the 
gastrointestinal absence of proline-cleaving proteases. The presence of long proline-rich 
gluten peptides in the small intestine can induce a wide range of gluten related disorders 
with different pathogenic pathways. Prolyl endoproteases are enzymes that possess the 
ability to cleave at internal proline residues within the gluten. In Chapter 2 we investigated 
the in vivo efficacy of an Aspergillus Niger-derived prolyl endoprotease (AN-PEP) in 
degrading gluten. AN-PEP efficiently degraded gluten from a meal in the stomach of 
healthy volunteers before entering the duodenum. Furthermore, increasing meal caloric 
density did delay gastric emptying time, but did not affect gluten degradation efficiency. In 
Chapter 3 of this thesis we critically evaluated the use of paracetamol as postprandial 
marker for gastric empyting. We showed that paracetamol, when added to a meal and 
mixed, was divided into two fractions; one fraction encapsulated by the meal and one 
fraction dissolved in the liquid content of the meal. The rate of absorption of these fractions 
was different, and both did not accurately reflect gastric emptying rate. 
 
Modulation of the gut microbiota by prebiotics appears to be an interesting approach to 
enhance gut barrier function, and to treat or even prevent the onset or deterioration of 
chronic diseases. A limitation of most prebiotics is their rapid fermentation in the proximal 
colon. Arabinoxylans (AX), the most abundant non-digestible carbohydrates present in 
wheat, represent an interesting novel class of potential prebiotics. Due to their structure, 
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they rely on a whole spectrum of (microbial) enzymes for degradation, resulting in a more 
distal fermentation and activity. Furthermore, AX structure affects the fermentation pattern 
and immune modulation, with highest acitivity observed for long-chain AX. In Chapter 4 we 
aimed to investigate the 6 weeks effect of two different doses high-molecular weight AX on 
the gut barrier, gut microbiota structure and activity, immune system and metabolic markers 
in overweight and obese individuals. Compared to placebo, AX intake did not significantly 
change the relative abundance of the dominant phyla, but a decrease in microbial richness 
and diversity was observed but only after 15 g AX intake, not with the lower dose of 7.5 g 
AX. Furthermore, the fecal concentrations of the individual short-chain fatty acids (SCFA) 
acetate, butyrate and propionate, and of the total SCFA were increased upon intake of 
AX, compared to the placebo group. Six weeks 7.5 g AX also significantly lowered fecal pH 
compared to placebo. This modulation in gut microbial activity may affect the gut barrier 
and the gut immune system. An upregulation in the transcription of the junction (TJ) proteins 
occludin, claudin-3 and claudin-4 in sigmoid biopsies, either after 7.5 g AX or 15 g AX 
supplementation, was observed. However, no significant changes in TJ protein expression 
nor in gastrointestinal permeability were found in the AX groups, compared to placebo. In 
addition, we observed a significant decrease in the production of the pro-inflammatory 
cytokine TNFα by stimulated peripheral blood mononuclear cells after 6 weeks 15 g AX 
intake. 
 
Large scale studies have shown that intake of flavonoid-rich food products has positive 
effects on cardiovascular diseases (CVD) and their related risk factors. To exert health 
effects in vivo it is essential that flavonoids are bioavailable, absorbed from the 
gastrointestinal tract and reach the systemic circulation. Hesperidin, a flavanone glycoside 
from sweet orange peels, is able to exert positive effects on metabolic and cardiovascular 
health, but has poor bioavailability in humans. An option to improve the bioavailability of a 
compound is to improve the dissolution process by micronization. Furthermore, hesperidin 
has a specific enantiomer configuration; it consists of a mixture of S- and R-enantiomers in a 
S:R ratio between 1:1 and 5:1 depending on its source. Stronger biological effects are 
elicited by the S-enantiomer compared to the R-enantiomer. While in nature the 2S-
enantiomer is dominant, commercially available hesperidin often contains a mixture of both 
stereo-isomers. In Chapter 5 we compared the bioavailability of standard hesperidin with 
that of micronized hesperidin 2S (S:R ratio of 4:1) in a cross-over study in healthy subjects. 
After ingestion of one dose, micronized hesperidin 2S proved to be more bioavailable than 
standard hesperidin. This was shown by a significant increase in the cumulative excretion of 
total hesperitin and of the individual metabolites in 24 hour urine, and by a significant 
increase in the AUC0-4h of plasma hesperetin after intake of micronized hesperidin 2S, 
compared to standard hesperidin. The improved bioavailability of micronized hesperidin 2S 
may positively affect its biological activity.  
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Stimulated by these favourable results, in Chapter 5, in Chapter 6 we studied the effects of 
6 weeks micronized hesperidin 2S supplementation on endothelial function, as measured by 
flow-mediated dilation (FMD), in overweight and obese subjects. Furthermore, also the 
effects on plasma adhesion molecules, blood pressure and metabolic markers were 
examined. Besides studying the effects on basal (fasting) endothelial function, we studied the 
effects of hesperidin 2S after inducing temporary, reversible endothelial dysfunction by 
providing participants a high-fat meal. In this randomized, placebo-controlled, double-blind, 
parallel-group study we observed no significant changes in fasted nor in postprandial FMD. 
However, trends towards downregulation of the adhesion molecules sVCAM-1, sICAM-1 
and sP-selectin and towards reduction of both the systolic and diastolic blood pressure 
were observed after 6 weeks hesperidin 2S intake, compared to placebo. Interestingly, in 
an exploratory subgroup analysis, excluding those subjects with a highly impaired basal 
flow-mediated dilation (exclusion of subjects with basal FMD < 3%),  hesperidin 2S protected 
from postprandial endothelial dysfunction and significantly downregulated sVCAM-1 and 
sICAM-1, as compared to placebo. 
In another randomized, placebo-controlled, double-blind, parallel-group study we aimed to 
assess the 12-week effects of the same hesperidin 2S formulation on gastrointestinal and on 
systemic metabolic parameters in subjects with features of metabolic syndrome (Chapter 7). 
In this study, no significant hesperidin-induced effects were observed regarding glucose 
regulation, blood pressure and blood lipids. However, although fecal total SCFA 
concentrations did not change, hesperidin 2S influenced the gastrointestinal environment as 
reflected by a significant shift in fermentation (SCFA) profile from acetate to butyrate, and a 
marked but non-significant reduction in fecal calprotectin concentrations. 
 
It has also been shown that high intake of carotenoids, lipophilic antioxidants abundant in 
fruits and vegetables, protects against the development of CVD and CVD related risk 
factors. The majority of commercially available natural carotenoids are derived from plant-
based materials. However, the quality and consistency of these carotenoids varies 
considerably. Carotenoid-like molecules can also be produced by bacterial species. Those 
produced by spore-forming bacillus strains are of specific interest. Previous in vitro and 
animal studies have shown that a specific bacillus strain, named PD01, is able to produce 
gastric-stable carotenoids with superior bioavailability and high antioxidant activity as 
compared to plant carotenoids. In addition, PD01 itself may also possess probiotic 
properties. In Chapter 8 we investigated whether PD01 is also able to survive transit 
through the gastroinestinal tract and to release systemically absorbable carotenoids in an in 
vivo setting. In addition, the gastrointestinal and systemic effects of PD01 and its bacterial 
carotenoids were studied in a overweight-obese study population. PD01 was shown to 
survive transit through the gastrointestinal tract and was able to germinate into vegetative 
cells under physiological intestinal conditions and to release bioavailable carotenoids in 
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vivo. No significant gastrointestinal nor systemic effects were observed after 6 weeks PD01 
intake, compared to placebo. 
 
In Chapter 9, we presented an overview of the main findings of this thesis, discuss new 
insights and future perspectives, and provide potential implications for further research. 
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Nederlandse samenvatting  
De primaire rol van voeding is kwantitatief en kwalitatief voldoende voedingsstoffen 
verschaffen zodat er aan de voedingsbehoeften van een individu kan worden voldaan. 
Daarnaast kan voeding ook gezondheidsbevorderende effecten hebben. Aanvankelijk 
richtte de voedingswetenschap zich op het identificeren van essentiële elementen uit de 
voeding en hun rol in de preventie en behandeling van diverse deficiëntieziekten. In de 
afgelopen jaren ligt de wetenschappelijke en klinische focus meer op de rol van voeding in 
ziekten geassocieerd met overmatige voedselinname. De ontdekking en ontwikkeling van 
functionele voedingsmiddelen heeft “functional foods” tot een snelgroeiend onderdeel van 
de voedselindustrie gemaakt. Functionele voedingsmiddelen worden gedefinieerd als 
voedingsmiddelen of voedselingrediënten die één of meer lichamelijk functies doelgericht 
beïnvloeden met een gezondheidsbevorderend effect, of wanneer het product een 
fysiologisch effect heeft of effect op psychisch functioneren anders dan het traditionele 
nutritionele effect. De rol van functionele voeding in ziektepreventie en gezondheids-
bevordering is tegenwoordig een belangrijk onderwerp van onderzoek. 
In dit proefschrift onderzochten we de effecten van verschillende voedingsinterventies op 
de gastro-intestinale en metabole gezondheid van gezonde individuen en van individuen 
met overgewicht en obesitas. We bestudeerden de effecten van een prolyl endoprotease, 
een potentieel prebiotisch en probiotisch product, en van twee verschillende fytonutriënten. 
Gluten, een eiwit rijk aan proline, wordt slecht afgebroken in het maag-darmstelsel door 
het ontbreken van proline splitsende proteasen in het maag-darmkanaal. De aanwezigheid 
van lange prolinerijke glutenpeptiden in de dunne darm kan meerdere gluten-gerelateerde 
aandoeningen via verschillende mechanismen induceren. Prolyl endoproteasen zijn 
enzymen die het vermogen hebben om de prolinerijke glutenpeptiden te splitsen. In 
Hoofdstuk 2 onderzochten we de in vivo werkzaamheid van Aspergillus Niger prolyl 
endoprotease (AN-PEP) in het afbreken van gluten. AN-PEP was in staat om gluten, 
verwerkt in een maaltijd, efficiënt af te breken in de maag van gezonde vrijwilligers 
voordat deze gluten de dunne darm bereikten. Daarnaast zorgde het verhogen van de 
calorische dichtheid van de maaltijd tot een vertraging in maagontledigingssnelheid, maar 
had het geen invloed op de efficiëntie van glutenafbraak. In Hoofdstuk 3 van dit 
proefschrift evalueerden we het gebruik van paracetamol als postprandiale marker voor 
maagontleding. We toonden aan dat paracetamol, wanneer toegevoegd en vermengd met 
een maaltijd, wordt onderverdeeld in twee fracties; één paracetamolfractie ingekapseld 
door het vaste deel van de maaltijd en één fractie opgelost in de vloeibare inhoud van de 
maaltijd. De snelheid van absorptie van deze fracties is verschillend, en geen van beiden 
geeft nauwkeurig de maagledigingssnelheid weer. 
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Het veranderen van de samenstelling van darmmicrobiota door prebiotische producten lijkt 
een interessante manier om de darmbarrièrefunctie te verbeteren en om het ontstaan of de 
progressie van chronische ziekten te behandelen of zelfs te voorkomen. Een beperking van 
de meeste prebiotica is hun snelle fermentatie in het proximale colon. Arabinoxylanen (AX), 
de meest voorkomende niet-verteerbare koolhydraten in tarwe, vormen een interessante 
nieuwe klasse van potentiële prebiotica. Door hun structuur hebben ze een breed spectrum 
van (bacteriële) enzymen nodig voor hun afbraak, hetgeen resulteert in een meer distale 
fermentatie en activiteit. Bovendien beïnvloedt hun structuur het fermentatiepatroon en 
bepaalt het de mate van immuunmodulatie, met de hoogste activiteit waargenomen voor 
lange-keten AX. In Hoofdstuk 4 onderzochten we de effecten van twee verschillende 
doseringen AX, na 6 weken toediening, in gezonde personen met overgewicht of obesitas. 
Uitkomstmaten waren darmbarrièrefunctie, samenstelling en activiteit van de darm-
microbiota, het immuunsysteem en metabole parameters. In vergelijking met placebo bleek 
AX de relatieve aanwezigheid van de dominante bacteriefyla in feces niet significant te 
beïnvloeden. Wel werd er een afname in microbiële rijkdom en diversiteit waargenomen na 
6 weken 15 g AX inname, maar niet na 6 weken 7,5 g AX inname. Daarnaast waren de 
fecale concentraties van de verschillende korteketenvetzuren acetaat, butyraat en 
propionaat en van de totale hoeveelheid korteketenvetzuren verhoogd na inname van 6 
weken AX, tegenover een daling in de placebogroep. Zes weken inname van 7,5 g AX 
zorgde voor een significante verlaging van de fecale pH, in vergelijking met placebo. Deze 
modulatie van microbiële activiteit in de darm zou de darmbarrièrefunctie en het 
immuunsysteem kunnen beïnvloeden. Ook werd er een toename van transcriptie van de 
tight junction (TJ) eiwitten occludine, claudine-3 en claudine-4 in sigmoid biopten 
waargenomen, zowel na 7,5 g AX als na 15 g AX suppletie. Echter, er werden geen 
significante veranderingen in TJ eiwitexpressie of in gastro-intestinale permeabiliteit gezien 
na AX suppletie, in vergelijking met placebo. Tenslotte zagen we in deze studie een 
significante daling in de productie van het pro-inflammatoire cytokine TNF-alfa door 
gestimuleerde perifere mononucleaire bloedcellen na 6 weken inname van 15 g AX 
vergeleken met inname van placebo. 
Studies van grote omvang hebben aangetoond dat flavonoïde-rijke producten gunstige 
effecten hebben op hart- en vaatziekten en de bijbehorende risicofactoren. Om in vivo  
gezondheidseffecten te bewerkstelligen is het essentieel dat flavonoïden goed 
biobeschikbaar zijn, met andere woorden dat ze worden opgenomen vanuit het maag-
darmstelsel en dat ze de systemische circulatie bereiken. Hesperidine, een flavonoïde 
glycoside uit sinaasappelschillen, kan wel degelijk positieve effecten uitoefenen op 
metabole en cardiovasculaire gezondheid, maar is in mensen maar in geringe mate 
biologisch beschikbaar. Een manier om de biologische beschikbaarheid te verbeteren is 
door het proces van oplossen te verbeteren middels micronisatie. Daarnaast heeft 
hesperidine een specifieke enantiomeer configuratie; het bestaat uit een mengsel van S- en 
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R-enantiomeren in een S:R-verhouding tussen 1:1 en 5:1, afhankelijk van de bron. De S-
enantiomeer heeft een sterker biologisch effect dan  de R-enantiomeer. Terwijl in de natuur 
de 2S-enantiomeer overheerst, bevatten commercieel verkrijgbare hesperidine producten 
vaak een mengsel van beide stereo-isomeren. In Hoofdstuk 5 vergeleken we de biologische 
beschikbaarheid van standaard hesperidine met die van gemicroniseerde hesperidine 2S 
(S:R-verhouding van 4:1) in een cross-over studie met gezonde proefpersonen. Na inname 
van één dosis bleek de gemicroniseerde hesperidine 2S beter biologisch beschikbaar te 
zijn dan de standaard hesperidine. Dit werd aangetoond middels een significante toename 
van de cumulatieve uitscheiding van totaal hesperetine en van de individuele 
hesperidinemetabolieten in 24-uurs urine. Daarnaast was er een significante toename van 
de AUC0-4h van plasma hesperetine na inname van de gemicroniseerde hesperidine 2S, in 
vergelijking met standaard hesperidine. De verbeterde biologische beschikbaarheid van 
gemicroniseerd hesperidine 2S zou tevens de biologische activiteit gunstig kunnen 
beïnvloeden. 
Naar aanleiding van bovengenoemde gunstige resultaten, bestudeerden wij in Hoofdstuk 6 
de effecten van 6 weken gemicroniseerde hesperidine 2S inname op endotheelfunctie, 
gemeten met flow-gemedieerde dilatatie, in personen met overgewicht en obesitas. 
Daarnaast onderzochten we ook de effecten op plasma adhesiemoleculen, bloeddruk en 
metabole parameters. Naast het bestuderen van de effecten op basale (nuchtere) 
endotheelfunctie, bestudeerden wij ook de effecten van hesperidine 2S na inductie van 
tijdelijke, reversibele endotheeldysfunctie door deelnemers een vetrijke maaltijd te geven. In 
deze gerandomiseerde, placebo-gecontroleerde, dubbelblinde, parallelle studie zagen we 
geen significante veranderingen in nuchtere noch in postprandiale flow-gemedieerde 
dilatatie. Wel zagen we een dalende trend in de adhesiemoleculen sVCAM-1, sICAM-1 en 
sP-selectine en in de systolische en diastolische bloeddruk na 6 weken hesperidine 2S 
inname, vergeleken met placebo. Daarnaast zagen we in een subgroep analyse dat 
hesperidine 2S een beschermend effect had ten aanzien van postprandiale 
endotheeldysfunctie, en dat het de adhesiemoleculen sVCAM-1 en sICAM-1 significant 
verlaagde, in vergelijking met de placebo. In deze subgroep analyse waren personen met 
een sterk verminderde basale flow-gemedieerde dilatatie (<3%) geëxcludeerd omdat 
verbetering van endotheelfunctie na een dergelijke korte termijn voedingsinterventie niet te 
verwachten is in personen met zo’n chronisch slecht functionerend endotheel. 
In een volgend gerandomiseerd, placebo-gecontroleerde, dubbelblinde, parallelle studie 
onderzochten we de effecten van hetzelfde hesperidine 2S supplement op gastro-
intestinale en systemische metabole parameters bij patiënten met kenmerken van het 
metabool syndroom na 12 weken inname (Hoofdstuk 7). In deze studie werden geen 
significante hesperidine-geïnduceerde effecten waargenomen ten aanzien van de 
glucoseregulatie, bloeddruk en lipidenconcentraties. Hoewel de totale korteketenvet-
zurenconcentratie in feces niet veranderde, beïnvloedde hesperidine 2S het gastro-
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intestinale milieu, weerspiegeld door een significante verschuiving in het fermentatie 
(korteketenvetzuren) profiel van acetaat naar butyraat. Daarnaast werd er een duidelijke 
maar niet-significante daling gezien in fecale calprotectine concentraties. 
Carotenoïden zijn lipofiele antioxidanten overvloedig aanwezig in fruit en groenten. Het is 
aangetoond dat een hoge inname van carotenoïden beschermt tegen de ontwikkeling van 
hart- en vaatziekten en gerelateerde risicofactoren. De meeste commercieel verkrijgbare 
natuurlijke carotenoïden zijn afkomstig van plantaardige materialen. Echter, de kwaliteit en 
consistentie van deze carotenoïden varieert aanzienlijk. Carotenoïden kunnen ook worden 
geproduceerd door bacteriën, met name carotenoïden die geproduceerd worden door 
sporenvormende bacillus-stammen zijn van belang. Eerdere in vitro en dierstudies hebben 
aangetoond dat een specifieke bacillus-stam, genaamd PD01, in staat is maagsapresistente 
carotenoïden met superieure biobeschikbaarheid en hoge antioxidant werking te 
produceren in vergelijking met carotenoïden afkomstig van planten. Daarnaast bezit PD01 
zelf mogelijk ook probiotische eigenschappen. In Hoofdstuk 8 onderzochten wij of PD01 in 
staat is om in vivo te overleven in het maagdarmstelsel en in staat is tot productie van 
systemisch opneembare carotenoïden. Daarnaast bestudeerden wij de gastro-intestinale en 
systemische effecten van PD01 en van de geproduceerde bacteriële carotenoïden in 
individuen met overgewicht en obesitas. PD01 bleek in vivo in staat te overleven in het 
menselijke maagdarmstelsel en te ontkiemen tot vegetatieve cellen met afgifte van 
biobeschikbare carotenoïden. Echter, er werden geen significante gastro-intestinale noch 
systemische effecten waargenomen na 6 weken PD01 inname, in vergelijking met placebo. 
In Hoofdstuk 9 gaven we een overzicht van de belangrijkste bevindingen van dit 
proefschrift, bediscussieerden we nieuwe inzichten en toekomstperspectieven, en droegen 
we mogelijke implicaties voor verder onderzoek aan. 
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Valorisation  
Valorisation is the process of value-creation out of knowledge, by making this knowledge 
suitable and available for economic or societal utilization and to translate it into high-
potential products, services, processes and industrial activity.1 With this thesis, we aim to 
improve our understanding of the effects of several nutritional interventions on 
gastrointestinal and metabolic health, and to make the acquired knowledge and expertise 
available for society. 
The relationship between food and health is complex, being multifactorial and 
multidimensional. Food provides sufficient quantitative and qualitative supply of nutrients and 
supplies the human body with materials that can be used for the construction and repair of 
structures, tissues and organs. Furthermore, the role of functional foods in disease prevention 
and health promotion is emerging. Functional foods are defined as foods or food ingredients 
that affect one or more functions in the body in a targeted way so that positive effects on 
health are to be expected, or when the component has a physiological or psychological 
effect beyond the traditional nutritional effect.2,3 On the other hand, food can also 
negatively influence health and initiate or contribute to illness. To date, in many low- and 
middle income countries access to food is still limited and the availability and quality of 
nutrition is poor, leading to severe undernourishment and food insecurity.4 In contrast, the 
prevalence of overweight and obesity, linked to excess food intake and ‘overnutrition’, has 
worldwide more than doubled since 1980. In 2014, approximately 39% of people aged 18 
years and over were overweight and 13% obese.5 Also in the Netherlands, the number of 
individuals with overweight and obesity is tremendous; in 2015, 50.3% of the adults aged 
20 years and older were overweight and 13.7% were obese.6 Overweight and obesity are 
associated with a broad spectrum of gastrointestinal and systemic metabolic alterations, 
serving as major risk factors for the development of chronic metabolic diseases such as 
diabetes mellitus type 2 and cardiovascular disease.7,8 As a consequence, obesity imposes a 
tremendous economic burden on society through increased total direct (treatment obesity-
associated diseases) and indirect (productivity losses) medical costs. In the Netherlands, it 
has been calculated that in general the direct health care costs of obesity account for up to 
total 2.2% of national health expenditure.9 The indirect health care costs could amount to 
twice the direct health care costs.10 Significant reductions in these costs can be 
accomplished by prevention of overweight and obesity or by a significant delay in the onset 
of overweight, obesity and associated diseases. 
Besides diseases linked to undernourishment and overnutrition, there exists another class of 
diseases related to food: food allergies and food intolerances. Important and 
epidemiologically relevant phenomenon are the gluten related disorders, such as wheat 
allergy, celiac disease and gluten sensitivity. The number of individuals embracing a gluten-
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free diet is increasing. However, a gluten-free diet is hard to comply with as gluten-free 
products may not always be correctly labelled, are expensive, and may not always be at 
hand during social events or travelling. Accordingly, the market for gluten-free products is 
constantly growing and research identifying alternative therapies is ongoing. 
 
The aim of this thesis was to investigate the effects of several nutritional interventions on 
gastrointestinal and metabolic health in healthy, overweight and obese individuals. The 
nutritional interventions we studied included a prolyl endoprotease, a putative prebiotic 
supplement, a putative probiotic species, and two different phytonutrients. 
 
Gluten is the main structural protein complex of wheat with equivalent toxic proteins present 
in barley and rye. These gluten-containing cereals have always been a main component of 
the Western diet, but their consumption is increasing in Eastern countries as well. Ingestion of 
gluten can induce a wide range of gluten related disorders with different pathogenic 
pathways. For all conditions, strict adherence to a gluten-free diet is still the only effective 
treatment. As such, the number of individuals on a gluten-free diet is increasing worldwide. 
However, the high cost and often poor availability and palatability of gluten-free products 
makes it difficult to maintain such diet on the longer term. Even in case of strict adherence, a 
subgroup of individuals may remain symptomatic due to inadvertent gluten indigestion. In 
addition, a gluten-free diet is nutritionally suboptimal, it may predispose to an undesirable 
high intake of fat and carbohydrates and lead to poor vitamin status and detrimental 
weight gain or weight loss. Due to these problems with gluten-free dieting a strong interest 
in the development of alternative therapies exists. A possible alternative treatment is 
enzyme supplementation therapy targeted at degradation of immunogenic gluten peptides 
before entering the intestinal epithelium. In this thesis, we evaluated the in vivo gluten-
degrading potential of Aspergilles Niger-derived prolyl endoprotease (AN-PEP). To 
standardize each meal intake, we intragastrically administered the test meal via a triple 
lumen nasogastroduodenal tube. AN-PEP showed to be able to efficiently degrade gluten 
from a meal in the stomach of healthy volunteers within the time period a meal normally 
resides in the stomach. The gluten-degrading efficacy of AN-PEP was independent of meal 
caloric density and gastric emptying rate. These in vivo results are promising but to optimise 
AN-PEP for clinical application it is important that future studies investigate the efficacy of 
AN-PEP in an actual meal setting, focusing on subjects intolerant to gluten. Furthermore, it is 
anticipated that these supplements will not fully replace the gluten-free diet, but will be 
marketed as a supplement that in conjunction with a gluten-free diet may help digest 
unintentional ingested gluten for subjects intolerant to gluten. 
To measure gastric emptying rate in the above-mentioned study, we used paracetamol as 
post-prandial marker molecule. This method is considered a well-established method and is 
extensively applied in research. It is assumed that paracetamol, mixed trough a meal and 
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ingested, will be absorbed immediately in the duodenum after leaving the stomach and that 
its passage time is identical to that of the meal. The gastric emptying rate can be derived 
from the time course of the plasma paracetamol concentration. However, in our study we 
obtained data which were in conflict with this widely accepted model. We observed that 
paracetamol was divided in two fractions; one fraction dissolved in the liquid content of the 
meal and another fraction encapsulated by meal contents that precipitate in the acid 
stomach environment. The aqueous phase is expected to leave the stomach quickly and the 
paracetamol is readily absorbed in the duodenum, the encapsulated paracetamol is slowly 
released from the bolus and not instantaneously taken up once it reaches the duodenum. 
Both fractions did not accurately reflect gastric emptying rate, instead these data show the 
effect of food on the rate of absorption of paracetamol. The absorption of a drug in the 
gastrointestinal tract bears major clinical relevance. Food-drug interactions are thus not 
limited to an effect of food on gastric emptying, but it also includes bioaccessibility. 
Bioaccessibility, i.e. the release of a compound from the matrix in the intestine, has an impact 
on both the onset and duration of the pharmacotherapeutic effect of a drug. 
 
The human gut is host to a diverse and dynamic community of several trillion microbes that 
play an important role in intestinal physiology, nutrient digestion, luminal metabolism and 
immune function.11 Colonization of the gastrointestinal tract is influenced by genetic 
background, gestational age, mode of delivery, type of feeding, exposure to antimicrobials 
and, very important, diet throughout life.12 Long-term perturbations to the intestinal 
environment can induce changes in the gut microbiome, contributing to the development of 
a variety of gastrointestinal diseases13 as well as systemic metabolic diseases including 
diabetes mellitus type 2 and cardiovascular disease.14 Thus, targeting the gut microbiome 
seems to offer a promising strategy to ameliorate or even prevent the development of 
above-mentioned diseases. A number of dietary strategies potentially modulating the gut 
microbiome are available; pre- and probiotics are among the most well established, while 
recent data suggest that also different types of polyphenolic compounds may influence the 
gut microbiome. 
In this thesis we evaluated the effect of a high-molecular weight arabinoxylan (AX) 
concentrate, a potential prebiotic product, on intestinal microbiota, gut barrier and immune 
function in overweight and obese subjects. AX form an interesting novel class of potential 
prebiotics as, due to their structure, they are more gradually fermented along the colon 
resulting in a more distal fermentation and activity. A limitation of most other prebiotics is 
their rapid fermentation (and thus activity only) in the proximal colon. Previous in vitro and 
animal studies have shown promising effects of this product on the gut barrier, gut 
microbiota, immune system and metabolic markers. In humans, AX administration did not 
result in a change in the overall microbiota composition, but AX resulted in significantly 
increased fecal concentrations of short-chain fatty acids (SCFA) and lower fecal pH. The 
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effects of AX on the gut barrier were explored at various levels. At gene transcription level, 
we found a significant upregulation of the tight junction (TJ) proteins occludin, claudin-3 and 
claudin-4, important transmembrane components regulating paracellular permeability. 
However, these changes in TJ gene expression were nog accompagnied with changes in TJ 
protein expression or in gastrointestinal permeability. Furthermore, results of this study 
suggest a capacity of AX to influence the immune function. At last, daily intake of AX for 
several weeks proved to be well-tolerated by the participants. Altogether, these data 
suggest that also in humans high-molecular weight AX modulates the gut microbiome and 
thereby may positively affect gut barrier and immune function. While more research in large, 
homogeneous study populations is required to confirm its in vivo microbiota modulating - 
and potentially gut barrier and immune system modulating- properties, AX is considered a 
promising prebiotic compound conferring health effects along the entire length of the colon. 
In this thesis, we also studied the effects of a putative probiotic product, a Bacillus indicus 
strain called PD01, on the intestinal microbiota and gut barrier in healthy, yet overweight 
and obese individuals. Several studies have already shown potential health benefits of 
bacillus strains. In addition, bacillus species as probiotics are particularly attractive for 
functional reasons as they can form robust endospores that are able to survive transit 
through the stomach, are stable to many food processing steps and can be long-term stored 
at room temperature. Previous in vitro data showed that this strain was able to survive and 
germinate in the gastrointestinal tract and to modulate the intestinal environment. In vivo, 
PD01 also survived transit throughout the digestive tract, but did not significantly influence 
the gut microbiome or gut barrier when compared to placebo. Repeated intake of PD01 
was well-tolerated by the participants, and was even accompanied with a decrease in 
reported gastrointestinal symptoms such as borborygmi, abdominal distension, eructation 
and increased flatulance. Previous studies in IBS patients showed that changing the gut 
microbiome by probiotics may induce quantitative and qualitative decreases in bacterial 
groups with gas-producing abilities.15,16 Possibly, a similar mechanism played a role in our 
study results. Although no significant effects of PD01 on gut microbial environment or gut 
barrier function could be established in this study, it does provide the first evidence in 
humans that PD01 survives transit through the gastrointestinal tract and is well-tolerated. To 
determine whether PD01 possesses additional probiotic properties, it is important that more 
in vivo studies will be conducted in future, including a homogeneous, more diseased study 
population or that a stressor is applied during the test period inducing an imbalance in 
homeostasis. 
As said before, also polyphenols may have the potential to affect the intestinal environment. 
We evaluated the relationship between the polyphenol hesperidin and SCFA production. 
Although we did not observe an effect on the quantity of SCFA production, twelve weeks 
hesperidin intake modulated the intestinal environment as reflected by a shift from the 
SCFA acetate to the health-promoting SCFA butyrate. These results strengthen the 
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hypothesis that also polyphenols are able to influence the gut microbiome. Research 
investigating the interactions between the gut microbiome and phenolic compounds is still in 
its early days. More human intervention studies are required to understand the underlying 
mechanisms and to establish the potential prebiotic-like effects of hesperidin and other 
polyphenols.  
 
It has been demonstrated that fruits, vegetables and grains exert protective effects against 
the development of chronic metabolic diseases such as diabetes mellitus type 2 and 
cardiovascular disease. This protective role can be mainly attributed to the antioxidant 
phytonutrients in them. Today, about 10,000 phytonutrients have been identified. In this 
thesis we studied the bioavailability and systemic effects of two main kinds of phytonutrients: 
polyphenols and carotenoids. 
Hesperidin, a polyphenol abundantly present in the peels of citrus fruits, has drawn attention 
due to its positive effects on metabolic and cardiovascular health. In order to exert systemic 
health effects, it is essential that a compound is bioavailable and absorbed from the 
gastrointestinal tract into the systemic circulation. However, the bioavailability of hesperidin 
in humans is low. We demonstrated that the bioavailability of a micronized hesperidin 2S 
formulation, having a similar enantiomer configuration as natural hesperidin, is higher than 
that of a non-micronized standard hesperidin product. The enhanced bioavailability may 
positively affect its biological activity. Furthermore, this study provided evidence that there 
exists a high inter-individual variation in polyphenol bioavailability, most likely the result of a 
great inter-individual diversity in the gut microbiome.  
Based on above results, we investigated the effect of micronized hesperidin 2S 
supplementation on cardiovascular and metabolic parameters in healthy, yet overweight 
and obese individuals. Results indicate a promising preventive role for hesperidin in 
cardiovascular disease. Given the high inter-individual variability of polyphenol 
bioavailability in humans, it would be particularly important and interesting to correlate the 
magnitude of observed changes with plasma polyphenol concentrations in future studies. 
Regarding glucose and lipid metabolism we did not observe hesperidin-induced beneficial 
effects in our generally healthy study population. Consequently, long-term intervention 
studies in subjects with(pre)diabetes, metabolic syndrome or hypercholesterolemia are 
warranted to establish and confirm beneficial hesperidin-induced effects on systemic 
metabolic health markers. 
Carotenoids are lipophilic antioxidants, synthesized mainly in plants, but also by a number of 
bacterial species. In contrast to plant-derived carotenoids, bacterial carotenoids are gastric-
stable, are equally or even more bioaccessible and bioavailable, and have a higher 
antioxidant capacity. In this thesis we evaluated the bioavailability of carotenoids, produced 
by a spore-forming Bacillus strain, in overweight and obese individuals. The bacterial 
carotenoids were present in the plasma and levels increased throughout the study period. 
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These results indicate that the bacillus strain was able to produce systemically absorbable 
bacterial carotenoids in vivo. However, no beneficial effects of the bacterial carotenoids 
regarding cardiovascular and metabolic parameters were observed, probably due to the 
fact that participants had normal baseline values for most parameters. It is clear that more 
and larger human intervention studies are needed to investigate and confirm an improved 
bioavailability, antioxidant capacity and systemic health effects of bacterial carotenoids 
over plant-derived carotenoids. 
 
In conclusion, beyond its nutritional value food can also play an important role in disease 
prevention and health promotion. All of the here studied nutritional interventions may affect 
one or more functions in the body in a positive way and therefore can be considered a 
functional food. Health-conscious consumers are increasingly seeking functional foods in an 
effort to control their own health and well-being. However, the field of functional foods is 
still in its infancy. Many functional foods showed to have beneficial effects in in vitro and in 
animal studies, but their efficacy in humans remains equivocal. A number of factors 
complicate the establishment of a strong scientific foundation for a functional food. Factors 
include complexity of the food substance, compensatory metabolic changes that may occur 
with dietary changes, lack of surrogate markers of disease development and, very 
important, the existing large variation between individuals regarding general health, genetic 
make-up and expression, gut microbiome and environmental factors. The development of 
nutritional therapies that target on prevention or on improvement of chronic gastrointestinal, 
cardiovascular and metabolic diseases is important and is considered an attractive 
alternative for medication use. Therefore, it is essential that in future more large, well-
designed, placebo-controlled randomized trials exploring the effects of nutritional 
interventions in well-defined study populations will be performed. Besides scientifically 
proven health effects, also consumer acceptance is key success factor for use of functional 
foods in the future. As a result, within the food industry, consumer behavior is currently an 
important research topic. 
. 
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Dankwoord 
Eindelijk krijg ik dan de kans om de mensen te bedanken die – direct of indirect – hebben 
bijgedragen aan dit proefschrift. Het is een uitdaging om de waarde van jullie bijdrage en 
mijn dank hiervoor in een paar regels uit te drukken, maar ik ga een poging wagen! 
 
Prof. Masclee, beste Ad, ik ben ontzettend blij dat u mij de mogelijkheid heeft gegeven te 
promoveren. Ik kan me herinneren dat wij beiden in het begin twijfelden of een 
promotietraject voor mij wel de juiste keuze was op dat moment. Met het AN-PEP project 
gaf u mij de kans om een tijdje van het leven als onderzoeker te proeven. Daarna was het 
duidelijk voor mij: ik wilde dit uitbouwen tot een promotietraject. Ik wil u bedanken voor alle 
hulp, de goede begeleiding en steun, en voor het snelle nakijken van manuscripten, zeker in 
de laatste fase van mijn promotie. 
 
Dr. Troost, beste Freddy, bedankt voor al je hulp en gezelligheid in de afgelopen jaren. 
Met name in de opstartperiode heb ik veel van je geleerd, daarna gaf je me de vrijheid 
mijn eigen pad te volgen. Onze vaste dinsdagmiddagbespreking werd steeds minder 
noodzaak, maar bleef altijd een goed excuus om gezellig samen een kop koffie te drinken.  
 
Dr. Possemiers, beste Sam, naast co-promotor was je ook mijn wetenschappelijk supervisor 
binnen BioActor. Ik heb in de afgelopen jaren zowel op wetenschappelijk als op 
commercieel vlak veel van je geleerd. Bedankt dat ik altijd voor alles bij je terecht kon, en 
je meestal snel en constructief commentaar gaf op mijn vragen, METC-protocollen en 
manuscripten. Daarnaast was je altijd fijn gezelschap op de vele BioActor-tripjes die we 
samen gemaakt hebben. 
 
Graag wil ik de leden van de beoordelingscommissie, prof. dr. K. Venema, dr. D. Jonkers, 
prof. dr. C.J.J. Mulder, prof. dr. J. Plat en prof. dr. R.F. Witkamp bedanken voor het kritisch 
beoordelen van mijn proefschrift, het zitting nemen in de promotiecommissie en voor hun 
bijdrage aan deze bijzondere dag. 
 
BioActor BV wil ik bedanken voor de mogelijkheid om als promovendus tegelijkertijd de 
functie van clinical research manager binnen dit bedrijf te bekleden. 
Hans, als managing director van BioActor heb ik veel met jou samengewerkt. Niet altijd 
waren wij het met elkaar eens, maar we kwamen er uiteindelijk toch altijd uit. Ik bewonder 
je om je tomeloze energie, dat zich onder andere uit in altijd nieuwe onderzoeksideeën. 
Nooit zit je lang bij de pakken neer als de data niet zijn zoals gehoopt. Met mijn functie als 
clinical research manager maakte jij me verantwoordelijk voor alle onderzoeksprojecten 
binnen het bedrijf. Ik leerde zelfstandig werken, delegeren, grenzen stellen en bewaken, ik 
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mocht naar meetings van Europese projecten en moest vele presentaties geven. Ik leerde 
wat het inhoudt om voor een bedrijf te werken en het heeft ervoor gezorgd dat ik de 
afgelopen jaren zelfverzekerder, zelfstandiger en assertiever ben geworden. Bedankt 
daarvoor! 
 
Uiteraard ben ik ook dank verschuldigd aan de onderzoeksschool NUTRIM, voor het 
raamwerk waarin ik mijn promotieonderzoek heb mogen uitvoeren. 
 
DSM, in het bijzonder Maaike en Luppo, bedankt dat ik degene was die het AN-PEP 
project mocht uitvoeren. Het was een fijne samenwerking met mooie resultaten, we hebben 
zelfs de nationale en internationale pers gehaald! 
 
Ik had mijn onderzoeksprojecten niet kunnen uitvoeren zonder hulp van alle MDL-artsen, 
MDL-assistenten, Ton Mestrom en het endoscopieteam. Hartelijk dank voor jullie hulp en 
geduld bij het afnemen van vele biopten in onvoorbereide darmen. 
Dan niet te vergeten, Mietsie en Elly. Altijd gezellig om even bij jullie langs te lopen en 
daarbij direct een antwoord te krijgen op al mijn vragen. Tiny, dank voor al je hulp bij de 
lay-out van mijn proefschrift. Ik ben trots op ons eindresultaat. 
 
Kira: bedankt voor het ontzettend gave design van dit boekje en de presentatie.  
Ik geloof in je! 
 
Mijn promotietijd was niet half zo leuk geweest zonder een fantastische groep 
onderzoekscollega’s. Mariëlle, Eveline, Kirsten P., Kirsten v/d B., Elhaseen, Tim, Bas, Zsa Zsa, 
Lisa, Pauline, Marin, Martine, Montserrat, Daisy, Annemiek, Annick, Selwyn, Dirk en Bram, 
bedankt voor de gezellige lunches, borrels, congressen en de interesse in de voortgang van 
mijn projecten. Daniel, Samefko en Mark: bedankt voor het onvergetelijk maken van mijn 
eerste DDW in San Diego. Mark, ik wil jou in het bijzonder bedanken voor alle hulp tijdens 
de afgelopen jaren. Je leerde me duodenumsondes plaatsen, galblaasecho’s maken en 
kwam menig keer opdraven als er weer een infuus geprikt moest worden. Zlatan, Givan, 
Marlou, Fedde, Maarten, Steven, Fabienne, Sander en Paul, met een grote grijns denk ik 
terug aan Orlando 2013. De avondjes in Senõr Frog’s en de snake op onze hotelgang zijn 
mijn favorieten. Wanneer is de volgende reünie? Roel, roomie, zoals je weet waren Chantal 
en ik niet heel blij toen we hoorden dat jij op onze kamer erbij kwam. Maar gelukkig pakte 
het bijzonder goed uit. Met jou erbij waren we altijd gegarandeerd van een luisterend 
(rood) oor en kritisch, doortastend mannencommentaar. Hao Ran, Harry, het laatste half jaar 
van mijn promotie vrolijkte jij onze werkkamer nog even op. Bedankt voor je grappige 
verhalen, de moestuintjes en de verkeerd geadresseerde WhatsApp berichten. 
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Ook wil ik mijn collega’s bij BioActor bedanken voor alle hulp bij de verschillende 
onderzoeksprojecten. In het bijzonder Yala, bij bijna ieder project in dit boekje ben je wel 
betrokken geweest. Heel veel succes met jouw eigen promotietraject. 
 
Mestreechter maedjes: Cor, Ief, Jans, Maart en Ray. Een mengeling van meisjes, 
onafscheidelijk sinds jaar 1 van onze studie. Maandagavond, ‘Greys Anatomy’-avond! Niks 
kwam hiertussen, zelfs geen man. Woensdagavond borrelen en op stap. Vanaf de co-
schappen werd deze doordeweekse stapavond gewoon verplaatst naar het weekend. We 
hebben samengewoond en zijn naar de meest prachtige oorden afgereisd. Bedankt voor 
deze vriendschap, voor het feit dat ik altijd alles met jullie kan delen, voor de goede 
etentjes en gezellige borrels, de mooie feestjes en fantastische vakanties. Ik mis onze 
maandagavonden nu al een tijdje, maar wees gerust, ik kom gewoon terug. 
Lieve An, ook jou hebben we sinds kort weer terug in het Maastrichtse. Fijn dat je er weer 
bent en dat we elkaar weer wat vaker zien. 
 
En dan niet te vergeten de oude garde van O.D.D. Missdaad: Cerès, Dree, Inge, Kim, Kira 
en Luus. Samen a-tijd gelopen en actief lid van O.D.D. Missdaad geweest. Zonder jullie had 
ik nooit zo’n fantastische studententijd gehad. Inmiddels een stuk rustiger, maar niet minder 
gezellig. Fijn dat we na al die jaren nog steeds zo close zijn. Ook al is het tegenwoordig 
niet meer zo vaak, ik geniet iedere keer weer van onze koffiedates, etentjes en borrels. 
Lieve Bel, ook jou wil ik bedanken voor de fijne vriendschap. Ondanks dat we elkaar niet 
zo vaak zien weten we altijd wel van elkaar wat ons op dat moment bezighoudt. Laten we 
vooral niet ophouden met het plannen van leuke festivals. 
 
Chantal en Ellen, allerliefste paranimfen, ik ben heel blij dat jullie naast mij staan deze 
belangrijke dag, maar uiteraard hebben jullie ook veel voor mij betekend in de afgelopen 
jaren. 
Chantal, onze eerste avonturen samen beleefden we in Nepal. De vierdaagse trekking, de 
jungletocht en de achtervolging door een neushoorn. Erna volgden er gelukkig nog vele 
andere. We deden gezamenlijk onze WESP/GEZP bij de MDL, en begonnen tegelijk aan 
onze promotie. We werden naast kamergenoten en collega’s ook goede vriendinnen, 
reisbuddy’s, feestmaatjes en heuse wijnkenners. Ik benijd je om jouw doorzettingsvermogen, 
gedrevenheid en doelgericht werken. Maar lieve Chantal, wees alsjeblieft niet altijd zo 
streng voor jezelf. Wat was ik trots dat ik zo’n 1,5 jaar geleden naast jou als paranimf 
mocht staan! Ik kijk ernaar uit dat we binnenkort weer collega’s zijn. 
Ellen, ik leerde je kennen als een enthousiaste, leergierige, kritische en assertieve control 
freak. Heerlijk dat dat mijn eerste stagiaire was. Ik was destijds nog niet zo goed in 
delegeren, maar al snel durfde ik veel onderzoekstaken aan jou over te laten. Sorry, ze 
waren niet altijd even leuk of dankbaar (denk aan de keren dat jij weer met een portie 
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urine of ontlasting in je rugzak op pad ging), maar nooit hoorde ik je klagen en altijd deed 
je je taken met evenveel toewijding. Ik herinner me vooral dat we, ondanks het meestal 
vroege tijdstip, altijd veel lol hadden. Heel blij was ik dus ook dat je niet veel later m’n 
directe collega werd bij de MDL. We hebben elkaar nog veel geholpen in de afgelopen 
jaren met onze afzonderlijke studies. En naast collega werd je ook een goede vriendin, mijn 
motivatie om te gaan spinnen en bestudeerden we samen de kunde van de wijn. 
 
Lieve Jorrit, mijn grote kleine broer. Vroeger waren we onafscheidelijk; speelde ik met de 
poppen, wilde jij ook; droeg ik nagellak, moest jij ook; lustte ik ineens paprika, vond jij het 
ook lekker. Toen we ouder werden, gingen we ieder onze eigen weg. Zie hier, ik ben (bijna) 
gepromoveerd en werk in het ziekenhuis; jij woont in Azië en runt je eigen internetbedrijf. 
Twee totaal verschillende werelden, maar toch voor altijd verbonden door onze lieve 
ouders en mooie jeugdherinneringen. Ik mis je soms wel, zou willen dat we weer meer 
herinneringen samen zouden maken. Maar het is goed zo. Ik ben trots op jou en op alles 
dat je hebt bereikt. 
 
Papa en mama, lieve ouders, jullie zijn de oorsprong van dit alles. Ik zou natuurlijk nooit 
gepromoveerd zijn als jullie me niet op deze wereld gezet hadden, en het zou me ook 
nooit gelukt zijn zonder jullie onvoorwaardelijke liefde, opvoeding, steun, vertrouwen en 
interesse. Ook al is het soms lastig uitleggen wat promoveren nu exact inhoudt, altijd zijn 
jullie even geïnteresseerd, trots en enthousiast. Sorry mam, ik had je eigenlijk al eerder een 
samenvatting van m’n promotie beloofd, maar bij deze verwijs ik je graag naar het vorige 
hoofdstuk. Pap en mam, bedankt voor alles, ik ben er trots op dat jullie mijn ouders zijn en 
hoop nog lang van jullie te genieten.  
 
Lieve Bas, lief vriendje. 
Bedankt dat jij in mijn leven bent. Ik vind je prachtig. Ik bewonder je doorzettingsvermogen, 
daadkracht en eerlijkheid, je vermogen tot relativeren, het feit dat je niet bang bent om 
fouten te maken en niet doet aan twijfelen. Je geeft me de ruimte en het vertrouwen mezelf 
te ontwikkelen. En allerbelangrijkst, je bent er voor me, iedere dag opnieuw. Ik hou van je. 
 
 
Dankwoord 
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